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Previous studies have shown that addition of recombinant prion into a cell free prion 
replication assay – PMCA inhibits the formation of PrPSc. Previously naturally existing 
versions of ovine prion protein were tested: rARQ, rARR and rVRQ within this assay. Of 
these, rVRQ was the most potent inhibitor of amplification of different scrapie isolates 
(IC50 value 120 nM) and bovine BSE (IC50 – 171 nM). The main aim of this study was 
to produce additional molecular clones for expression of recombinant ovine prion protein 
where codon 136 had been mutated to code for different amino acids. These rPrPs were 
tested in dose response experiments in order to investigate whether the change at 136 
position in ovine PrP could impact on the ability to inhibit or stop the prion protein 
misfolding compared to previously tested rVRQ. In order to produce rPrP mutants at 
codon 136, site-directed mutagenesis was used. All rPrPs were purified by metal affinity 
chromatography taking advantage of the metal binding properties of PrP molecule. All 
mutated rPrPs were added to protein misfolding cyclic amplification (PMCA) at different 
concentration and compared to rVRQ. After amplification, samples were digested with 
Proteinase K (100 µg/ml) and quantified on immunoblots. The best inhibitors were 
tested with different ovine scrapie (ARQ/VRQ, VRQ/VRQ, AHQ/VRQ), bovine BSE and 
ovine BSE isolates (ARQ/ARQ). The results showed that three of the recombinant prion 
proteins: rRRQ, rKRQ and rPRQ (with arginine, lysine and proline at 136 position, 
respectively) were found to inhibit the PrPSc misfolding significantly better than naturally 
occurred rVRQ.  
The structure of rPrP variants and amino acid substitution at 136 position were analysed 
and different length peptides containing the valine, arginine, lysine and proline at 136 
position were designed. None of these peptides analysed in PMCA gave similar levels of 
inhibition to the equivalent full length recombinant prion protein response. Moreover, 
structural analysis showed that introduction of longer amino acids at position 136 did 
not alter the whole scaffold of prion protein. In addition, the longer side chains for 
arginine136 and lysine136 or pyrrolidine loop in proline could result in more interatomic 
bonding in comparison to valine136 and therefore could act to stabilize the whole PrP 
molecule. Furthermore, the presence of the longer side chains of arginine136 and 
lysine136 would not predict further structure changes because of the ‘structural’ pocket 
present on the opposite site of position 136 in ovine PrP.  
The Rov9 cell line could be persistently infected with processed (heated and sonicated) 
scrapie brain homogenate SSBP1 (VRQ/VRQ) and SSBP1 derived, NaPTA precipitated 
PrPSc. In both cases, PrPres was detected in cell lysates from induced with 1 µg/ml 
doxycycline and when 500 µg of total protein was digested with 20 µg/ml of PK followed 
by PrPres concentration by centrifugation. The best inhibitory rPrPs were used in 
experiments to prevent the infection with SSBP1 isolate or reduce the PrPres in 
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persistently infected Rov9 cells. As a result, addition of 250 nM of rRRQ, rKRQ and rPRQ 
prevented the infection of Rov9 cells at culture passage 1. The rPrP variants showed 
more promising results than natural rVRQ. In contrast, no significant reduction of PrPres 
was observed when persistently infected Rov9 cells were treated with 250 nM of either 
variants or natural rPrPs for 4 days.  
Overall, this work demonstrated a novel therapeutic approach for prion diseases using 
recombinant prion proteins. The recombinant protein treatment was effective not only 
in scrapie model but also among other TSEs and therefore these rPrPs or analogous 
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RT-QuIC Real time quaking induced conversion 
S Serine 
sCJD Sporadic Creutzfeldt-Jakob Disease 
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SDS Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis  
SiO2 Silicon dioxide 
SMA Powdered milk 
SNCA α-synuclein gene 
SOD Superoxide dismutase 
sPMCA Serial protein misfolding cyclic amplification 
T  Threonine 
TBS Tris buffered saline 
TBST Tris buffered saline with 0.05 % tween 20 
ThT Thioflavin T 
TNTs Tunnelling nanotubes 
TSE Transmissible Spongiform Encephalopathy 
µg Microgram 
µl Microliter 
µM Micromolar  
V Valine or Voltage 
v/v Volume per volume 
vCJD New variant Creutzfeldt Jakob Disease 
VPSPr Variable Protease-Sensitive Prionopathy 
W Tryptophan or Watts 
w/v Weight per volume 










1.1 Transmissible Spongiform Encephalopathies 
Transmissible spongiform encephalopathies (TSEs, also known as prion diseases) are 
a group of progressive, fatal neurodegenerative disorders with no treatment or cure. 
Among this group are both human and animal diseases. These disorders are 
characterised by spongiform changes within the neural tissue resulting in neuronal loss 
and this occurs without an inflammatory reaction. Furthermore, the incubation period is 
typically very long (Prusiner, 1998; Belay, 1999). The main pathological event that is 
thought to occur in these diseases is the conversion of a benign cellular protein (cellular 
prion protein, PrPC) into a unique conformation called PrPSc. This misfolded protein then 
accumulates in neuronal tissue, a process accompanied by neurodegeneration.  
1.1.1 Human Prion Diseases 
Human prion diseases can be inherited (familial), transmitted (acquired via medical 
procedures (iatrogenic)) or meat consumption) and sporadic. Inherited forms of human 
TSEs include familial Creutzfeldt Jakob Disease (fCJD), FFI (fatal familial insomnia) and 
GSS (Gerstmann-Sträussler-Scheinker syndrome) (Belay, 1999; Chesebro, 2003). 
Inherited human prion diseases are mostly associated with point mutations within the 
prion protein gene (PRNP) or changes in the number of octapeptide-repeats within the 
protein sequence (Belay, 1999). In FFI, for example, a mutation at codon 178 in the 
PRNP gene results in substitution of aspartic acid (D) to asparagine (N). This event is 
the main trigger for the disease development and no exposure to the TSE agent is 
needed for the progression of inherited TSE forms (Forloni et al., 2013). Additionally, 
two different mechanisms were proposed for sporadic TSE occurrence in humans (sCJD 
and sporadic FI (fatal insomnia)) (Puoti et al., 2012). The first suggests that there is 
a sporadic, somatic mutation, which causes PrPSc formation and aggregation, while the 
second mechanism describes spontaneous formation of PrPSc in neural tissues (Belay, 
1999; Colby and Prusiner, 2011). Furthermore, there is no clear evidence that exposure 
to the TSE agent might trigger the sporadic TSE development in patients (Chesebro, 
2003). On the other hand, transmitted prion diseases have been described as a direct 
result of prion disease agent exposure. For example, iatrogenic CJD (iCJD) developed in 
patients treated with prion contaminated growth hormone or gonadotropins and after 
brain tissue implants from TSE infected patients. Furthermore, PrPSc was also 
transferred into healthy patients during the use of contaminated electroencephalogram 
(EEG) electrodes or neurosurgical instruments (Will, 2003).  
A distinct TSE in humans is kuru, an acquired disease described in the Papua New Guinea 
Fore people, spread through the ritualistic ingestion of TSE infected brain tissue of dead 
tribe members (Belay, 1999). vCJD was similarly acquired through the oral route as 
a result of BSE transmission to human via BSE contaminated meat (Will et al., 1996; 
Chesebro, 2003). In comparison to sporadic CJD, vCJD is characterised by early disease 
symptoms and other distinct neuropathological changes within the brain tissue 
(Chesebro, 2003).  
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Also, an atypical human prion disease – Variable Protease-Sensitive Prionopathy 
(VPSPr) – has been described. VPSPr exhibits distinct features from other human prion 
diseases. In these cases, the PrP from patients has distinct biochemical characteristics 
to previously analysed human TSEs, for example it is unusually sensitive to proteases. 
Furthermore, the clinical disease progression is relatively slow and brain tissues show 
different PrP immunostaining patterns in comparison to other human TSEs (Gambetti et 
al., 2008; Zou et al., 2010, 2013).  
1.1.2 Animal prion diseases 
Animal TSEs include a range of diseases affecting food related animal species. These 
include scrapie in sheep and goats, BSE (bovine spongiform encephalopathy) in cattle 
and CWD (chronic wasting disease) in deer. 
Scrapie was the first described prion protein disease, although the scrapie agent was 
unknown at the time (Stockman, 1913). Susceptibility and resistance to scrapie in sheep 
seems to depend mainly on the polymorphisms at positions 136, 154 and 171 within 
the PrP protein sequence (Belt et al., 1995; Goldmann, 2008). Furthermore, a different 
type of sheep scrapie, now described as atypical or Nor98, was identified in Norway in 
2003 (Benestad et al., 2003). In comparison to classical scrapie, atypical scrapie was 
described in animals with ARR (alanine136, arginine154, arginine171) genotype which is 
highly resistant to classical scrapie but also in ARQ (alanine136, arginine154, glutamine171) 
and AHQ (alanine136, histidine154, glutamine171) animals (Benestad et al., 2003; Moum 
et al., 2005; Arsac et al., 2007; Luhken et al., 2007). In addition, polymorphisms at 
positions 141 (change from leucine (L) to phenylalanine (F)) were found in atypical 
scrapie cases that may influence susceptibility (Moum et al., 2005; Luhken et al., 2007). 
Furthermore, phenylalanine at 141 position was usually found associated with ARQ 
polymorphisms in sheep (A136F141R154Q171) (Luhken et al., 2007; Andréoletti et al., 
2011; Silva et al., 2018). The main difference between these two forms of scrapie is 
that classical scrapie can spread through the lymphatic system as well as the central 
nervous system (CNS) and peripheral nervous system, while PrPSc deposits in atypical 
scrapie affected sheep were limited to brain (Benestad et al., 2003; Buschmann et al., 
2004; Nentwig et al., 2007; Vascellari et al., 2007; Vidal et al., 2008; Maddison, Baker, 
et al., 2010; Andréoletti et al., 2011). Different patterns of spongiform changes in the 
brain were noted for atypical scrapie compared to classical scrapie, suggesting that PrPSc 
deposits are distributed in a different way (Benestad et al., 2003). In addition, atypical 
scrapie was described as a spontaneous disease affecting older animals rather than an 
infectious disease, with probable influence from genetic or environmental factors 
(Benestad et al., 2008; Fediaevsky et al., 2009). The PrPSc of these two diseases also 
differs biochemically, after Proteinase K (PK) treatment, western blot analysis of atypical 
scrapie cases displays distinct PrPSc band patterns to classical scrapie. First of all, these 
two forms of scrapie differ in a number of bands on western blot with classical scrapie 
having 3 bands and Nor98 having up to 5 bands. Secondly, the di-glycosylated band 
 24 
shows higher molecular weight for atypical scrapie than classical, giving bands at around 
31 kDa and 27-28 kDa, respectively. Moreover, a fast migrating band was detected for 
atypical scrapie at around 11-12 kDa or 7-8 kDa, whereas for classical scrapie display 
the smallest band is at around 19 kDa (Arsac et al., 2007; Benestad et al., 2008). 
BSE is a prion protein disease in cattle. It was firstly described in the United Kingdom 
in 1986 (Wells et al., 1987). BSE is a unique prion disease that can cross the species 
barrier and appear in unrelated species via natural infections. Because of this feature, 
it was linked to human vCJD and BSE-like tissue changes in greater kudu and goats 
(Will et al., 1996; Cunningham et al., 2004; Spiropoulos et al., 2011). In addition, it 
has been reported, that BSE also had some atypical forms called L- (also known as 
bovine amyloidotic spongiform encephalopathy – BASE) and H-BSE. One of the 
differences between classical BSE (C-BSE) and the atypical forms is the migration profile 
of the PK-resistant PrPSc bands shown on western blots. In all forms of BSE, three bands 
are present on blots but in H-type, the PK resistant core migrates higher than C-BSE 
and in L-BSE this migrates lower (Biacabe et al., 2007; Jacobs et al., 2007). 
Furthermore, C-type BSE seems to be more resistant to PK digestion than the atypical 
forms of BSE (Jacobs et al., 2007). After tissue staining, the pattern of L-BSE amyloid 
plaques was different than in classical BSE, whereas for H-type there were no differences 
that allow to differentiate from C-BSE types based on PrPSc deposits in brain (Casalone 
et al., 2004; Sisó et al., 2007). Moreover, atypical BSE forms were described as sporadic 
affecting older animals compared to infectious C-BSE (Biacabe et al., 2004).CWD 
(chronic wasting disease) is a prion disease found in the Cervidae family, including elk, 
deer, reindeer and moose. It was reported in both free-ranging and captive animals, 
with transmission routes being investigated. Within the CWD cases, abnormal prion 
protein was detected in tonsil lymph nodes, follicular dendritic cells and also in gut 
associated lymphoid tissues (Sigurdson et al., 1999; Miller et al., 2004). Some reports 
indicate that the CWD occurrence might be associated with some polymorphisms within 
the Prnp gene, however the correlation between polymorphism and disease 
susceptibility or resistance is not as strong as in scrapie cases (Johnson et al., 2003; 
Robinson et al., 2012; Hoover et al., 2017).All animal prion diseases are a major concern 
for food security because these TSEs affect food chain species and the transmission 
routes still remain unclear. Furthermore, there is a possibility that they might be 
transferred to humans, as BSE causing vCJD has shown. Therefore, surveillance 
programs and regulations were established to monitor animal TSE cases and try and 
reduce their incidence in food producing animals.  
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1.1.3 Prion diseases occurrence 
In the UK, the most common animal prion diseases have been scrapie in sheep and BSE 
in cattle. The first scrapie case was described in 1853 in the UK, and since then many 
scrapie cases have been reported both in the UK and around the world (Stockman, 
1913). In the UK in recent times, scrapie was an endemic disease in sheep and goats. 
In order to help with the reduction of scrapie prevalence in the UK, in 2001 the National 
Scrapie Plan (NSP) was introduced (Table 1.1.1). The program consisted of identifying 
sheep as being in 1 of 5 genotype groups based on susceptibility to classical scrapie, 
where group 5 is the highest scrapie susceptibility and group 1 is the lowest risk for 
scrapie development (Goldmann, 2008). The NSP aimed to breed sheep in the UK to 
increase the levels of genetic resistance of the UK flock to scrapie. This breeding 
programme along with increased surveillance and culling of diseased animals resulted 
in the incidence of classical scrapie disease being 0 cases in 2018 (Animal and Plant 
Health Agency, 2019b). BSE was recognised in 1986 in UK cattle and became 
established as an epidemic (Belay, 1999). Nearly 180,000 cases of BSE were confirmed 
in the UK with the peak of the epidemic in early 1990s (Animal and Plant Health Agency, 
2019a). Moreover, the first reported case of BSE outside the UK was in 1989 in Ireland 
and then more BSE cases were described in Europe and North America. Since then, the 
number of classical BSE cases has decreased due to effective control measures and in 
2017 for the first time since the BSE outbreak, no cases of classical BSE were reported 
(World Organisation for Animal Health, 2019). Although the disease source might be 
eliminated (thought to be BSE contaminated meat and bone meal feed), it is possible 
that infectious prions could be present in the environment and act as a reservoir of 
infectivity. 
Chronic wasting disease (CWD) was first reported in captive deer in the USA State of 
Colorado in late 1960s. Subsequently, cases in wild deer were confirmed (Williams and 
Young, 1980). Since then, the disease has spread in free-ranging cervids and is 
established in 24 US states or Canadian provinces (Centers for Disease Control and 
Prevention, 2019). Furthermore, CWD was also reported in South Korea after a CWD 
infected elk was imported from Canada (Sohn et al., 2002). In addition, the first 
European case was reported in March 2016 in Norway. From that time, Norway has 
detected 23 cases of CWD (data until September 2019). The first reported case of CWD 
in the European Union (EU) was in Finland (March 2018) and since then, new cases were 
also reported in Sweden (Koutsoumanis et al., 2019). So far, there are no cases of CWD 
reported in the UK and the risk of importing infectivity is estimated to be very low (Gale 
and Roberts, 2018). 
In humans, the most common form of human prion disease is sporadic sCJD with the 
number of sCJD cases increasing in the UK from 48 in 2000 to 135 cases in 2018. 
Worldwide, sCJD occurred at 2.06 cases per million in 2018. Also, iatrogenic and genetic 
CJD cases are being reported at lower levels (NCJDRSU, 2019). Moreover, it is now 
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established that BSE transmission to humans via consumption of meat contaminated 
with infectious prions has affected 178 people in the UK with the last reported case of 
new variant CJD (vCJD) in 2016 (NCJDRSU, 2019).  
Table 1.1.1 Ovine genotypes occurring in sheep in the UK and their degree of 
resistance/susceptibility to scrapie according to the National Scrapie Plan. Adapted from 
(DEFRA, 2001). 
 Genotype 








Resistant to scrapie  








Little resistance to scrapie 
Yes, but with 
caution 





Highly susceptible to scrapie  No 
 
1.1.4 TSE transmission 
TSE transmission is a considerable concern after the interspecies transmission of BSE 
to humans and other animal species via presence of cattle BSE in meat/feed. Despite 
this, there is no evidence of other TSEs transmissibility to distinct, non-related species 
outside of a laboratory setting. However, the possible routes of infectious prion secretion 
and excretion, environmental storage, and animal uptake are being investigated (Table 
1.1.2).  
Infectious prions are released from the body of sick or dead animals via many routes 
(Gough, Baker, et al., 2015). For both classical scrapie and CWD, TSE agent is shed 
from nasal and oral secretion, in urine, faeces, milk, blood, antler velvet and skin. In 
addition, possible transmission of infectivity through placenta from infected mothers to 
offspring (in utero transmission) was described for both scrapie and CWD (Race, Jenny 
and Sutton, 1998; Tuo et al., 2001, 2002; Andréoletti et al., 2002; Miller and Williams, 
2003; Nalls et al., 2013). Infectivity could also derive from decomposed or buried 
carcasses of infected animals for many years after death (Brown and Gajdusek, 1991).  
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(Maddison, Rees, et al., 2010; 
Gough et al., 2012) 
Milk 
(Maddison, Whitelam and Gough, 
2007; Konold et al., 2008; 
Maddison et al., 2009) 
Skin (Thomzig et al., 2007) 
Placenta 
(Race, Jenny and Sutton, 1998; 
Tuo et al., 2001, 2002; 
Andréoletti et al., 2002) 
Urine (Murayama et al., 2007) 
C-BSE 
Contaminated meat and tissues 
(and to different species) 
(Will et al., 1996; Bruce et al., 
1997; Bons et al., 1999; 
Cunningham et al., 2004; Jeffrey, 
González, et al., 2006; Jeffrey, 
Martin, et al., 2006) 
CWD 
Saliva 
(Sigurdson et al., 1999; Mathiason 
et al., 2006; Haley et al., 2009; 
Denkers, Telling and Hoover, 
2011; Henderson et al., 2013) 
Nasal/aerosol (Denkers et al., 2013) 
Semen (Kramm et al., 2019) 
Urine (Haley et al., 2009) 
Faeces (Cheng et al., 2016) 
Antler velvet/skin (Angers et al., 2009) 
Blood (Mathiason et al., 2006) 
Placenta (Miller and Williams, 2003) 
Human TSEs 
vCJD Blood (Llewelyn et al., 2004) 
iCJD 
Neurological medical equipment 
(eg. EEG equipment) 
(Bernoulli, Siegfried and 
Baumgartner, 1977; Will and 
Matthews, 1982; Will, 2003) 
Contaminated growth hormone 
(hGH) 
(Centers for Disease Contol, 1985; 
Gibbs et al., 1985; Koch et al., 
1985) 
Dura mater grafts (Thadani et al., 1988; Will, 2003) 
 
Once released to the environment, prions can bind to soil minerals, remain infectious 
and act as a disease reservoir (Johnson et al., 2006; Genovesi et al., 2007; Maddison 
et al., 2015). In the environment, TSE infectivity can survive for several years. Studies 
showed that CWD derived PrPSc was found on the surfaces 2 years after CWD affected 
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animals were present, and scrapie infectivity was detected on a farm even after a 16 
year period (Williams, 2005; Georgsson, Sigurdarson and Brown, 2006). In this period 
of time, susceptible animals can come into contact with prions on fomites or soil particles 
containing the PrPSc could be taken up by an animal. It has also been suggested that 
plants could bind and retain the PrPSc from soil via roots, leading to transport of the TSE 
agents to leaves and stems creating another source of infectivity (Pritzkow et al., 2015). 
Moreover, research conducted by Maddison et al., showed the presence of PrPSc on 
metal, concrete, wood and plastic fomites on a farm, indicating  environmental 
reservoirs of prion (Maddison, Baker, et al., 2010). Another study conducted by Konold 
et al., demonstrated that scrapie could indeed be transmitted via these fomites when 
susceptible sheep were exposed to them (Konold et al., 2015). A further study 
investigated the possibility of prion transmission after binding to fomites (wood, rock, 
cement, aluminium, glass, stainless steel or polypropylene). Not only were prions able 
to bind to these surfaces but the PrPSc could seed in vitro amplification assays and was 
infectious in hamster bioassays. Furthermore, the same study found that, animals could 
take up the environmental prions by direct exposure such as by licking or sniffing. Also, 
direct transfer of the prions to the bedding site also resulted in infection of the animals, 
although this transmission method gave the lowest attack rate (Pritzkow et al., 2018). 
Further studies have also shown that scrapie prions can be spread via dust on an 
‘infected farm’. It was also shown that PrPSc were detected on the surfaces that were 
not in any direct contact with sick animals, Indeed, scrapie PrPSc was found in the dust 
samples collected at 30 m distance from farm buildings (Gough, Baker, et al., 2015). 
In order to investigate the risk of prion transfer from interred tissues of dead animals, 
mouse passaged BSE was experimentally buried for a 5 year period and area 
surrounding soils and rainwater samples that has passed through the site were collected 
and analysed. It appeared that the BSE infectivity survived at very high titres in the 
brain tissue for the study duration. Additionally, only limited migration of prion through 
the soil was observed. However, some prion was seen in rainwater that had passed 
through the burial site. This research showed the importance of having contained burial 
sites for any prion infected animals and in particular for those affected with BSE 
(Somerville et al., 2019).  
1.2 Cellular prion protein 
The normal prion protein, also known as cellular prion protein PrPC, is a membrane 
attached glycoprotein encoded by a host Prnp gene. In humans PRNP gene is localised 
on the short arm of chromosome 20 and is built from 2 exons, with the entire open 
reading frame (ORF) for prion protein localised within the second exon (Prusiner, 2004; 
Mead, 2006). PrPC has several distinct domains and also undergoes post translational 
modification (Figure 1.2.1). Briefly, PrPC is translated from the mRNA in the 
endoplasmic reticulum and after the polypeptide chain is created, the N-terminal signal 
peptide and GPI-anchor signals are cleaved (Hope et al., 1986). The 
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glycosylphosphatidylinositol (GPI) anchor is added to serine (S) at position 231 and then 
the protein is carried through the Golgi apparatus, where the N-glycan chains are added 
to some of the asparagine residues at positions 181 and 197. The N-terminal domain of 
PrPC is built from a nonapeptide (PQGGGGWGQ) followed by nine octapeptide repeats 
(OR) with 4-6 copper ion binding sites (Acevedo-Morantes and Wille, 2014). On the C-
terminal, cysteines (C) at positions 179 and 214 are connected with a disulphide bond. 
The processed and glycosylated PrPC is transported to the cell surface and attached to 
lipid rafts in the cell membrane through the GPI anchor (Maiti and Surewicz, 2001; 
Mead, 2006; Acevedo-Morantes and Wille, 2014). Mammalian PrP protein sequences 
are homologous in more than 90 % of residues and only differ in, for example, N-
glycosylation or disulphide bond sites (Groschup, Harmeyer and Pfaff, 1997). 
 
 
Figure 1.2.1. Human PrPC structure. After translation, human PrP consists of 253 amino 
acids and its N-terminus contains: a signal peptide (1-22), octapeptide repeats with 
Cu2+ binding sites (51-90), a hydrophobic region (113-135), and on the C-terminus: 
a disulphide bond between cysteines at positions 179 and 214, two N-glycosylation sites 
on asparagine at 181 and 197 residues and a GPI-anchor signal peptide. GPI – 
glycosylphosphatidylinositol, PK – proteinase K. Adapted from (Acevedo-Morantes and 
Wille, 2014), modified.  
On the other hand, the sheep Prnp gene is localised on chromosome 13 and in 
comparison to the human gene, ovine Prnp contains 3 exons and 2 introns. The whole 
ORF is contained within the longest, 3rd exon. Furthermore, the ovine prion protein is 
longer than human PrP and contains 254 amino acids and bovine PrPC contains 264 
amino acids (Yoshimoto et al., 1992; Goldmann, 2008). The main difference between 
the PrP sequences between species is usually the presence of different numbers of 
octapeptide repeats in the protein sequence (Yoshimoto et al., 1992; Schläpfer et al., 
1999). 
Many attempts have been made to obtain complete three-dimensional (3-D) structure 
of PrPC, however the most accurate structural information comes from nuclear magnetic 
resonance (NMR) studies of recombinant prion protein (Figure 1.2.2). So far, NMR 
data has been obtained for the globular, C-terminal structure of recombinant mouse, 
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hamster, sheep, human and bovine PrP (Donne et al., 1997; Riek et al., 1997; Zahn et 
al., 2000; Lopez Garcia et al., 2002; Haire et al., 2004). In general, within the globular 
domain (C-terminus) of the prion protein three α-helices and an anti-parallel β-sheet is 
present. Furthermore, the disulphide bridge connects helices 2 and 3 (Riesner, 2003). 
The N-terminus of PrP is more flexible than the globular C-terminus and as mentioned 
before, its main feature is an OR region with copper ion binding sites and a hydrophobic 
region (Zahn et al., 2000; Riesner, 2003). Overall, the benign cellular prion protein 
structure contains more α-helices than β-sheets and because the PrP sequence is highly 
conserved between mammalian species, the 3-D structure between species is very 
similar (Zahn et al., 2000). 
 
Figure 1.2.2. Ovine PrPC structure. Protein N-terminus is flexible, whereas the C-
terminus is highly structured and contains three α-helices and an anti-parallel β-sheet. 
The figure was generated using Phyre2 and EzMol1.3 software. 
Cellular prion protein is attached through the GPI anchor to lipid rafts on the cell 
membrane. Research using antibodies against different parts of the prion protein (C-, 
N-terminus and central protein regions) has also localised the PrPC to different cellular 
structures within murine cells: e.g. on the Golgi complex, endoplasmic reticulum, and 
on the plasma membrane (Naslavsky et al., 1997; Mironov et al., 2003). Moreover, PrPC 
was also found in the cell nuclei and mitochondria (Gu et al., 2003; Hachiya et al., 2005; 
Morel et al., 2008; Sorice et al., 2012). In addition, for some brain regions like 
hippocampus, thalamus and neocortex, cellular prion protein was also observed in the 
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neuron’s cytoplasm. Despite the fact that PrPC is synthesised at relatively high levels in 
neurons in the CNS compared to other tissues and cell types, the amount of mRNA 
differs between brain regions from relatively high levels in hippocampus or neocortex to 
very low levels in internal regions of the cerebellum. The same amounts of PrPC were 
found in the pre- and postsynaptic membranes. Apart from brain tissue and CNS, 
relatively high expression levels of PrPC were also found in heart and lungs, while lower 
levels were found in spleen or intestinal epithelial cells, keratinocytes and brain 
endothelial cells (Manson et al., 1992; Morel et al., 2004, 2008; Viegas et al., 2006; 
Wulf, Senatore and Aguzzi, 2017). 
The biological function of the normal prion protein is still being investigated and several 
possible roles have been suggested. Its presence in pre- and postsynaptic membranes 
might be correlated to synaptic ion channels and receptor control. Moreover, some 
studies indicate that PrPC probably participates in neurobiological processes like memory 
and sleep regulations, while other authors describe a possible role for PrP in murine 
embryo development (Manson et al., 1992; Mironov et al., 2003; Wulf, Senatore and 
Aguzzi, 2017). Furthermore, a role for prion protein in apoptosis was described and 
different sources indicate that PrP might act as either a protector or an apoptosis 
stimulator and the function is determined by PrPC intra- or extracellular localization 
(Sorice et al., 2012). Alternatively, the presence of PrPC in the nucleus of actively 
dividing cells suggests that it might take part in cell division (Morel et al., 2008). 
Furthermore, GPI-anchored PrPC might contribute in cell–cell and cell–extracellular 
matrix adhesion and even mediate some signals between these structures For example 
for intestine endothelium enterocytes, where PrPC was found to interact with adhesion 
proteins e.g. β- or -catenin (Morel et al., 2004; Besnier et al., 2015). As mentioned 
previously, the PrP sequence contains copper binding sites, therefore a role in copper 
binding and metabolism is also possible. Moreover, copper binding with the cellular prion 
protein might activate some protein shape changes from α-helices to β-sheets, therefore 
it is possible that copper binding promotes PrPSc formation or even starts the pathogenic 
process (Stöckel et al., 1998). 
1.3 Disease associated prion protein 
The first scrapie cases in England were dated back to 1853. From that time, many 
different attempts to characterise the ‘scrapie agent’ were performed (Stockman, 1913). 
Until Prusiner’s seminal publication in 1982, scrapie and other neurodegenerative 
diseases were thought to be caused by a ‘slow virus’ (Hadlow, 1959; Hadlow et al., 
1980). The term ‘prion’ was introduced by Prusiner for small ‘proteinaceous infectious 
particles’. This ‘particle’ was described as UV radiation, ionisation resistant and stable 
in high temperatures (Prusiner, 1982). Moreover, the prion protein coding mRNAs were 
analysed and compared between healthy and diseased brains. Oesch and co-workers 
reported that both forms of prion protein – healthy and misfolded – are encoded by the 
same gene and its expression is at the same level between healthy and diseased brain 
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tissues. They suggested that during post translational modifications PrP might be 
converted into two different forms. However, Taraboulos et al., published that one of 
the post translational alterations – N-glycosylation – had no impact on resistant prion 
protein levels (Oesch et al., 1985; Taraboulos et al., 1990). Since this time, many 
attempts have been performed and a range of methods used to describe the prion agent. 
Research showed that the PrPC and disease associated prion protein, PrPSc, have the 
same amino acid sequence but they differ in their secondary and tertiary structure and 
also in biochemical properties with the major structural difference between them being 
the content of α-helixes and β-sheets. The amount of α-helix content changes from 
40 % in PrPC to 30 % in PrPSc, while nearly undetectable amounts of β-sheets in PrPC 
increase to 45 % in PrPSc. This structural conversion is the major factor involved in prion 
disease associated tissue neurodegeneration (Pan et al., 1993). Furthermore, in 
comparison to cellular prion protein, PrPSc has a protease resistant core and is insoluble 
in detergents (Taraboulos et al., 1990; Pan et al., 1993). Proteinase K digestion only 
partially digests PrPSc (around 80 amino acids are truncated from both N- and C-termini) 
leaving the protease resistant core, also called as PrP27-30, while under the same 
conditions, cellular prion protein is completely digested (Oesch et al., 1985). In addition, 
the truncated PrPSc is still infectious (Wille et al., 2002). When PK digested samples are 
analysed on a western blot, a characteristic three band pattern is shown, with bands 
derived from the 3 possible glycosylation states of PrP protein: un-glycosylated, mono-
glycosylated and di-glycosylated (Hunter, 2003). Furthermore, the size and relative 
abundance of each band differs between prion diseases and this feature is one of the 
distinguishing methods for prion disease strains (Jacobs et al., 2011). Structurally 
modified PrPSc is prone to aggregate within the tissue creating amyloid fibrils and these 
aggregates of misfolded PrPSc in the brain tissue are characteristic for prion diseases 
(Taraboulos et al., 1990).  
1.3.1 PrPSc dissemination within the body 
The understanding of the mechanisms involved in PrPSc infection of various cells and 
tissues is extremely important in order to understand TSE pathogenesis (Brown, 1997). 
The most common way of prion infection in natural infections is via the oral route, 
however other routes cannot be excluded. But whether and how the disease will develop 
depends on many different factors including host PrP genotype, TSE strain and 
genotype, and the dose of TSE agent (Beekes and McBride, 2000; Van Keulen, Vromans 
and Van Zijderveld, 2002). For infectious prion spread within tissues, expression of 
cellular prion protein on the cell membrane is necessary (Brandner et al., 1996; 
Caughey et al., 2009). After prions are delivered orally, they travel to the intestine and 
cross the intestinal epithelium. Many different intestine epithelium cells have been 
implicated in prion transport and mechanisms have been proposed. The first hypothesis 
describes PrPSc entering the intestine epithelium due to the β-sheet rich structure, while 
other theory shows that the epithelial cells such as M cells or dendritic cells capture 
 33 
infected prions from the intestine lumen (Cobb and Surewicz, 2009; Natale et al., 2011). 
Next, the PrPSc is transported along the epithelium, where it is phagocytosed by either 
macrophages or dendritic cells and transported to gut-associated lymphoid tissue 
(GALT). Here, transported cells are in contact with follicular dendritic cells (FDC) on the 
Peyer’s patches. FDCs express high levels of cellular prion protein and their main role is 
to catch and present antigen on their surfaces. Therefore, these cells can trap and keep 
infectious prions on their cell membranes and are replication sites for prions in 
lymphoreticular system (LRS) tissues (McCulloch et al., 2011; Bradford, Crocker and 
Mabbott, 2014). The PrPSc then starts to accumulate and amplify within the GALT 
(Beekes and McBride, 2000; Cobb and Surewicz, 2009). Studies using transmissible 
mink encephalopathy showed that PrPSc may be accumulated in the spleen, however 
other research with mouse adapted scrapie (263K strain) demonstrated that 
accumulation of prions in spleen was not an absolute requirement (Hadlow, Race and 
Kennedy, 1987; Race, Oldstone and Chesebro, 2000). The dissemination routes and 
involvement of particular LRS tissues is likely to be dependent of host Prnp genotype, 
the strain of invading prion and the entry route to a body (Figure 1.3.1). Prion strains 
that are more neuroinvasive could propagate more efficiently in lymphoid tissues and 
intensify neuroinvasion. Furthermore, the spreading process could depend on the size 
of prion aggregates, with smaller aggregates able to penetrate the peripheral nerves 
more easily than large amyloid deposits. In addition, stability of the specific strain 
aggregates may also play a role – instable strains will generate high doses of small 
infectious prion particles. These small fragments facilitate effective spreading of 
infectivity within peripheral nerves. As a result, higher strain stability can cause longer 
disease incubation times (Bett et al., 2012). These multiple factors explain why there 
are many differences in finding PrPSc deposits in different tissues at different disease 
stages between cases. In sheep scrapie, the LRS involvement depends on Prnp 
genotype. Langeveld et. al., reported that VRQ (both homo and heterozygote) animals 
showed PrPSc positive deposits in LRS much earlier than in the brain tissue. The only 
exception from this are sheep with genotype VRQ/ARR, which usually show no LRS 
involvement but with some exceptions (Ersdal et al., 2003; Langeveld et al., 2006). In 
addition, no deposits in LRS were reported for either atypical scrapie or CH1641 strains 
(Benestad et al., 2003; Jeffrey, González, et al., 2006). It is considered that after 
accumulation in the GALT, PrPSc starts neuroinvasion, spreading firstly to the enteric 
nervous system (ENS) and next to the CNS (Natale et al., 2011). It was described that 
PrPSc moves to neurons associated with GALT or epithelial cells through direct contact 
via axons or dendrites (Natale et al., 2011). This transport might be possible e.g. due 
to significantly reduced or even absent myelin layer on nerves (Kimberlin, Hall and 
Walker, 1983). In addition to that, FDC have also been found close to sympathetic nerve 
fibres, suggesting that this could also be a route into the peripheral nervous system 
(PNS) (Glatzel and Aguzzi, 2000; Davies et al., 2006). The involvement of the 
sympathetic nervous system was described e.g. in vCJD patients (Haïk et al., 2003). 
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Once in the PNS, PrPSc could travel using either axonal or non-axonal transport or even 
using the Schwann cells (Glatzel and Aguzzi, 2000; Glatzel et al., 2001). A ‘domino 
mechanism’ has been described, in which transported PrPSc entering a neuronal tissue 
acts as a template for the PrPC expressed in that tissue, which then misfolds (Race, 
Oldstone and Chesebro, 2000; Glatzel et al., 2001; Natale et al., 2011). Moreover, the 
PrPSc could be transferred between nerves and into the CNS by retrograde transport 
(Bartz, Kincaid and Bessen, 2002). The analysis and understanding of PrPSc spread 
within the body may help to develop new therapeutic approaches and targets (Bradford, 
Crocker and Mabbott, 2014). 
 
  
Figure 1.3.1. The PrPSc neuroinvasion route depends on the administration route. After 
oral administration, PrPSc is more likely to propagate within GALT, from where it spreads 
to the peripheral nervous system through peripheral nerves. Next, it enters the CNS. 
After intraperitoneal injection, B-cells were described to play a crucial part in the spread 
into the spleen and CNS. i.p. – intraperitoneal, CNS – central nervous system. Adapted 
from (Glatzel and Aguzzi, 2000) (licence nr 5064751273253).  
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1.3.2 Prion protein propagation  
Analysis of the formation and structure of β-sheet rich prion protein aggregates is 
a challenge. As mentioned, the PrPSc aggregates are insoluble in detergents, heterogenic 
and the protein structure is fibrillar. Therefore methods based on NMR or X-ray 
crystallography were unsuccessful (Spagnolli et al., 2019). However, methods like FTIR 
(Fourier-transform infrared) spectroscopy and CD (circular dichroism), showed that 
PrPSc is characterised by high beta sheet content but details of the fibril formation 
process were still unknown (Requena and Wille, 2014). One of the crucial methods for 
visualising PrPSc is electron microscopy with some structure modelling (Requena and 
Wille, 2014). Using both, cryo-electron microscopy and structural analysis, a 4-rung β-
solenoid model was described with two types of parallel β-helical folds the right- and 
left-handed β-helices (Wille et al., 2002; Govaerts et al., 2004; Vázquez-Fernández et 
al., 2016). Left-handed β-helices (Figure 1.3.2, A) are formed by triangular rungs with 
usually 18 residues per rung and each triangle made of six residues. Then, parallel rungs 
can trimerize (Figure 1.3.2, B and C) where the three monomers assemble together 
at the β-sheet level. Moreover, the α-helices and glycans attached to the PrP structure 
are located outside the main fibril core. In comparison to left-handed β-helices, right-
handed β-helices are described as larger in diameter and much less regular. In addition 
to that, each rung in right-handed β-helices could be formed from 22 to 25 residues 
(Govaerts et al., 2004). In both kinds of β-helices, when the whole rung is formed, the 
most lower or upper parts can act as a ‘sticky surface’ and template for the unfolded 
prion proteins (Figure 1.3.3) (Wille and Requena, 2018). Furthermore, the differences 
in amino acid compositions on the rungs can cause many variations in the whole fibril 
structure, that could be the source of different prion strains (Wille and Requena, 2018). 
In addition, a different model of PrPSc structure – PIRIBS (parallel in-register 
intermolecular β-sheet) was also described, however this model is not entirely 
consistent with structural analysis data (Wickner et al., 2018; Baskakov et al., 2019). 
These proposed mechanisms of prions conversion are crucial for any structural 
therapeutic approaches that targets the misfolding process and PrPSc accumulation in 
the nervous tissue (Spagnolli et al., 2019).  
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Figure 1.3.2. Modelling of the 87-174 residues of PrP27-30. A – monomeric model of 
PrP27-30. B – Trimeric model of PrP27-30 monomers with α-helices located outside the 
main structure. C – PrP27-30 fibre model. Adapted from (Govaerts et al., 2004) 
(Copyright (2004) National Academy of Sciences, U.S.A.).  
Whether the PrPC conversion occurs on the cell membrane or during protein transport 
is still poorly understood, however, a two-step seeded polymerization mechanism was 
described for PrPC conversion. In the first part, PrPSc aggregates – ‘seeds’ - bind PrPC 
and in the second step, PrPC undergoes structural changes and is converted into PrPSc. 
In the 4-rung β-solenoid model, structure extension is provided by the lowermost or/and 
the uppermost rungs. These can act as a template for the unstructured or structured 
PrPC. Arriving cellular PrPC would interact with β-solenoid structure, create or change its 
conformation and self-template into a β-sheet rich molecule (Figure 1.3.3) (Wille and 
Requena, 2018). The PrPSc aggregates and fibrils then accumulate within the cell or 





Figure 1.3.3. Schematic PrPSc fibril extension with the approaching unfolded PrPC. This 
model shows only the uppermost rung extension, whereas additional extension from the 
lowermost rung has been proposed. The incoming unstructured PrPC molecule links to 
the β-solenoid structure and mimics the β-sheet rich configuration. Adapted from (Wille 
and Requena, 2018) (licence under the CC by 3.0). 
1.4 Mutations and polymorphisms within the Prnp gene 
Various mutations within the human prion protein gene can cause inherited prion 
diseases such as GSS, FFI and fCJD. Mutations within the PRNP gene usually include 
point mutations, where a single nucleotide is substituted and results in an amino acid 
change within the protein sequence. Other types of mutation found in the PRNP gene 
are insertion or deletion mutations usually within the OR region. In FFI, a mutation 
causing the change from aspartic acid (D) into asparagine (N) at position 178 in human 
PrP is thought to determine the disease (Medori et al., 1992; Medori and Tritschler, 
1993). Also, other missense mutations are associated with GSS. These include 
substitutions at different positions alongside the protein chain as well as insertion of the 
larger octapeptide fragments into the peptide chain (Hsiao et al., 1989, 1992; Kitamoto, 
Lizuka and Tateishi, 1993; Laplanche et al., 1999). Similarly, fCJD was correlated with 
single amino acid changes in the protein sequence and addition of octapeptide repeats 
(Goldfarb et al., 1991; Kitamoto, Lizuka and Tateishi, 1993; Peoc’h et al., 2000). In 
addition, polymorphisms were described within the prion protein amino acids sequence. 
These changes, in comparison to genetic mutations, are sequence variations that are 
common in the population. As a result, polymorphisms in both human and animal PrP 
do not lead to the prion diseases directly, however they may determine the possibility 
of developing a prion disease as they can determine susceptibility to the acquired 
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disease (Belt et al., 1995; Acevedo-Morantes and Wille, 2014). The most common 
polymorphism in the human gene is an amino acid change at codon 129. Here, the 
methionine (M) is substituted with valine (V) (Mead, 2006). Both, V/V and M/M 
homozygotes are over-represented in sporadic and iatrogenic CJD, whereas the M/V 
patients are described to have a level of resistance for these diseases. In variant CJD 
most cases were represented by 129 M/M with only one case reported recently being 
M/V (Mastrianni, 2010; Brown et al., 2012; Acevedo-Morantes and Wille, 2014; Mok et 
al., 2017). In contrast, polymorphism at position 219, where glutamate (E) is 
substituted with lysine (K), correlates with a resistant genotype for sporadic CJD 
(Acevedo-Morantes and Wille, 2014). Heterozygotes E/K were found to be 
underrepresented in sporadic CJD cases (Shibuya et al., 1998). In addition, both E/K 
and K/K patients could have an increased susceptibility to vCJD (Kobayashi et al., 2015). 
Similar to in humans, polymorphisms in animal Prnp genes can influence susceptibility 
to acquired prion diseases. A well-studied example is sheep where distinct Prnp genes 
have an impact on scrapie. These variations include a codon change at positions 136 
(alanine in valine), 154 (arginine in histidine) and 171 (glutamine in arginine/histidine), 
abbreviated as ARQ, ARR, ARH, VRQ etc. (Belt et al., 1995; Goldmann, 2008). ARR 
genotypes are associated with the highest disease resistance, whereas the VRQ 
genotype is correlated with disease susceptibility (Goldmann et al., 1994). These amino 
acid substitutions are the most commonly found, however other rare mutations at these 
positions have been reported e.g. T (threonine) instead of A/V at position 136, leucine 
(L) at position 154 and lysine (K) at position 171 (Billinis et al., 2004; Goldmann, 2008). 
However, these amino acid changes were not correlated to increased or decreased 
disease susceptibility (Billinis et al., 2004). Polymorphisms in goat PrP in relation to 
classical scrapie have also been described. In contrast to sheep PrP, the goat prion 
protein sequence is not polymorphic at 136 position, but the presence of histidine (H) 
at position 154 was described to have an impact on atypical scrapie development 
(Benestad et al., 2008; Mead, Lloyd and Collinge, 2019). Furthermore, the most studied 
polymorphisms in caprine PrP include changes at 222 position (Q/K) and N to S or D at 
146 position. These changes are correlated to scrapie resistance in European 
populations of goats (Acutis et al., 2006; Goldmann et al., 2011; Papasavva-Stylianou 
et al., 2011). In addition, a change at position 32 that translates into a stop codon has 
been described as natural in Norwegian Dairy Goats. This results in the presence of 
animals naturally lacking PrP (Benestad et al., 2012). In compare to ovine and caprine, 
the bovine prion protein sequence displays less alterations, with the most common 
change being alterations within the octapeptide repeats number (Goldmann, 2008). 
Moreover, a deletion or an insertion of a 12 or 23 base pair sequence in the Prnp gene 
promoter was recognised and corelated to susceptibility to BSE (Sander et al., 2004). 
Lastly, PrP polymorphisms that have an impact on CWD development were described. 
In elk, a change at position 132, where methionine is replaced with leucine was 
reported. This position corresponds to human 129 codon and research showed that 
 39 
homozygotes M/M at 132 codon correlates with susceptibility to CWD in both farmed 
and wild Rocky Mountain elk and wapiti (O’Rourke et al., 1999; Perucchini et al., 2008). 
Moreover, three other polymorphic positions (95, 96 and 116) were described in white-
tailed deer, where histidine, serine and glycine, respectively, were in the minority for 
CWD cases (Mead, Lloyd and Collinge, 2019). 
1.4.1 Prion strain concept  
Many different factors can lead to phenotypic variation between different prion diseases 
such as scrapie, BSE, CJD and also between distinct prion isolates within some of these 
diseases. Two possible mechanisms were described for the generation of ‘new’ prion 
strain that differs from the original PrPSc (Figure 1.4.1). Firstly, the cloud hypothesis 
reports that the single prion strain consists of multiple PrPSc conformers. Only 
a subgroup of these PrPSc conformers would develop within the new host and 
environment, therefore creating a new prion strain. Secondly, the deformed template 
theory hypothesised that none of the present conformers could adapt in the new 
environment leading to production of novel PrPSc derived from the original strain that 
would fit to the new host (Makarava and Baskakov, 2013). These two hypotheses are 
not exclusive, and both could participate in the emerge of new prion strains. Moreover, 
these explain the difference in prion diseases phenotypes. When these become stable 
over multiple transmissions within the same host they are known as prion strains 
(Collinge et al., 2007; Makarava and Baskakov, 2013). Moreover, these variations are 
being considered as biochemical changes and are not caused by genetic background 
(Murdoch and Murdoch, 2015). To analyse different variants, prion diseases were 
usually transmitted to rodent models. After the first transmission, incubation periods 
were usually long, however after subsequent passages within the same species and the 
same genetic background, some phenotypic changes, incubation times and other 
disease features stabilised (Gough, Rees, et al., 2015). So far, the best described rodent 
model for prion strain typing is mice. However, there are some drawbacks to this 
approach. These include the facts that many animals are required, the disease 
incubation periods are long and it is very difficult to determine the infection efficiency 
(Thackray et al., 2008). Furthermore, there are cases of both classical (e.g. ARQ/ARQ 
and ARQ/VRQ genotypes) and atypical scrapie, that cannot be transferred into specific 
mouse lines (Bruce et al., 2002; Thackray, Hopkins, et al., 2012). Recently, a bank vole 
model was described for TSE bioassays. In comparison to the mouse models, bank voles 
show susceptibility to all tested scrapie isolates, sporadic and familial CJD, BSE  and 
CWD (Cartoni et al., 2005; Nonno et al., 2006; Agrimi et al., 2008; Di Bari et al., 2008, 
2013; Watts et al., 2014). They also display much shorter incubation times, therefore 
bank voles are thought to be the most universal prion acceptor (Watts et al., 2014). 
The only TSE that shows lower transmission levels in bank voles is Variable Protease-
Sensitive Prionopathy (Nonno et al., 2019). Overall, prion strain typing bioassays in 
mammalian species require time, ethical consideration and are very costly. Therefore, 
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other methods or hosts need to be developed in order to reduce the use of animals, 
time of experiments and financial requirement. Recent studies showed that Drosophila 
melanogaster – fruit fly – can be used in a prion bioassay. The fruit fly was engineered 
to express ovine PrP and after oral exposure showed phenotypic changes characteristic 
for prion diseases like reduction of locomotion. One of the major features of this model 
is that fruit fly species multiply very quickly and the organism’s genetics is well known 
(Thackray, Muhammad, et al., 2012). However, all models based on non-mammalian 
species need to be considered carefully as whist they can demonstrate PrP pathology 
and could be used for transmission studies, the use of rodent models still allows more 
complex analysis and disease type differentiation (Younan et al., 2018). In addition, 
recent studies showed that Drosophila flies have been engineered to express rodent PrP 
with human FFI or fCJD mutations and this approach allowed comparison of the 
mutations’ effects on the flies. These tools could be potentially used to discover new 
prion diagnostic markers or therapeutics (Thackray et al., 2017).  
 
Figure 1.4.1. The cloud and deformed templating hypotheses. A – The cloud hypothesis 
the demonstrates that the single prion strain consists of multiple PrPSc conformers 
(shown in different colours). Only a subgroup of these PrPSc conformers would develop 
within the new host and environment. B – the deformed template theory presents that 
none of the PrPSc conformers adapt in the new host environment leading to production 
of novel PrPSc derived from the original isolate. Adapted from (Makarava and Baskakov, 
2013) (licence under the CC by 3.0). 
Other than animal bioassays, biochemical prion strain typing assays have been 
developed. Biochemical analysis uses the PK cleavage and glycosylation patterns of PrPSc 
on western blotting (Cobb and Surewicz, 2009). The glycosylation patterns are 
compared between different TSE isolates using an antibody that binds to the protease-
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resistant core region of PrP. An example is the differentiation of scrapie and BSE in 
sheep. In addition, the molecular weight of the lower, un-glycosylated band in scrapie 
is higher than that for BSE and can be used in diagnosis. Also, the highest, di-
glycosylated band, is more abundant in BSE than in scrapie (Hill et al., 1998; Stack, 
Chaplin and Clark, 2002; Thuring et al., 2004; Jacobs et al., 2011). In another example, 
the atypical forms of scrapie show 4 bands on the western blotting and these bands 
have lower molecular weights when compared to classical scrapie cases (Arsac et al., 
2007). Moreover, thermolysin (a thermostable protease) has also been applied in 
biochemical strain typing methods as an alternative to PK. The digestion pattern for this 
protease also allowed the differentiation of scrapie and BSE. In addition, the analysis 
was not affected by scrapie type or host genotype (Owen et al., 2007). Further tests 
involve the use of PK digestion followed by prion protein core antibody detection 
alongside monoclonal P4 antibody detection. The latter binds to an epitope situated near 
the N-terminus of PrP that is partially or completely lost following digestions of BSE PrPSc 
with PK, but is retained in scrapie PrPSc. From western blotting analysis, the core 
antibody:P4 western blot signal ratios were lower for BSE compared to classical scrapie 
cases (Stack, Chaplin and Clark, 2002; Jeffrey, González, et al., 2006). It has been 
noted that some scrapie cases were hard to differentiate using the methods mentioned 
above. One of the most difficult isolates to differentiate from BSE was an experimental 
scrapie isolate maintained in sheep – CH1641 (Foster and Dickinson, 1988). Recently, 
a method that uses serial in vitro prion replication (a method called protein misfolding 
cyclic amplification, PMCA) allowed the differentiation of ovine BSE from CH1641. After 
5 days of in vitro amplification with alternating PrPC substrates AHQ/AHQ and VRQ/VRQ, 
only BSE PrPSc was amplified and not CH1641 or any of the atypical or classical scrapie 
isolates tested. The main feature of this method is that it substitutes the use of animal 
model in the assay and allows to differentiate between two very closely related prion 
strains (Taema et al., 2012). Additionally, alternative to PMCA method – real time 
quaking induced conversion (RT-QuIC) – was described for prion propagation and was 
also used in prion strain typing experiments for human and animal TSEs (Orrú, 
Groveman, et al., 2015; Masujin et al., 2016; Levavasseur et al., 2017). 
Alternative methods for identifying prion strains within ruminants use 
immunohistochemical (IHC) examination of tissues. ‘PrPSc profiling’ is a method that 
uses antibodies against specific PrP domains to determine intra- and extra-cellular 
locations of PrPSc within a brain tissue (González, Martin and Jeffrey, 2003; González et 
al., 2005). Moreover, ‘PrPSc epitope mapping’ applies antibodies to define specific 
epitopes across the PrPSc length within the brain and LRS cells and in extracellular matrix 
(Jeffrey, González, et al., 2006). The use of antibodies in PrPSc profiling and epitope 
mapping was used to determine different morphological types of PrPSc, association with 
cells type and levels of PrPSc accumulation within multiple neuroanatomical sites. Based 
on these features both methods helped with distinguishing between scrapie and BSE 
cases (Jeffrey et al., 2001; Jeffrey, Martin, et al., 2006).  
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Methods based on prion stability analysis have also been proposed. These involve 
conformational stability assays (CSA) and conformation-dependent immunoassay 
(CDI). The main feature of these methods is to monitor changes in protease resistance 
(CSA) or epitope accessibility during a process that incrementally denatured PrPSc (CDI) 
(Safar et al., 1998; Peretz, 2001). 
The presence of many different prion strains has been determined by distinct disease 
phenotypes within the same host species. However, the variations seen were explained 
as being due to different conformations of PrPSc aggregates rather than the presence of 
other factors that might determine the prion strain features (Cobb and Surewicz, 2009). 
Therefore, the findings regarding the differences between prion isolates still fully 
supports the prion-only hypothesis developed by Prusiner (Prusiner, 1998). 
1.5 Methods used in TSE research for prion protein amplification 
1.5.1 Protein misfolding cyclic amplification 
Protein misfolding cyclic amplification (PMCA) is a technique which facilitates the 
conversion of cellular PrPC into the protease resistant PrPSc in vitro. PMCA was developed 
by Saborio et al. (Saborio, Permanne and Soto, 2001). In this method, the PrPSc acts as 
a template for the cellular prion protein, and the conversion is fully dependent on the 
presence of the misfolded PrPSc. This in vitro protein replication method is thought to 
simulate the exact process of PrPSc formation found in vivo and can faithfully replicate 
prion infectivity. The reaction consists of two steps: incubation, which allows the 
formation of protein aggregates, and sonication, which break down the aggregates into 
oligomers. Every created oligomer can then act as a template for further seeding of 
aggregation (Figure 1.5.1). Moreover, the properties of newly synthesised PrPSc 
through PMCA are the same as for the PrPSc found in TSE affected brains – they are 
proteinase K resistant, insoluble in detergents and infectious in rodent bioassays 
(Saborio, Permanne and Soto, 2001; Shikiya and Bartz, 2011). PMCA is a very useful 
tool in prion disease research and there are now many examples that it can be used for 
prion protein detection in brain tissue, secreta or excreta e.g. urine, blood, faeces, milk 
or saliva, elk antler velvet or deer semen and reproductive system tissues (Castilla et 
al., 2005; Maddison, Whitelam and Gough, 2007; Murayama et al., 2007; Angers et al., 
2009; Krüger et al., 2009; Maddison et al., 2009; Gough and Maddison, 2010; 
Maddison, Baker, et al., 2010; Kramm et al., 2019). Moreover, the PMCA method was 
also been used for the detection of a wide range of animal and human prion types 
including vCJD, FFI, scrapie, CWD and classical and H-type BSE from brain homogenates 
and other tissues (Saá, Castilla and Soto, 2006; Maddison, Whitelam and Gough, 2007; 
Gough, Bishop and Maddison, 2014; Redaelli et al., 2017; Barria et al., 2018; Kramm 
et al., 2019). In addition, PMCA was also used to differentiate between experimental 
BSE and the BSE like scrapie isolate CH1641 – an isolate that shares BSE-like 
biochemical properties but is not transmissible to mice (Jeffrey, González, et al., 2006; 
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Taema et al., 2012). However, despite many attempts there are no evidence that sCJD 
could be amplified and detected using PMCA (Giaccone and Moda, 2020). 
PMCA was developed for the misfolding of prion protein but it has also been used for α-
synuclein (α-syn) or tau fibril formation. Production of α-syn fibrils is a slow and variable 
process but applying the PMCA method increased the speed of this process. Moreover, 
the generated α-synuclein aggregates had the same biophysical and biochemical 
features as α-synuclein fibrils produced in vivo (Herva et al., 2014; Jung et al., 2017). 
Also, PMCA can be used to convert the monomeric tau into long filaments of protein 
aggregates (Meyer et al., 2014).  
1.5.2 Real time quaking induced conversion 
RT-QuIC is a variant of the PMCA technique, where instead of a sonication step, intensive 
shaking is used, and a Thioflavin T (ThT) fluorescence assay monitors in real time 
amyloid formation, as opposed to western blot analysis of protease-resistant protein 
(Figure 1.5.1). Shaking breaks down the formed PrP aggregates into multiple reactive 
seeds (Kang et al., 2017). RT-QuIC was firstly used by Atarashi and co-workers who 
found this method to be easier and faster to perform than standard PMCA (Atarashi, 
Sano, et al., 2011). They used recombinant PrP (rPrP) as a substrate for resistant prion 
protein formation when seeded with hamster cerebrospinal fluid (CSF) derived prions 
(Atarashi et al., 2008). Later, human peripheral tissues and sheep CFS were used as 
seed. QUIC allowed the correct differentiation between healthy and disease samples 
(Orrú et al., 2009). Next, RT-QuIC has been used to detect prion protein in sCJD cases. 
Atarashi et al. detected the PrPSc in 14 out of 16 (87.5 %) CJD cases, while none of the 
negative samples showed elevations in ThT fluorescence (Atarashi, Satoh, et al., 2011). 
Based on these results, two international and independent trials of PrPSc detection from 
CJD cases using patients CFS were run and all laboratories correctly identified all positive 
cases (McGuire et al., 2016). Moreover, obtaining some biopsy materials from patients 
is a complicated and invasive process. Therefore, research into finding less invasive 
procedure of collecting tissues was investigated. For example, Orru and co-workers 
tested whether RT-QuIC could be used to determine sCJD prion protein presence in the 
olfactory epithelium. Testing materials were obtained from patients by a nasal brushing 
procedure and RT-QuIC analysis was found to be sensitive and accurate for PrPSc 
detection (Orrú et al., 2014). Furthermore, other human prion diseases like familial CJD, 
GSS, and FFI were detected through RT-QuIC with high sensitivity (Sano et al., 2013). 
In addition, this method has also been applied for the recognition of animal prion 
diseases. Orru et al. used cattle brain homogenates from classical (C-BSE) and atypical 
forms of BSE. They detected and even distinguished between different types of BSE 
using RT-QuIC (Orrú, Favole, et al., 2015). Moreover, the use of RT-QuIC in deer 
infected with CWD has been described and the technique allowed the detection of prion 
even before clinical signs appeared (Hoover et al., 2017). There is also evidence of 
positive disease recognition from samples collected ante-mortem and post-mortem from 
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deer and elks. These include analysis of faeces, saliva, recto-anal mucosa-associated 
lymphoid tissue (RAMALT), nasal brush samples, urine, CSF and lymph nodes (Haley et 
al., 2013, 2014, 2016; Henderson et al., 2013; John, Schätzl and Gilch, 2013; Cheng 
et al., 2016). 
Even though the RT-QuIC method was first described for prion diseases, a similar assay 
was developed for α-synuclein detection in CSF for other protein misfolding diseases like 
dementia with Lewy bodies (DLB) and Parkinson’s Disease (PD) (Fairfoul et al., 2016; 
Sano et al., 2017). 
All described cases of using RT-QuIC show high specificity and sensitivity for both animal 
and human protein misfolding disease. Its further development has the potential to 
deliver a powerful, ante-mortem diagnostic tool and can also help with disease 
surveillance. However, RT-QuIC products have not been shown to be infectious in an 
animals in vivo assays so the method may have less applications for screening for 
therapeutics or in understanding prion infectivity (Groveman et al., 2017; Haley and 




Figure 1.5.1. Comparison between PMCA and RT-QuIC. PMCA (top) involves incubation 
and sonication cycles. In this method, PrPSc interacts with PrPC and converts it into PrPSc 
aggregates. Sonication breaks the aggregates into smaller oligomers, which then act as 
seeding nuclei over the next incubation step. RT-QuIC (bottom) is analogous to PMCA 
but it uses shaking instead of sonication to break the PrPSc aggregates. While PMCA 
formed PrPSc aggregates are protease resistant and usually detected by western 
blotting, QUIC formed amyloid fibrils are detected in real time by ThT binding and 



















1.6 Cell culture models for prion diseases  
Prion disease bioassays in rodents are an extremely useful tool to determine the prion 
strain type, infectivity rates and titres, although they are slow and require the use of 
many animals (Neale et al., 2010). Therefore, research into TSE infection permissive 
cells lines have been extensively investigated. The use of cell models increases the 
speed of infection and disease incubation. Moreover, PrPSc infected cell lines help to 
investigate the cell-cell spreading mechanisms of PrPSc, prion protein metabolism and 
also to characterize prion strains (Harris, 1999; Solassol, Crozet and Lehmann, 2003). 
Furthermore, cell culture methods also allow the analysis of PrPC and PrPSc levels and 
infection rates. In addition, cell culture models can also be used for faster therapeutic 
compound screening or finding possible infection markers with the highest physiological 
and diagnostic gain (Solassol, Crozet and Lehmann, 2003). Moreover, it was 
investigated whether, strain characteristics change with cell model multiplications. 
Analysis using different murine strains and several cell lines, as well as RK13 cells with 
murine, ovine and vole derived strains showed that clinical signs, incubation rates and 
brain vacuolation patterns remain unchanged with cell multiplication (Birkett et al., 
2001; Arjona et al., 2004; Arima et al., 2005; Courageot et al., 2008). Furthermore, 
cell lysates were shown to be infectious to transgenic mice bioassays (Vorberg et al., 
2004). Whilst a single cell line is able to propagate more than one strain (Vilette, 2008) 
a limitation of the reported models is that not all prions strains/isolates can infect the 
cell lines (van der Merwe et al., 2015).  
1.6.1 Cell models for animal prion diseases  
The first successful attempt to infect the mouse neural cell line – SMB – was carried out 
in 1970. The cells were inoculated with mouse adapted scrapie Chandler strain (Clarke 
and Haig, 1970). Later, infection of mouse neuroblastoma cells – N2a - with scrapie was 
described and N2a cells remain one of the most intensively studied and used models for 
prion infections (Race, Fadness and Chesebro, 1987; Vilette et al., 2001). Since then, 
both neural and non-neural cell lines have been found to be susceptible to prions and 
to be able to maintain prion infection (Table 1.6.1) (Solassol, Crozet and Lehmann, 
2003). Moreover, it was also found that mouse prions could be successfully transmitted 
into cells from different species. For example, in 1984 the rat cell line PC12 was infected 
with mouse adapted scrapie prion strain 139A (Rubenstein, Carp and Callahan, 1984). 
In addition, rodent adapted prion isolates were found to propagate in mouse fibroblast 
cell line NIH/3T3 and gave high levels of PrPSc post infection and after multiple passages. 
Moreover, cerebellar granule neurons (CGN) isolated from transgenic mice expressing 
ovine, hamster or murine PrP were found to be susceptible and propagate sheep, 
hamster and murine TSE isolates, respectively (Cronier et al., 2007). In addition, the 
rabbit epithelial cell line RK13 cells were engineered to express different species PrPC in 
a doxycycline induced manner (Vilette et al., 2001; Courageot et al., 2008). When 
mouse or bank vole PrPC was expressed in these cells, the cell cultures were permissive 
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to different prion isolates including mouse adapted scrapie and vole adapted ovine BSE 
(Courageot et al., 2008).  
Vilette et al., presented transgenic RK13 cells as an infection model with sheep scrapie, 
not previously adapted to rodents (Vilette et al., 2001). The RK13 cell line variant Rov9 
was engineered with doxycycline regulated expression system for ovine PrP (VRQ type) 
(Vilette et al., 2001). Later, it was found that Rov9 cells are also permissive and 
maintain the infection of other natural scrapie isolates (Neale et al., 2010). Moreover, a 
Schwann cell like line – MovS – was isolated from transgenic mice expressing ovine VRQ 
(Archer et al., 2004). This cell line was found to be permissive to many natural scrapie 
isolates and in addition, infected MovS cells propagated infectivity as measured by 
mouse bioassays (Archer et al., 2004; Neale et al., 2010).  
In addition to natural and rodent adapted scrapie isolates, other TSEs have been 
propagated in cell cultures. Tark et al., exposed the MDBK (Madin-Darby Bovine Kindey) 
cells to natural BSE brain homogenate. MDBK cells were engineered to overexpress 
bovine PrPC using the lentivirus expression system and these cells maintained the BSE 
infection (Tark et al., 2015). After transmission to mice, BSE infected cells showed 
similar brain lesion profiles to that observed in cattle C-BSE however they differed 
slightly in their biochemical features (Suh et al., 2017). Moreover, a brain derived MDB 
(mule deer brain) cell line has been successfully infected with CWD. Microsomes from 
CWD infected brain homogenates were shown to infect cells and the infection rates were 
stable over passages (Raymond et al., 2006). In addition, differentiated neurosphere 
cultures derived from mouse brain cells expressing the elk PrPC were successfully 
infected with non-adapted CWD (Iwamaru et al., 2017). In addition, new approach of 
engineering murine cells to express bank vole PrPC was proposed to increase their 
susceptibility to prion infection (Walia et al., 2019). As mentioned before, bank vole PrP 
was found to be the most susceptible to conversion within the range of tested species, 
therefore this model may help to establish and analyse other prion strains’ infections in 
cell cultures (Watts et al., 2014; Walia et al., 2019). In addition, 33 different cell lines 
were challenged with different natural and experimental scrapie and BSE isolates. These 
cells lines were chosen from a eukaryotic species bank of Veterinary Medicine cell lines 
(Collection of Cell Lines in Veterinary Medicine – CCLV). The final 33 cell lines derived 
from different age and tissues of cattle, sheep, goat, mink, cat, wild and domestic pig, 
deer, human, hamster, rabbit and mouse. Among them, the bovine derived MDBK-PES 
cell line was infected with natural scrapie but not BSE. In addition, this study provided 
the first evidence showing infection and propagation of ARQ/ARQ natural scrapie in cell 
culture models, as previously VRQ homozygotes or ARR/VRQ isolates were shown to be 
infectious (Oelschlegel et al., 2015). 
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Table 1.6.1. Neural and non-neural cell lines susceptible to prion infection. Adapted 
from (Grassmann et al., 2013; van der Merwe et al., 2015), modified.  
Cell line Cell line origin Species 
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Mo – mouse passaged 
Ha – hamster passaged 
Ov – ovine isolates 
 
As well as their value in diagnostics, the use of cell culture models could help with the 
characterisation and understanding of the involvement of different nervous system cell 
types in prion propagation. Primary cell cultures may also allow the study of cell 
degeneration mechanisms after exposure to infectious prions. Cronier and co-workers 
analysed neurons and astrocytes after inoculation with scrapie. It was found that both 
cell types take part in PrPSc propagation and could be the primary replication site for 
prion proteins (Cronier, Laude and Peyrin, 2004).  
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1.6.2 Cell models for human prion diseases 
The use of cell lines to model prion diseases has been established for a range of animal 
TSE isolates. Furthermore, some early reports demonstrated that sporadic CJD can 
infect human derived cell lines – neuroblastoma SH-SY5Y (Ladogana et al., 1995). 
However, the use of this human cell line was never reported again for human TSE cell 
infection assays (Groveman et al., 2019). Another human model susceptible for infection 
with sCJD brain was described more than 20 years later. In this study, the use of induced 
pluripotent stem cells (iPSC) was reported. The iPSC were differentiated into astrocytes 
and were able to replicate three different sCJD isolates (Krejciova et al., 2017). 
Moreover, human iPSC can organise into structures called cerebral organoids and 
therefore can be used as a brain tissue model (Lancaster and Knoblich, 2014; Groveman 
et al., 2019). These larger structures were also tested for permissiveness to sCJD prions 
and were found to be susceptible. This novel model gave new perspectives on prion 
disease modelling and might increase the understanding of PrPSc pathogenesis in brain 
tissue (Groveman et al., 2019).  
Furthermore, a RK13 cell variant expressing human PrP was described, however this 
attempt failed to propagate human PrPSc (Lawson et al., 2008). In contrast, RK 13 cells 
expressing mouse PrPC were found to propagate mouse passaged human GSS isolate – 
Fukuoka 1 (Courageot et al., 2008). In addition, murine GT hypothalamic cells were 
found to be susceptible for infection with CJD. For these assays, ‘slow’ (SU) and ‘fast’ 
(FU) virulent Asian CJD isolates were used. Infections with both strains showed the 
presence of PrPSc after mutiple passages (Arjona et al., 2004; Manuelidis et al., 2007). 
Apart from sCJD isolates, a murine GT hypothalamic cell line has been shown to 
propagate vCJD and kuru PrPSc (Miyazawa, Emmerling and Manuelidis, 2011). Moreover, 
murine spleen-derived stromal cells were susceptible to ‘fast’ virulent strain of sCJD as 
well as a vCJD isolate (Akimov et al., 2008).  
Some primary cell cultures infected with human PrPSc have also been established. 
Cronier and co-workers demonstrated the use of a transgenic mouse model expressing 
human PrPC as a source for primary neuronal cell line CGN (cerebellar granule neurons). 
The CGN cells were exposed to murine adapted CJD isolates and were found to be 
permissive (Cronier et al., 2007). Later, the primary CGN cells were also found to be 
susceptible to brain homogenates of various human sCJD, vCJD and iCJD isolates 
(Hannaoui et al., 2014).  
1.6.3 PrPSc spread between cells in cell culture 
Despite the availability of many different cell types that are permissive to prion infection, 
the cellular PrPSc transmission routes between cells are still being investigated (Mattei 
et al., 2009). Firstly, research showed that PrPC can be transferred between different 
cell lines in vitro. This used M17 cell line (human neuroblastoma) expressing the PrPC 
and IA cells (human erythroleukemia) that lack PrPC, grown in co-cultures. The study 
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also demonstrated that direct cell-to-cell contact was necessary for successful PrPC 
uptake (Liu et al., 2002). It was next established that as well as cellular prion protein 
being transferred between cells in vitro, PrPSc was also transferred. Prion infected cells 
were described that released the PrPSc and triggered the conversion of PrPC into PrPSc. 
There are several described routes for the spreading of infectious prions between cells 
(Figure 1.6.1), however the conversion of PrPC into PrPSc seems to occur at the cell 
membrane level (Aguzzi and Lakkaraju, 2016; Vilette et al., 2018). Cell-to-cell 
transmission may involve the use of membrane-bound extracellular vesicles (EV) like 
microvesicles or exosomes packed with PrPSc, tunnelling nanotubes (TNTs) and direct 
cell-to-cell contact (Aguzzi and Lakkaraju, 2016). Firstly, the role of exosomes, 
cytoplasmic organelles has been described. In general, exosomes are created within the 
cell in order to remove non-functional proteins from cells or mediate some cell functions 
(Vella et al., 2008). Fevrier and co-workers analysed the scrapie prion infected Rov and 
Mov cells and found that infectious prions were present in culture media. 
Ultracentrifugation fractions were analysed and showed that PrPSc was linked with 
exosomes and this was confirmed by electron microscopy analysis. In addition, PrPSc 
contained within exosomes retained its infectivity in mouse bioassay (Fevrier et al., 
2004). Later, a range of cells types, RK13 expressing mouse PrP, GT1 hypothalamic 
cells, neuroblastoma N2a cells, dendritic cells and lymphocytes, were infected with 
different scrapie isolates and the secretion of PrPSc from cells was associated with 
exosomes (Vella et al., 2007; Alais et al., 2008; Castro-Seoane et al., 2012; Coleman 
et al., 2012). The involvement of microvesicles (MV) in intracellular prion transport has 
also been described. MVs are usually smaller than exosomes and are membrane-
bounded structures displaying some adhesion molecules on their surfaces. Usually 
secreted by blood cells, platelets or endothelial cells, MVs were found to be carriers for 
PrPSc (Mattei et al., 2009). After release of either exosomes or MVs into the extracellular 
matrix, the structures would form direct contact with other cells, fuse and insert the 
PrPSc into the cell (Caughey et al., 2009; Guo and Lee, 2014).  
Another possible route for transmission of PrPSc between cells are tunnelling nanotubes. 
These tubular structures are made from microtubules and F-actin (Ahmed and Xiang, 
2011). Moreover, TNTs are formed de novo in order to provide a transfer route between 
cells (Rustom et al., 2004). TNTs are packed with cytoskeletal and motor proteins and 
can transport cell organelles, membrane vesicles and also nucleic acids, calcium cations, 
proteins and even pathogens (Gerdes and Carvalho, 2008; Sisakhtnezhad and Khosravi, 
2015). Research using the fluorescent labelling of PrPC and live cell imaging showed that 
tunnelling nanotubes transport cellular prion protein between murine neuron like cells 
(CAD cells) in vitro. Furthermore, TNTs could mediate the transfer of fluorescently 
labelled infectious prion between dendritic cells (DC) and neurons. TNTs were formed 
after overnight incubation and PrPSc was transported between DC and CAD cells in vitro 
(Gousset et al., 2009). Moreover, a possible TNT mediated transfer for prion proteins 
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was also described between astrocyte–astrocyte, and astrocyte–neuron pathways 
(Victoria et al., 2016).  
The third mechanism for PrPSc transport is through direct cell-to-cell contact. Kanu and 
co-workers used SMB cells infected with mouse adapted scrapie and showed that 
propagation of infectious prions is possible through direct cell-cell contact. Furthermore, 
no membrane associated PrPSc were found in cell culture media indicating that EVs were 
not mediating transfer of prions (Kanu et al., 2002). In addition, prions added directly 
to cell media could enter cells by direct cell membrane penetration or endocytosis (Guo 
and Lee, 2014). 
 
Figure 1.6.1. Possible transmission routes of PrPSc between cells. a – uptake of media 
floating PrPSc monomers through (1) direct penetration of recipient cell membrane, (2) 
endocytosis or (3) receptor-mediated endocytosis. b – PrPSc seeds that are released 
within extracellular vesicles (EV) integrate with recipient cell membrane (4). PrPSc seeds 
transport between cells might also take place via cytoskeletal structures - tunnelling 
nanotubes (TNTs) (5). Adapted from (Guo and Lee, 2014), modified. 
The existence of different PrPSc transmission routes between cells in distinct cell culture 
models could lead to the conclusion that different prion strains and isolates could 
influence the route of transmission (Paquet, Langevin, et al., 2007; Arellano-Anaya et 
al., 2015). Furthermore, all of the mentioned in vitro analyses are difficult to examine 
in in vivo situations. However, in vivo research has showed that EVs could be isolated 
from many types of animal body fluids including CFS, urine, saliva, milk or even blood 
and plasma (Vilette et al., 2018). In addition, some EV derived from plasma, urine or 
CFS were found to be PrPC positive indicating that this might also be the way of 
spreading infectious PrPSc (Robertson et al., 2006; Vella et al., 2008; Gough and 
Maddison, 2010; Conde-Vancells and Falcon-Perez, 2012). On the other hand, detection 
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of TNTs in vivo is a very challenging process. There are no TNT specific markers and 
visualisation methods in solid tissues face some technical difficulties and do not provide 
sensitive and robust data. In addition, conditions required to detect PrPSc in these tissues 
are very specific and together with difficulties connected with TNT detection make it 
impossible for visualisation of PrPSc in TNTs in vivo (Vilette et al., 2018).  
1.7 Prion diseases as an example of protein misfolding diseases  
The aggregation of misfolded proteins leading to a serious disease is not an exclusive 
hallmark for prion diseases. It affects a larger range of proteins and these disorders are 
grouped as protein misfolding diseases (PMDs). PMDs are caused by a change in 
a protein’s conformation into β-sheet rich organised structures and this change in 
protein structure appears to be the only disease trigger. Most PMDs appear sporadically 
and have no genetic background however some could be inherited (Moreno-Gonzalez 
and Soto, 2011). Misfolded protein aggregates are observed in more than 20 human 
PMDs (Table 1.7.1), including Alzheimer’s disease (AD), Parkinson’s Disease (PD), 
Huntington Disease, type II diabetes and amyotrophic lateral sclerosis (ALS) (Moreno-
Gonzalez and Soto, 2011).  
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1.7.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is known from its first case in 1906 in Germany and is one of 
the most common protein misfolding disorders. AD affects mainly people over 65 years 
old, however familial AD form also occurs in younger patients. In general, the disease 
is characterised by changes in behaviour and personality and progressive memory loss 
(Liu et al., 2019). AD symptoms are caused by intracellular aggregates of misfolded 
proteins tau and amyloid β (Aβ). These two proteins create so-called neurofibrillary 
tangles and neurotic plaques in the brain tissue, respectively. Amyloid β is a 4 kDa 
protein, that is created by the proteolysis from glycosylated transmembrane amyloid 
precursor protein (APP), that is synthesised in neurons (Glenner and Wong, 1984; 
Weidemann et al., 1989; Wirak et al., 1991; Lee et al., 2008). There is evidence 
indicating that it plays a role in cell growth and viability, may be a receptor for 
a glycoprotein F-spondin and participate in neuronal repair and development (Ho and 
Sudhof, 2004; O’Brien and Wong, 2011). Moreover, Aβ plays a role in synaptic release 
regulation (Abramov et al., 2009). The majority of APP peptides that are produced are 
Aβ(1-40) and Aβ(1-42). It has been suggested that the misfolded Aβ(1-42) is mostly 
found to be correlated with disease (Jarret, Berger and Lansbury, 1993; Bayer et al., 
1999). 
Tau protein aggregates create neurofibrillary tangles (NFT). In healthy tissue, tau 
proteins are microtubule-associated proteins (MAP) that bind and stabilise cell or 
organelle movement. They are also involved in cell shape maintenance (Weingarten et 
al., 1975). Moreover, tau proteins undergo some posttranslational modifications with 
phosphorylation being the most important one. It has been suggested that the role of 
tau proteins in the tissue depends on the phosphorylation state (Buée et al., 2000). Tau 
protein has been detected in many different tissues such as rat heart, kidneys, skeletal 
muscles, lungs and liver, but mainly in neurons axons (Lee, Goedert and Trojanowski, 
2001; Gu, Oyama and Ihara, 2002). In AD, tau is hyperphosphorylated and not able to 
form microtubules within neurons. Instead, it aggregates in insoluble inclusions, the 
NFTs. As a result, the presence of NFT becomes toxic to cells as the intracellular 
transport is disrupted (Ballatore, Lee and Trojanowski, 2007), leading to changes in 
cytoskeleton structure and function (Roy et al., 2005). Overall, the presence of NFT in 
the brain tissue is one of the main hallmarks of AD (Grundke-iqbals et al., 1986; Kondo 
et al., 1988).  
1.7.2 Parkinson’s disease  
Parkinson’s disease (PD) is a neurodegenerative disease characterised by the presence 
of Lewy Bodies (LB) and nerve cell loss. LB appears intracellularly, mainly in the 
cytoplasm of neurons within different brain regions with its highest abundance in 
substantia nigra and hypothalamus (Forno, 1995; Soto, 2003). The main component of 
LBs are misfolded α-syn aggregate filaments about 5-10 nm long. In general, α-syn is 
140 amino acids long (Spillantini et al., 1997, 1998) and encoded by the SNCA gene 
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located on the chromosome 4. It is expressed to the highest levels in brain tissue but is 
also found in lungs, placenta and kidneys (Ueda et al., 1993). The function of α-syn is 
not fully known, however it may be involved in synaptic protein release (Narayanan and 
Scarlata, 2001). Moreover, α-syn contains some fatty-acid binding regions, therefore it 
might also have a role in fatty acid metabolism (Sharon et al., 2001).  
1.8 Misfolded protein cross-seeding 
Every protein misfolding disease is characterised by the presence of protein aggregates 
specific to the illness and these aggregates can exhibit similar features like β-sheet rich 
structure, morphology and tissue staining pattern. Moreover, it is possible they might 
also recruit other proteins and create cross-seeded protein aggregates (Morales, 
Moreno-Gonzalez and Soto, 2013). The recruitment of protein to misfold is called 
‘homologous seeding’ when engaging the same protein, or ‘heterologous seeding’, also 
known as ‘cross-seeding’ when different proteins are involved. The seeding process is 
based on the nucleation hypothesis, which consists of two steps, lag and elongation 
phases (Kocisko et al., 1994; Soto, Estrada and Castilla, 2006). During the lag process, 
a nuclei is formed from misfolded protein oligomers. This phase is relatively slow and 
its main determinant is the formation speed of a nucleus of thermodynamically stable 
β-sheet rich conformer (Morales, Green and Soto, 2009). In vivo, this process can be 
spontaneous, determined by some genetic mutations or acquired. Following the nuclei 
formation, the elongation step is rapid. The seeds bind to cellular protein and compel it 
to change conformation. Furthermore, the lag phase could be accelerated by addition of 
already formed nuclei of different kinds of seeds (Soto, 2001). Such seeding  provides 
an explanation for vCJD that appears in younger patients (Collinge et al., 1996; Morales, 
Moreno-Gonzalez and Soto, 2013). Moreover, in vitro results also demonstrate that the 
production of misfolded protein during PMCA is accelerated by addition of misfolded 
protein seeds (Katorcha et al., 2017). 
In addition, many scientific sources described the co-occurrence of different pathologic 
misfolded proteins in human brain tissue and from in vivo and in vitro studies. These 
include Aβ occurring with α-syn for both AD and PD (Paik et al., 1998; Masliah et al., 
2001; Mandal et al., 2006; Tsigelny et al., 2008), Aβ with prion protein for AD (Morales 
et al., 2010), tau protein with α-synuclein for AD and PD (Arima et al., 1999; Giasson 
et al., 2003; Ishizawa et al., 2003; Muntané et al., 2008; Waxman and Giasson, 2011) 
and α-synuclein with prion protein for TSEs (Haïk et al., 2002; Adjou et al., 2007; Vital 
et al., 2007, 2009; Mougenot et al., 2011; Masliah et al., 2012; Katorcha et al., 2017). 
The co-occurrence of different protein aggregates within the same PMD is a quite 
common occurrence. An interesting hypothesis described by Katorcha and co-workers 
suggests that the determining factor for protein cross-seeding other protein aggregates 
might be the similarity in protein folding pattern rather than amino acids sequences or 
seed homology with the ‘substrate’ protein (Katorcha et al., 2017). The impact of cross-
 56 
seeding events needs to be better understood in order to deliver improved diagnostic 
and therapeutic approaches for PMDs (Morales, Green and Soto, 2009). 
1.9 Therapeutics for prion diseases 
Prion diseases are fatal and characterised by a very prolonged asymptomatic incubation 
period. There is no treatment or cure for disease development. When developing 
therapeutic to TSE diseases, many factors must be considered e.g. availably of the 
therapeutic to cross the blood-brain barrier, and that the treatment cannot be toxic for 
the patient (Forloni et al., 2013). To date, many therapeutic approaches have been 
tested in vitro and in vivo, targeting the cellular PrP, misfolded PrPSc or even the whole 
process of PrPC misfolding (Figure 1.9.1) (Trevitt and Collinge, 2006). Therapeutics, 
which target PrPC involve mostly switching off the Prnp gene by classical gene knockout 
or RNA interference (Trevitt and Collinge, 2006; White and Mallucci, 2009). 
Furthermore, a range of drugs were screened and analysed in terms of decreasing or 
even stopping PrPSc formation, examples include amphotericin B, antimalarial drugs: 
quinacrine and mefloquine, congo red (CR), pentosane polysulphate (PPS), heparin, 
antibodies, peptides and recombinant proteins (Chabry, Caughey and Chesebro, 1998; 
Kocisko et al., 2003; Bertsch et al., 2005; Forloni et al., 2013; Yuan et al., 2013). Most 
of these agents successfully inhibited PrPSc formation in cell-free system or mouse 
neuroblastoma cells, however in vivo the majority did not delay the disease onset or 
the drug appeared to be toxic for the organism. Both quinacrine and mefloquine were 
able to cross the blood-brain barrier but lacked activity to block PrPSc formation in in 
vivo models (Kocisko et al., 2003; Kocisko and Caughey, 2006a; Rochet, 2007). 
Moreover, quinacrine has been tested in hospital trials on patients. One of the clinical 
trials was started in the UK and included familial, iatrogenic, sporadic and variant CJD 
patients. This study was called PRION-1 and showed that the drug did not affect the 
progression of prion diseases and CJD patients mortality rates did not change in 
comparison to untreated patients (Collinge et al., 2009). In addition, another quinacrine 
clinical study was performed in the US between 2005 and 2009. Repeatedly, there was 
no significant difference in survival time of sCJD in compare to placebo controls 
(Geschwind et al., 2013). Another drug that has been tested on prion disease patients 
was PPS. In the UK, this drug was delivered to 5 vCJD patients intraventricularly. The 
majority of them showed longer survival, however post mortem research showed no 
differences in pathological changes in the brain tissue (Newman et al., 2014). A similar 
study was performed in Japan with iCJD, fCJD and sCJD patients. However in this case, 
there were no differences in the patients survival times, suggesting that the response 
to this drug was disease or patient specific (Tsuboi, Doh-Ura and Yamada, 2009; Teruya 
and Doh-Ura, 2017). Doxycycline was also tested in clinical trials. In Italy and in France, 
patients with sCJD and fCJD were treated orally but the therapy showed no differences 
in disease progression or patient survival between placebo and doxycycline treated 
patients (Haïk et al., 2014). In addition to that, another preventive study with patients 
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affected with FFI was started in Italy, in which FFI patients will be exposed for 
doxycycline treatment for 10 years. To date, no results from this trial have been 
published (Forloni et al., 2015). 
 
Figure 1.9.1. Possible targets for prion disease treatments. These targets include 
modification of the Prnp gene or PrPC expression level. Therapies might be also directed 
towards degradation of cellular PrP, or limitation of the interaction between PrPC and 
PrPSc. In addition, degradation of PrPSc and inhibition of PrPSc derived oligomer formation 
were also proposed as therapeutic targets. Furthermore, on the cell level, therapeutics 
could inhibit neuronal degeneration. Adapted from (Teruya and Doh-Ura, 2017) 
(Copyright to Cold Spring Harbour Laboratory Press).  
Testing the therapeutic potential of polyclonal and monoclonal antibodies that bind to 
PrPC or PrPSc have been reported, and antibodies can have an inhibiting effect on PrPSc 
formation in cell cultures and in the spleen in an in vivo model (White et al., 2003; 
Trevitt and Collinge, 2006). A monoclonal antibody 6H4 was investigated in N2a cell 
culture inhibition. 6H4 binds to mouse PrP residues 144-152 corresponding to helix 1 in 
the PrP structure. When added to N2a cell infected with scrapie, the monoclonal antibody 
cured the scrapie infected cells. In addition to that, 6H4 molecule added to the cell 
culture media was also found to prevent the scrapie infection in these cells (Enari, 
Flechsig and Weissmann, 2001). Generated in transgenic mice lacking the PrPC, 
antibodies were raised against two human PrPSc isoforms: α and β. When these were 
applied to Rov9 cells infected with scrapie, both kinds of antibody blocked accumulation 
of misfolded PrPSc (Beringue et al., 2003, 2004). Furthermore, another study involved 
screening 145 different monoclonal antibodies in order to determine its effect on PrPSc 
formation in two cell culture models: Rov9 and N2a. Amongst them, two antibodies, 
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Sha31 and BAR236 that binds the central and C-terminal region, respectively, were 
shown to have the highest inhibition response. They produced IC50 value of 0.6 nM for 
N2a cells in the initial screening (Féraudet et al., 2005). In addition, monoclonal 
antibodies ICSM18 and ICSM35 were also assessed in mice that were infected 
peripherally with scrapie agent. These antibodies recognise region 146-159 and 91-110, 
respectively (Beringue et al., 2003; White et al., 2003). Results showed that levels of 
PrPSc in spleen were significantly reduced and survival time was increased for animals 
treated peripherally with antibodies (White et al., 2003). In addition to that, Peretz et 
al., investigated recombinant antibodies fragments (Fabs) for their ability to inhibit prion 
protein propagation in mouse ScN2a cells. They tested a range of concentrations and 
found out that the D18 antibody was the most effective and significantly reduced the 
level of PrPSc in cells (Peretz et al., 2001). Because the Fab bound to the 132-156 region 
in mouse PrPC is was suggested that it blocks or changes the site of interaction with 
PrPSc (Williamson et al., 1998; Peretz et al., 2001). In contrast, Fabs that were binding 
to the C-terminal of N-terminal of PrP were found to have no inhibitory effect (Peretz et 
al., 2001). Furthermore, polyclonal antibodies were also used in a ScN2a cell model and 
demonstrated inhibition of de novo PrPSc accumulation (Gilch et al., 2003). All of these 
examples highlight the potential for antibodies to be used for prion diseases therapies, 
however, their use is still limited (White et al., 2003). Only recently, an ICSM18 
derivative human antibody – PRN100 - was given to small number of patients with 
different staged of sCJD in clinical trials in the UK. Thus, the outcomes are still not 
presented (White et al., 2003; Dyer, 2018; Aguzzi and Frontzek, 2020).  
Heterologous or homologous recombinant prion protein can also inhibit TSE disease 
progression in vitro and in vivo. Priola and co-workers showed that expression from 
a non-homologous Prnp gene, which differed from host Prnp, was able to interfere with 
misfolded prion protein aggregation and could prevent its accumulation (Priola et al., 
1994). Moreover, Skinner et al., conducted in vivo research, where mice were inoculated 
with a scrapie strain and two doses of recombinant hamster PrP (rhamPrP). The rhamPrP 
proteins was administered intracerebrally at the inoculation time and orally on the 
following day (Skinner et al., 2015). At the end of the study, 50 % of animals treated 
with the high dose of rhamPrP were free of any scrapie signs at the time of death, 
however animals developed some characteristic TSE-related brain tissue changes. 
Furthermore, addition of recombinant PrP was also reported to inhibit ovine and bovine 
PrPSc amplification in vitro (Workman, Maddison and Gough, 2017). Further in vitro 
research showed that homologous recombinant prion protein was reported to act as an 
inhibitor and was more effective than introduced heterologous rPrPs (Yuan et al., 2013). 
Studies to date indicate that the addition of any recombinant PrP might significantly 
delay the PrPSc accumulation, however the mechanism is still unclear. Yuan and 
colleagues reported that inhibition of PrPC misfolding involves both the N- and C-terminal 
regions of PrP, suggesting that PrPSc binding sites are contributed to by sites across the 
whole PrP molecule. In addition, recombinant PrP proteins bind to misfolded PrPSc and 
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therefore might block the possible sites for cellular PrP to interact (Yuan et al., 2013). 
However, synthetic peptides made from only the central part of hamster PrP were tested 
for inhibition of in vitro amplification and could successfully inhibited PrPC conversion. 
This data indicated that the PrP protein central region might be the most important 
domain in its interaction within PrPSc in the misfolding process (Chabry, Caughey and 
Chesebro, 1998).  
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1.10 Study aims 
The central hypothesis to this study was that mutated recombinant PrP could 
be a potent inhibitor of PrPSc formation.  
This hypothesis was tested through the following aims:  
Verification of rVRQ as an inhibitor for scrapie prion misfolding 
It was demonstrated previously that addition of recombinant prion protein into PMCA 
inhibit the infectious prion protein amplification (Yuan et al., 2013). Later, Workman 
investigated hamster recombinant PrP, rARQ, rVRQ and rARR. Of these natural variants 
and a heterologous rPrP, rVRQ was found to inhibit the scrapie amplification most 
efficiently (Workman, 2017). As a starting point to the present study, the aim was to 
reproduce and confirm the rVRQ inhibition pattern with representative scrapie isolate 
ARQ/VRQ PG1361/05. The rVRQ was tested at different concentrations and then IC50 
values was calculated and compared to previously obtained results.  
Preparation and screening of ovine rPrP mutants as inhibitors of PrPSc 
formation 
Previous data showed that polymorphisms at position 136 of ovine scrapie has 
a considerable influence not only of the susceptibility to natural scrapie but also on the 
efficacy of rPrP inhibition of PrPSc formation. In order to investigate whether other point 
mutations at 136 position will increase or decrease the inhibition level of scrapie isolate, 
all possible amino acid changes at this position were made using site directed 
mutagenesis. Once mutations were confirmed, all rPrP proteins were expressed in E. coli 
and purified. All variants were compared to rVRQ to identify improvements in inhibition 
efficacy. More potent inhibitors were characterised in terms of IC50 values.  
Investigation of rPrP mutants with different prion disease isolates 
The best rPrP inhibitors of scrapie ARQ/VRQ PG1361/05 were then analysed with other 
scrapie isolates, as well as bovine and ovine BSE. First of all, optimal PMCA and serial 
PMCA conditions were determined for the amplification of these disease isolates. Once 
determined, the previously tested rPrP were added into PMCA rounds at specific 
concentrations and final rounds of amplifications were analysed and inhibitor efficacies 
determined. 
Investigation of peptides from rPrP mutants as inhibitors of PrPSc amplification 
and structural analysis of rPrP proteins 
Previously, the potential use of synthetic peptides instead of recombinant proteins in 
prion disease inhibition was demonstrated (Chabry, Caughey and Chesebro, 1998; Yuan 
et al., 2013). This current study aimed to design and produce various ovine PrP derived 
peptides of different lengths, each containing the 136 position. These were screened for 
inhibition properties and compared to equivalent rPrP inhibition. Additionally, to 
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investigate how a single amino acid change at position 136 in ovine PrP influenced 
changes in a 3-D structure of the whole protein, the structures of rPrPs were analysed 
in silico and compared.  
Application of rPrP inhibition of prion formation to a cell cultures model of 
scrapie infection  
It has been shown that TSE permissible cells lines have had a huge potential in 
understanding mechanisms of disease development, prion protein conversion and 
assessing therapeutics (Vilette et al., 2018). In this project, the aim was to infect Rov9 
cells expressing ovine PrP (genotype VRQ) with ovine scrapie isolates/strains. After the 
establishment of infection, the efficacy of rPrPs to inhibit scrapie development in cells 
were assessed.  
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2.1 Brain tissue samples details 
Both healthy and TSE positive brain tissue samples were obtained from the Animal and 
Plant Health Agency (APHA) or the Roslin Institute (University of Edinburgh). All sample 
details are shown in Table 2.1.1. 
Table 2.1.1. Details of healthy and TSE positive samples. 
Isolate number Description Host Genotype TSE status 
PG0648/09 Brain 16 Ovine VRQ/VRQ Healthy 
PG0146/12 Brain 42 Ovine VRQ/VRQ Healthy 
PG0211/12 Brain 51 Ovine AHQ/AHQ Healthy 
PG0209/12 Brain 49 Ovine AHQ/AHQ Healthy 
Bovine Bovine Bovine Bovine Healthy 
PG1361/05 Scrapie Ovine ARQ/VRQ TSE 
PG1207/03 Scrapie Ovine VRQ/VRQ TSE 
PG1499/02 Scrapie Ovine AHQ/VRQ TSE 
J3011 CH1641 scrapie Ovine AHQ/AHQ TSE 
J2935 CH1641 scrapie  Ovine ARQ/AHQ TSE 
SE1945/0035 BSE Bovine Bovine TSE 
PG1693/03 BSE Ovine ARQ/ARQ TSE 
SSBP1 Scrapie Ovine VRQ/VRQ TSE 
PG1212/03 Scrapie Ovine VRQ/VRQ TSE 
PG1517/01 Scrapie Ovine VRQ/VRQ TSE 
 
2.2 Production of non-available clones of rPrP mutants 
2.2.1 Plasmid preparations 
In order to produce recombinant prion proteins with specific mutations at position 136, 
site directed mutagenesis was performed. The plasmid pet22b(+) containing the rVRQ 
(valine136, arginine154 and glutamine171) sequence was purified from E. coli (NovaBlue, 
isolate BL21 (DE3), Novagen). Briefly, DE3 were grown in 5 ml of 2 x Yeast Tryptone 
(2YT) media containing 100 µg/ml of ampicillin and 3 % (w/v) glucose (2YT-AG) from 
glycerol stock overnight at 37 °C with shaking. Then, bacteria were harvested by 
centrifugation at 17000 x g for 3 minutes. For plasmid preparation, a Qiagen Kit 
(QIAprep Spin Mini Prep Kit) was used according to the protocol. Briefly, after 
centrifugation, supernatant was removed and bacteria were re-suspended in 250 µl of 
buffer P1 and next, 250 µl of P2 buffer was added and samples were mixed. 350 µl of 
buffer N3 was added, samples were centrifuged for 10 minutes at 17000 x g. Then, 800 
µl of supernatant were added in the kit provided column and centrifuged for 1 minute 
at 17000 x g. The flowthrough was discarded and the column was washed with 700 µl 
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of buffer PB. Samples were centrifuged as described before and once the flowthrough 
was removed, columns were centrifuged for an additional minute. Next, columns were 
moved to a new tube, 30-50 µl of EB buffer was added and incubated for 2 minutes at 
room temperature. Samples were then pulsed at 17000 x g and columns were discarded. 
The DNA concentration was estimated by Nanodrop (Thermo Scientific). This DNA was 
then used as a template in the inverse PCR. 
2.2.2 Inverse PCR primer design 
Non-overlapping primers were designed, so that the forward primer starts at the 
mutation site, and the reverse primer is complimentary to the sequence before the 
mutation position (Figure 2.2.1).  
 
Figure 2.2.1. Representative scheme for inverse PCR primer design for 136 position 
mutation in ovine PrP. Forward primer starts at the mutation site and first codon was 
mutated in order to obtain proper mutation at 136 mutation. The reverse primer is 
complimentary to the sequence before the mutation position. Reverse primer is 
universal for each rPrP.  
All the primers were phosphorylated at the 5’ end. Primer sequences with their melting 
temperatures are showed in Table 2.2.1. Each primer was resuspended in ultrapure 





5’… GGT GGC TAC ATG CTG GGA AGT GCC ATG AGC AGG CCT CTT ATA CAT TTT … 3’
Forward primer
Reverse primer
GCC 136 position in ovine PRNP
3’ CCA CCG ATG TAC GAC CCT TCA 5’





5’… GGT GGC TAC ATG CTG GGA AGT AAG ATG AGC AGG CCT CTT ATA CAT TTT … 3’
New sequence after amplification by inverse PCR:
PCR
Forward primer




Table 2.2.1. Inverse PCR primers.  




rPrP-Rev acttcccagcatgtagccacc 61.8 
rPrP-For-K aagatgagcaggcctcttatac 58.4 
rPrP-For-G ggcatgagcaggcctcttatac 62.1 
rPrP-For-W tggatgagcaggcctcttatac 60.3 
rPrP-For-Q-(1) cagatgagcaggcctcttatac 60.3 
rPrP-For-Q-(2) caaatgagcaggcctcttatac 58.4 
rPrP-For-P cccatgagcaggcctcttatac 62.1 
rPrP-For-T accatgagcaggcctcttatac 60.3 
rPrP-For-D gacatgagcaggcctcttatac 60.3 
rPrP-For-E gagatgagcaggcctcttatac 60.3 
rPrP-For-M atgatgagcaggcctcttatac 58.4 
1Rev – reverse, For – forward, the amino acid change is indicated in the primer 
name: V – valine, K – lysine, G – glycine, W – tryptophan, Q – glutamine, P – 
proline, T – threonine, D – aspartic acid, E – glutamic acid, M – methionine. 
2aag – amino acid codon change 
 
2.2.3 Inverse PCR  
Inverse PCR was performed as described in Table 2.2.2. Q5 Reaction Buffer (cat. no. 
B9027S), dNTPs (cat. no. N0447S), Q5 High GC Enhancer (cat. no. B9028A) and Q5 
High Fidelity DNA Polymerase (cat. no. M0491L) were purchased from New England 
BioLabs. PCR primers were obtained from Eurofins. All PCR reactions were carried on in 
PCR machine LifeECO, BioER. 
PCR reactions were performed with initial denaturation at 95 °C for 5 minutes. Next, 30 
cycles of denaturation at 95 °C for 30 seconds, annealing at 61 °C for 30 seconds and 
elongation at 72 °C for 5 minutes were completed. For some cases, gradient inverse 
PCR was performed with annealing temperatures ranging from 50 to 63 °C. Lastly, the 
final extension was performed for 10 minutes at 72 °C. When necessary, PCR products 
were stored at either 4 C or -20 C.  
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Q5 Reaction Buffer 1x 10 
dNTPs 0.4 µM 2 
DNA template 0.2 ng/µl 1 
Forward primer 0.3 µM 1.5 
Reverse primer 0.3 µM 1.5 
Q5 High GC Enhancer 1x 10 
Q5 Polymerase 20 U/ml 0.5 
H2O Up to 50 µl 23.5 
 
2.2.4 Agarose Gel Electrophoresis 
PCR products were analysed on a 1 % (w/v) agarose gel. Briefly, 1 g of agarose was re-
suspended in 1 x TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA) and Nancy-
520 (Sigma-Aldrich) was added to a final concentration of 1 mM. All samples were mixed 
with Gel Loading Dye (cat. no. B70256, New England BioLabs) and 60 µl of each sample 
were loaded on the gel. As a DNA size reference, 1 kb DNA Ladder was used (cat. no. 
N3232S, New England BioLabs). The agarose gel was run for 45 minutes at 100 V. Gels 
were visualised using a BioRad Imager. 
2.2.5 Gel Extraction 
PCR products of the expected size were extracted from the gel using the Nucleospin Gel 
and PCR clean up kit following the manufacturer’s instructions (Macherey-Nagel). 
Briefly, PCR products were cut from the gels and placed in tubes. Then, tubes were 
weighed and NTI buffer was added to the sample. Next, samples were incubated for 10 
minutes at 50 °C with vortexing every 2 minutes. Fully dissolved gel products were 
loaded on the columns and centrifuged at 11000 x g for 30 seconds. Flow through was 
discarded and columns were washed twice with 700 µl of NT3 buffer and centrifuged 
again. Afterwards, columns were centrifuged for 3 minutes at 11000 x g in order to dry 
the silica. PCR products were eluted using 20 µl of buffer NE. DNA concentrations were 
estimated using NanoDrop (Thermo Scientific). 
2.2.6 Digestion with DpnI  
In order to remove the DNA template from the mixture, 20 µl of eluted DNA was mixed 
with 2 µl of CutSmart Buffer (cat. no. B7204S, New England BioLabs) and 1 µl of DpnI 
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enzyme (cat. no. R0176S, New England BioLabs). Samples were incubated for 2 h at 
37 °C. Next, enzyme was heat inactivated at 80 °C for 20 minutes. 
2.2.7 PCR clean up 
Samples were purified using the same kit as for the gel extraction (Macherey-Nagel) 
with some modifications. Briefly, 70 µl of DEPC water and 140 µl of NTI buffer were 
added and the samples and incubated for 10 minutes at 50 °C. Then, samples were 
added to the columns and centrifuged at 11000 x g for 30 seconds. Flow through was 
discarded. Next, 700 µl of NT3 buffer were added to the columns and centrifuged at 
11000 x g for 30 seconds. This step was repeated once. Columns were centrifuged for 
another 3 minutes in order to dry the silica and then placed in a clean tube, 20 µl of NE 
buffer were added and samples were incubated for 2 minutes at room temperature. 
Samples were then centrifuged at 11000 x g for 1 minute and DNA concentration was 
measured by NanoDrop. 
2.2.8 Ligation 
4 µl of Ligase Buffer (cat. no. B020S, New England BioLabs), 0.4 µl of T4 DNA Ligase 
(cat. no. M0202S, New England BioLabs) and 150 ng of DNA were mixed together and 
up to 40 µl of DEPC water was added to each reaction. Then, samples were incubated 
at 16 °C overnight and enzyme heat inactivated for 10 minutes at 65 °C. 
2.2.9 Transformation 
Competent DE3 E. coli NovaBlue cells (Novagen) were thawed on ice and 4 µl (150 ng) 
of DNA was added to the cells (20 µl of cells per transformation). Samples were 
incubated on ice for 5 minutes and quickly transferred at 42 °C for 30 seconds. Next, 
samples were incubated on ice for 2 minutes. Then, 80 µl of pre-warmed SOC media 
was added to the cells, mixed and 50 µl of cells were plated on the 2YT-AG (yeast 
tryptone with 100 µg/ml ampicillin and 3 % (w/v) glucose) plates. Bacteria were grown 
overnight at 37 °C. 
2.2.10 Bacteria cultures 
Single colonies from agar plates were selected and grown in 5 ml of 2YT-AG media 
overnight at 37 °C. Plasmid preparation was performed as previously described (2.2.1). 
Glycerol stocks were prepared in 50 % of glycerol and stored at -80 °C for further use.  
2.2.11 Sequencing  
10 µl of 100 ng/µl of DNA were sent for Sanger sequencing (Source BioScience). All 
samples were sequenced using T7 Forward primer derived from the company stock. 
Sequencing results were analysed using SnapGene Viewer software (GSL Biotech LLC).  
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2.3 Expression and purification of recombinant prion proteins  
2.3.1 Recombinant prion protein expression 
Bacterial glycerol stocks were grown at 37 °C overnight in 10 ml of 2YT-AG media. 
Cultures were then diluted 1/100 and transferred into 250 ml of 2YT-AG media and 
grown at 37 °C with 180 rpm shaking until OD600 reached 0.4. Afterwards, bacteria were 
centrifuged at 1500 x g at 4 °C and resuspended in 250 ml of 2YT media with 100 μg/ml 
of ampicillin and 1 mM IPTG (isopropyl β-D-1-thiogalactopyranoside) (2YT-AI) followed 
by overnight growth at 37 °C with shaking. Bacteria were centrifuged at 1500 x g at 
4 °C for 30 minutes, supernatant was removed and pellets were stored at -20 °C until 
required. Bacteria pellets were then re-suspended in 10 ml of lysis buffer (50 mM 
NaH2PO4, 300 mM NaCl, pH 8.0, 0.1 % (v/v) NP-40, 10 mg/ml lysozyme, 1 tablet of 
Protease and Phosphatase Inhibitor (Thermo Scientific)) and incubated at 37 °C for 1 h. 
Then, 240 μl of 1 mg/ml DNase (cat. no. DN25, Sigma) and 120 μl of 1 M MgCl2 were 
added and incubated at room temperature for 15 minutes. The lysate was then 
centrifuged at 9600 x g for 20 minutes and supernatant was removed. Bacterial pellets 
were washed three times using 10 mM Tris, pH 8.0, 0.1 % (v/v) NP-40. After the first 
wash, 20 minutes incubation on ice was performed. Every wash was followed by 
centrifugation at 9600 x g for 20 minutes. Afterwards, supernatant was removed and 
bacterial pellet re-suspended in 20 ml of solubilisation buffer (8 M Urea, 50 mM NaH2PO4, 
300 mM NaCl, pH 7.5). Pellet solubilisation was performed overnight at room 
temperature and then samples were centrifuged at 9600 x g for 1 h. Supernatant was 
collected and stored at 4 °C until required. 
2.3.2 Protein purification 
Recombinant proteins were purified using the Fast Protein Liquid Chromatography 
(FPLC) on an AKTA prime FPLC machine (GE Healthcare). Briefly, the column (cat no. 
71-7005-00 AZ, HiTrapTM Chelating High Performance Column) was charged with 50 mM 
CuSO4, washed and supernatant containing the protein of interest was passed through 
the column. Recombinant prion proteins were eluted using imidazole gradient (0 – 0.5 
M) in elution buffer (50 mM NaH2PO4, 300 mM NaCl, pH 7.5). Afterwards, the protein 
purity was analysed on the polyacrylamide gel stained with Instant Blue (Expedeon) and 
fractions with rPrPs were pooled together. Protein concentration was estimated using 
Bradford assay (2.3.3) and then protein was frozen at –80 °C in the elution buffer with 
20 % (w/v) sucrose until required. 
2.3.3 Bradford Assay 
Bovine Serum Albumin (BSA) standard curve (1.4 mg/ml – 0.25 mg/ml) was prepared 
by diluting the BSA stock solution (2 mg/ml) in sample buffer. Briefly, 1.4, 1.0, 0.5 and 
0.25 mg/ml standards were made in tubes and 5 μl of each standard and samples were 
put in duplicates on the Nunc-Immuno Maxisorp ELISA 96 well plate (Thermo Scientific) 
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and 250 μl of Bradford Reagent (cat. no. B6916, Sigma) were added into wells. Plates 
were incubated for up to 15 minutes and the absorbance at 595 nm was measured in 
the Tecan plate reader (Tecan GENios). Blank absorbance values (sample buffer only) 
were subtracted from each measurement and an average value was calculated. Average 
value was plotted against concentration and the amount of protein in samples was read 
from the curve. 
2.3.4 Protein concentration and dialysis  
Before every experiment with the recombinant prion protein, rPrPs were thawed and 
the protein concentration was estimated with Bradford Reagent (see chapter 2.3.3). 
Protein batches were then concentrated using the Pierce Protein Concentrators with 
a molecular weight cut off (MWCO) of 10K (cat. no. 88516, Thermo Scientific) and a 2-
step dialysis was performed on ice using the 0.5 ml G2 dialysis cassettes with the same 
MWCO – 10K (cat. no. 88250, Thermo Scientific). Briefly, 400 μl of protein concentrate 
was loaded into a previously hydrated cassette and the protein was dialysed in buffer 1 
(PBS with 10 % (w/v) sucrose) for 1 h on ice and then dialysed for 1 hour in buffer 2 
(PBS only). Sample was then recovered from the cassette and a Bradford assay was 
performed in order to estimate the protein concentration. Dialysed recombinant prion 
proteins were stored at 4 °C until further use. 
2.4 Recombinant PrP mutants and PrP peptides analysis 
2.4.1 Protein Misfolding Cyclic Amplification with scrapie isolate PG1361/05 
Protein misfolding cyclic amplification (PMCA) was used to amplify prion and assess any 
inhibitory properties of the recombinant PrP or peptides of PrP. Each reaction was 
performed in clear 0.2 ml tubes (Sarstedt). Routinely, scrapie strain PG1361/05 
(genotype ARQ/VRQ) was the source of the PrPSc seed, while the 10 % healthy brain 16 
(genotype VRQ/VRQ) was the source of PrPC substrate. A range of concentrations of 
rVRQ (0.25 nM – 1200 nM) and rVRQ mutants were added to samples before the 
amplification started. As seed, 5 μl of 1 % scrapie PG1361/05 brain homogenate was 
added into every reaction to a final reaction volume 100 μl. PMCA was performed for 24 
h with repeat cycles of 40 seconds of sonication and 29 min 20 seconds incubation at 
37 °C (48 cycles in total). Power was set to 180 – 200 W (S-4000 Misonix, Ultrasonic 
Liquid Processors). Amplification products were stored at -20 °C. 
2.4.2 Serial Protein Misfolding Cyclic Amplification 
In serial Protein Misfolding Cyclic Amplification (sPMCA) multiple rounds of sonication 
and incubation at 37 °C were used. Again, this method was used to assess the inhibitory 
ability of rPrP. After round 1 (24 h), PMCA reaction products were diluted 1/3 into fresh 
PrPC substrate (negative brain homogenate) and amplified for another 24 h (up to 5 
PMCA rounds were performed). Amplification conditions were as detailed in 2.4.1. In 
inhibition sPMCA, different TSE isolates were tested with 50 nM of rRRQ, rKRQ and rPRQ 
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added into every PMCA round. For round 1 of serial PMCA, seeds of PrPSc were added as 
follows: 0.5 µl of 10 % brain homogenate for PG1361/05 (ARQ/VRQ), PG1207/03 
(VRQ/VRQ), and 5 µl of 10 % brain homogenate for ovine scrapie PG1499/02 
(AHQ/VRQ), bovine BSE (SE1945/0035), ovine BSE (PG1693/03, ARQ/ARQ) and 
CH1641 like scrapie isolates – J3011 (AHQ/AHQ) and J2935 (ARQ/AHQ). Round 1 PMCA 
products were diluted 3/7 into fresh PrPC substrate. All mentioned scrapie isolates were 
amplified in VRQ/VRQ (brain 16) substrate, whereas the bovine BSE was amplified in 
bovine substrate. Ovine BSE PG1693/03 amplification was tested in VRQ/VRQ (brain 
16) substrate in all rounds of amplification and also in AHQ/AHQ (brain 51 – for rounds 
1, 3 and 5) and VRQ/VRQ (brain 42 – for rounds 2 and 4) substrates. On the other hand, 
CH1641 like scrapie isolates: J3011 and J2935 were amplified in AHQ/AHQ negative 
brain homogenate (brain 49). 
2.4.3 Peptides design and inhibition 
In order to identify whether fragments of recombinant prion proteins that include the 
136 position are still able to inhibit the misfolding process, non-overlapping peptides 
derived from ovine prion protein were designed and ordered (Figure 2.4.1) (Biomatik, 
GeneCust). Two different peptide sizes were designed for rVRQ, rRRQ, rKRQ and rPRQ, 
33 amino acids (aa) and 18 aa long. In addition, a 43 aa long peptide, residues OvR130-
173, was designed for rRRQ, containing position 136, 154 and 171. Furthermore, 
sequence for the fragment OvV112-144 was randomised and used as a control. All 
peptides were acetylated on the N-terminus and amidated on the C-terminus. Peptides 
information including names, mutations, sequences and molecular weights are 
described in Table 2.4.1.  
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33 aa 3325.24 
OvV122-139 V GAVVGGLGGYMLGSVMSR 18 aa 1751.84 
OvR122-139 R GAVVGGLGGYMLGSRMSR 18 aa 1809.66 
OvK122-139 K GAVVGGLGGYMLGSKMSR 18 aa 1780.74 




















43 aa 5606.16 
1RND – randomised, V – valine, R- arginine, K – lysine, P – proline; 
2The amino acid change has been underlined in peptide sequence; 
3aa – amino acid; 
4MW – molecular weight; 
 
Peptides were resuspended in the buffers recommended by the company. Therefore, 
peptides ovRND, OvV112-144, OvR112-144, OvK112-144 and OvP112-144 were 
resuspended in 80 % (v/v) acetonitrile. Peptide OvV122-139 was resuspended in 2 % 
(v/v) HCOOH, 18 % (v/v) acetonitrile. Peptides OvR122-139, OvK122-139, OvP122-
139 were resuspended in ultrapure water. For peptide OvR130-173, the supplier did not 
provide the recommended buffer, therefore peptide net charge was calculated using an 
on-line calculator pepcalc and peptide was resuspended in water (Lear and Cobb, 2016). 
Resuspended peptides were aliquoted and stored at -20 C.  
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Figure 2.4.1. Peptide alignment on ovine PrPC structure. A – 18 amino acids long 
peptide showed in green on the PrPC structure. B – 33 amino acid long peptide showed 
in yellow on the PrPC structure. C – 43 amino acids long peptide showed in red on the 
PrPC structure. All peptides contain the 136 position. Peptide 130-173 (43 amino acids 
shown in red in C) contains position 136, 154 and 171 in ovine PrP protein. The figure 
was generated using Phyre2 and EzMol1.3 software.  
2.4.4 Testing peptides and solvent inhibition of PMCA 
It was investigated if different concentrations of acetonitrile and acetonitrile with formic 
acid could interfere with misfolded prion protein amplification. Different concentration 
of acetonitrile (from 2.7 to 0.005 % (v/v)) and the mixture of formic acid with 
acetonitrile (from 0.04 % (v/v) HCOOH, 0.3 % (v/v) acetonitrile to 0.00007 % (v/v) 
HCOOH, 0.0006 % (v/v) acetonitrile) were added to PMCA reactions. It was then tested 
whether the designed peptides can inhibit the amplification of prion protein better in 
comparison to the recombinant proteins rVRQ, rRRQ, rKRQ and rPRQ. The PMCA 
reactions were performed as previously described (2.4.1). 
2.4.5 Proteinase K digestion of PMCA products 
PK stock solution was prepared at 0.2 mg/ml with 0.045 % (w/v) SDS. Amplified 
samples were mixed 50:50 by volume with PK stock solution, giving a final PK 
concentration of 100 μg/ml. Then samples were incubated at 37 °C for 1 h in a water 
























2.4.6 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and western blotting 
NuPAGETM 12 % Bis-Tris gels (cat. no. NP0342, Invitrogen) were placed in the XCell 
SureLockTM Mini (Invitrogen) and the 1 x MOPS buffer (cat. no. NP0001, Invitrogen) was 
added. 15 μl of each sample was mixed with 5 μl of 4 x LDS Sample Buffer (cat. no. 
NP0008, Invitrogen) with 5 % (v/v) β-mercaptoethanol and boiled at 100 °C for 
10 minutes. 10 μl of SeeBlueTM Plus2 Pre-Stained Protein Standard (cat. no. LC5925, 
Invitrogen) and 20 μl of each sample were loaded into gels and electrophoresis 
performed for 1 h at 200 W. Proteins were then stained with InstantBlue (Expedeon) 
and destained with ultrapure water. Gel images were captured using the ChemiDocTM 
Imaging System (BioRad). Alternatively, gels were used for western blotting, in which 
proteins were transferred onto polyvinylidene difluoride (PVDF) membrane. The wet 
transfer was performed for 75 minutes at 30 V in NuPAGE 1 x Transfer Buffer (cat. no. 
NP00061, Invitrogen). Then, membranes were blocked overnight in 5 % (w/v) milk 
powder (SMA) in 1 x TBST at 4 °C. 
2.4.7 Dot blot and PrPSc detection 
PK digested samples were mixed with 4 x LDS Sample Buffer (cat. no. NP0008, 
Invitrogen) with 5 % (v/v) β-mercaptoethanol, boiled at 100 °C for 10 minutes and 
2.5 μl of each were spotted onto nitrocellulose membrane (cat. no. 10600002, 
Amersham Protran) in duplicates. Membranes were then left to dry for 5 minutes and 
blocked overnight in 5 % (w/v) SMA in TBS with 0.05 % (v/v) Tween 20 (TBST) at 4 °C. 
Blocked overnight dot blots were incubated with SHA31 monoclonal antibody 1:40000 
in 0.5 % (w/v) SMA in TBST for 1.5 h. SHA31 antibody binds to the epitope YEDRYYRE, 
which in ovine prion protein is equivalent to positions 145-152 (Féraudet et al., 2005). 
Then, blots were washed 3 x 10 minutes with 0.5 % (w/v) SMA in TBST and incubated 
for 1 hour with a 1:2000 dilution of secondary antibody (cat. no. P0447, polyclonal goat 
anti-mouse HRP, Dako) in 0.5 % (w/v) SMA in TBST. Afterwards, blots were washed 
4 x 10 minutes in 0.5 % (w/v) SMA in TBST and once in ultrapure water. Then, 
membranes were incubated with HRP substrate EZ-ECL (Biological Industries), sealed 
in clear plastic and visualised using the ChemiDocTM Imaging System (BioRad). 
2.4.8 rVRQ mutants screening for inhibition of PMCA  
All rPrP mutants details are provided in Table 2.4.2. These 136 position rVRQ mutants 
were screened at 100 nM and compared to rVRQ at 1200 (100% inhibition control) and 
100 nM (direct comparison control). Inhibitors that appeared to have higher inhibition 
than the rVRQ were chosen for further analysis and the estimation of the IC50 value. 
To do this, a range of mutant concentrations were added to amplification reaction and 
then the samples underwent PMCA as previously described. PK digestion was performed 
and 2.5 μl of each sample was added on dot blots in duplicates and incubated with 
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primary and secondary antibodies, as described previously. Membranes were visualised 
using ChemiDoc Imaging System (BioRad). 
Table 2.4.2. rPrPs mutants at 136 position details. 
Mutation1 Mutant name MW2 [Da] 
V rVRQ 22782.19 
V → I rIRQ 22796.22 
V → F rFRQ 22830.24 
V → N rNRQ 22797.16 
V → S rSRQ 22770.14 
V → R rRRQ 22839.25 
V → C rCRQ 22786.22 
V → L rLRQ 22796.22 
V → Y rYRQ 22846.23 
V → H rHRQ 22820.2 
V → K rKRQ 22811.2 
V → G rGRQ 22740.1 
V → W rWRQ 22869.3 
V → Q rQRQ 22811.2 
V → P rPRQ 22780.2 
V → T rTRQ 22784.2 
V → D rDRQ 22798.2 
V → E rERQ 22812.2 
V → M rMRQ 22814.3 
1V – valine, I – isoleucine, F – phenylalanine, N – asparagine, S 
– serine, R – arginine, C – cysteine, L – leucine, Y – tyrosine, 
H – histidine, K – lysine, G – glycine, W – tryptophan, 
Q – glutamine, P – proline, T – threonine, D – aspartic acid, 
E – glutamic acid, M – methionine; 
2Molecular weight (MW) was calculated from its protein 
sequence using the ExPASy calculator, Da – daltons 
 
2.4.9 Analysis 
The dotblot images were analysed using the ImageJ software (Figure 2.4.2) 
(Schneider, Rasband and Eliceiri, 2012). First of all, average light density for a defined 
spot area was measured for 100 % inhibition control. Then, this value was subtracted 
from the average light density for all spots measured on that same blot. Percentage of 
inhibition was calculated and compared to either uninhibited or 100 nM rVRQ control. 
Values were plotted in GraphPad Prism. For all data distribution was established using 
normality tests. Then, equivalent parametric or non-parametric statistical test was used. 
In order to calculate the half maximal inhibitory concentration (IC50 values), non-linear 





Figure 2.4.2 Flowchart of experiment set up and analysis for testing the rPrPs in PMCA. 
PrPSc was amplified in the absence or presence of rVRQ or different rPrPs. 1200 nM of 
rVRQ was treated as a background control, whereas 100 nM rVRQ was a direct 
comparison control. In first experiments rPrPs were added at 100 nM into the PMCA. 
PrPC control was also included on the blot and acted as a background/PK digestion 
control. When dotblots were analysed, firstly the background spots for 1200 nM rVRQ 
were measured and subtracted from blot. Then, average densitometry signal for rPrPs 
and no inhibition control spots were measured. For each rPrP (including 100 nM rVRQ) 
percentage of no inhibition control average was calculated. The values were next 
compared to rVRQ at 100 nM. rPrPs that were better than rVRQ were further analysed 
in IC50 values experiments, whereas rPrPs worse than rVRQ were not analysed further.  
2.5 Structural analysis of rPrP mutants at 136 position 
In order to assess and predict the impact of specific mutation at 136 position in ovine 
PrP, structures of recombinant prion proteins were analysed. As an example of PDB data 
entry, we used previously deposited file 2N53. This entry showed the solution structure 
of ovine PrP with valine at 136 position (Munoz-Montesino et al., 2016). We used this 
file to extract the NMR analysis in PYMOL by using the PYMOL commend ‘show 
all_states’ (Schrodinger, 2010). The ClustalW on-line tool was used for sequences 
alignment (Higgins, Thompson and Gibson, 1996). Then, rPrP structures pdb files were 
created using the online tool DynaMut with the mutation effect prediction resource 
(Rodrigues, Pires and Ascher, 2018). Pdb files were downloaded and data were analysed 
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2.6 Inhibition of α-synuclein misfolding with rRRQ 
Recombinant α-syn was a gift from a research group member Juan Fernandez Bonfante. 
Methodology for α-syn fibrils formation was optimised and described by Juan Bonfante 
Fernandez (personal communication). Briefly, 20 µM of monomeric α−synuclein was 
spiked with misfolded α−synuclein from PD patients brains or healthy control brains. 
Recombinant prion protein with R at 136 position (rRRQ) at concentrations 1, 50 or 100 
nM was added into the reactions. In addition, also rKRQ and PRQ were added at 50 nM. 
Then, samples were amplified with 40 seconds of sonication and 29 minutes 20 seconds 
of incubation at 37 °C with power was set to 100 – 120 W (S-4000 Misonix, Ultrasonic 
Liquid Processors). Amplification was performed for 72 h. Next, samples were digested 
with PK at 17 µg/ml and products were analysed on the NuPAGETM 4-12 % Bis-Tris gels 
(cat. no. NP0322, Invitrogen) in 1 x MES buffer (cat. no. NP0002, Invitrogen). Gels were 
run for 30 minutes at 200 V and stained with Instant Blue (2.4.6).  
2.7 Rov9 cell culture 
Rov9 are a cell line created from rabbit kidney epithelial cells - RK13. These cells were 
transfected with pTRE plasmid containing ovine PrP sequence (VRQ variant). In addition, 
the level of ovine PrP is controlled by the presence of doxycycline (Vilette et al., 2001). 
Rov9 cells were a gift from Hubert Laude (Virologie et Immunologie Moléculaires, Jouy-
En-Josas, France). Cells were visualised using the inverted biological microscope (Ceti). 
All cells images were taken with Panasonic DMC-FS7 camera and cropped in GIMP 
(version 2.10.14). Moreover, Rov9 cells persistently infected with SSBP1 were a gift 
from Dr Fiona Houston (Roslin Institute). These cells were used as a comparison to our 
infected cells.  
2.7.1 Rov9 cells maintenance 
The main stock of Rov9 cells was maintained in Eagle’s Minimum Essential Medium 
(EMEM, cat. no. M2279, Sigma) at 37 °C, 5 % CO2 in a humidified incubator. To generate 
this, the liquid nitrogen stored cell stock was thawed and immediately re-suspended in 
EMEM with 5 % (v/v) Fetal Bovine Serum (FBS, Fisher Scientific) and 1 % (v/v) of total 
pre-mixed solution of Penicillin, Streptomycin and Glutamine (Pen/Strep/Glu, cat. no. 
G1146, Sigma). Media with addition of FBS and Pen/Strep/Glu is referred to as media 
complete. Next, cells were centrifuged at 300 x g for 5 minutes and supernatant was 
discarded. Then, Rov9 cells were re-suspended in 5 ml of EMEM complete and grown in 
a 25 cm2 tissue culture flask (Greiner Bio-One) at 37 °C, 5 % CO2.  
After Rov9 cells reached around 70-80 % confluence, sub passage of cells was 
performed. Briefly, flasks with Rov9 cells were washed with Dulbecco Phosphate 
Buffered Saline (D-PBS) with MgCl2 and CaCl2 (cat. no. D8662, Sigma). Then, cells were 
detached from the tissue culture flasks using 0.25 % (w/v) trypsin – EDTA (cat. no. 
T4049, Sigma). Cells were collected in complete media to neutralise the trypsin-EDTA 
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solution and centrifuged for 5 minutes at 300 x g. Supernatant was discarded, Rov9 
cells were washed in D-PBS and centrifuged again. The wash step was repeated twice. 
Afterwards, cell pellets were re-suspended in EMEM complete. Part of the cells was 
mixed with 0.4 % trypan blue solution (cat. no. 15250-061, Gibco) in order to assess 
cell viability. Cell count and viability was analysed using the Neubauer Haemocytometer 
counting chamber and Ceti Inverted Microscope. Then, Rov9 cells were seeded at 1/5 
or 1/8 ratio in EMEM complete. One T75 cm2 flask (Greiner Bio-One) with Rov9 cells in 
EMEM complete was maintained for the whole experiment. 
Cell culture experiments were interrupted by a sudden University laboratory closure due 
to the Covid-19 pandemic. Therefore, samples were collected and frozen with addition 
of freezing mix (80% (v/v) FBS and 20 (v/v) % of dimethylsulfoxide (DMSO)) at -80 °C. 
2.7.2 Rov9 cells storage 
For longer storage cells were frozen and stored at either -80 °C or in liquid nitrogen. 
For both storage strategies, cells were prepared as follows. When Rov9 cells reached 
about 80 % confluence, they were washed 1 x with D-PBS, trypsinised and counted as 
described in chapter 2.7.1. Next, freezing mix and media complete were mixed together 
in 1:1 ratio and slowly added on the cells. The cell density was 1 x 106 cells/ml. For 
longer term storage, cells were moved to a container with isopropanol and placed at -
80 °C for 3 days. After this period, cells were moved to liquid nitrogen and stored until 
required. For short term storage, cells were immediately placed on ice and then at -80 
°C until required. 
2.7.3 Induction of PrP expression in Rov9 cells 
Rov9 cells were seeded on T75 cm2 flask at a density 0.7 x 106 cells or 12 well plate 
(ThermoFisher Scientific) at 0.1 x 106 cells per well. Seeded cells were grown for 48 h 
or until they reached 90 % confluence in EMEM complete. Then, in order to express the 
ovine PrPC in Rov9 cell membranes, cells were stimulated with 1 µg/ml of doxycycline 
(cat. no. D9891, Sigma) and incubated for 48 h in OPTI MEM complete (5 % FBS, 1 % 
Pen/Strep/Glu, cat. no. 11524456, Gibco) for 48 h. Next, cells were washed with D-PBS 
and lysed in lysis buffer (50 mM Tris, 0.5 % (v/v) Triton X-100, 0.5 % (w/v) sodium 
deoxycholate, pH 7.4) for 10 minutes on ice. Then, cell lysates were centrifuged for 2 
minutes at 400 x g. Finally, supernatants were collected and stored at -20 °C for further 
analysis. 
2.7.4 Investigation of PrPSc amplification in sPMCA from scrapie isolates used as 
inocula in cell culture  
sPMCA with multiple rounds of sonication and incubation at 37 °C was used for 
amplification of scrapie isolates used in cell culture to assess their amplification in 
VRQ/VRQ substrate. For that purpose, 10 µl of each 10 % SSBP1, PG1207/03, 
PG1212/03 and PG1517/01 (all VRQ/VRQ) were mixed with 90 µl of negative brain 
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homogenates (B16) and amplified for round 1 (24 h). After round 1, PMCA reaction 
products were diluted 1/3 into fresh PrPC substrate (negative brain homogenate) and 
amplified for another 24 h (up to 5 PMCA rounds were performed). In addition, serial 
PMCA for PG1361/01 was also performed and 0.5 μl of 10 % scrapie PG1361/05 brain 
homogenate was added into every reaction to a final reaction volume 100 μl. 
Amplification conditions were as detailed in chapter 2.4.1. 
2.7.5 Infection of Rov9 cells with scrapie 
Rov9 cells were seeded on 12 well plates at 0.1 x 106 cells per well and grown at 37 °C 
in EMEM complete for 48 h. Then, media was discarded and cells were washed 1 x with 
D-PBS. OPTI MEM complete with or without 1 µg/ml of doxycycline was added and cells 
were incubated for 48 h. Next, infectious inoculas were prepared (as specified for each 
method below) and 1 ml of media with or without PrPSc was added onto the cells and 
incubated for 3 days at 37 °C, 5 % CO2 in a humidified incubator. After this time (72 h 
post infection), media was discarded and fresh OPTI MEM media complete with or 
without 1 µg/ml of doxycycline was added on the cells and incubated for 48 h. After that 
time (120 h post infection), media was discarded and cells were washed with 1 x D-
PBS. Next, D-PBS was discarded and cells were passaged. Briefly, 500 µl of 
1 x Trypsin/EDTA was added and cells were incubated for 5 minutes at 37 °C, 5 % CO2. 
Cells were then collected into sterile 1.5 ml tube and 500 µl of media complete was 
added. Cells were washed 2 x with sterile PBS and then seeded further on two wells on 
12-well plates in OPTI MEM complete with or without 1 µg/ml of doxycycline. This was 
the passage 1 of cells infected with scrapie. Then, cells were grown for 7 days. 
Afterwards, cells from 1 well were collected using 1 x Trypsin/EDTA and these cells were 
seeded further, whereas the cells from second well was washed 2 x with PBS and lysed 
with 500 µl of lysis buffer. These steps were repeated for every infection condition from 
passage 2 onwards.  
2.7.5.1 Rov9 cells infection with brain homogenates 
Healthy and scrapie brain homogenates were used for Rov9 cells infection. Briefly, 
10 % negative brain homogenate – B16 (VRQ/VRQ) and 10 % scrapie positive brain 
homogenates SSBP1 (VRQ/VRQ), PG1207/03 (VRQ/VRQ), PG1212/03 (VRQ/VRQ), 
PG1517/01 (VRQ/VRQ) or PG1361/05 (ARQ/VRQ) were added on non-induced or 
induced for 48 h with 1 µg/ml doxycycline Rov9 cells at ratios 1/500, 1/80 and 1/40 (2 
µl, 12.5 µl or 25 µl of 10 % brain per 1 ml of media, respectively). In addition, brain 
homogenates buffer controls were added on the cells at the same ratios as scrapie brain 
homogenates. These included conversion buffer (0.5 % (w/v) sodium deoxycholate, 0.5 
% (v/v) NP-40 in PBS) control and brain homogenate buffer (0.15 M NaCl, 1 % (v/v) 
Triton X-100, 4 mM EDTA, Protease Inhibitor Cocktail) control. Next, cells were 
incubated with inoculas in OPTI MEM complete with or without 1 µg/ml doxycycline for 
72 h and then media was replaced with OPTI MEM complete with or without 1 µg/ml 
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doxycycline. Culture was maintained for another 48 h, after which 1 passage was 
performed. 
In other alternative experiments, scrapie brain homogenates SSBP1 (VRQ/VRQ), 
PG1207/03 (VRQ/VRQ), PG1212/03 (VRQ/VRQ) or PG1517/01 (VRQ/VRQ) aliquots were 
heated at 80 °C for 20 minutes sonicated for 2 minutes (180-200 W) (4000 Misonix, 
Ultrasonic Liquid Processors) at 37 °C. Treated brain homogenates were mixed with 
OPTI MEM media with or without 1 µg/ml doxycycline and added on the induced Rov9 
cells in 1/40 (25 µl of 10 % brain for PG1207/03, PG1212/03, PG1517/01) or 1/80 (12.5 
µl of 10 % brain homogenate for SSBP1) ratio. Then, cells were incubated for 72 h at 
37 °C, 5 % CO2 and infectious inocula were replaced with OPTI MEM complete with or 
without 1 µg/ml doxycycline. Samples were incubated for further 48 h, after which cells 
were passaged. After splitting, cells were further maintained for 7 days before passaging 
further.  
2.7.5.2 Inoculation of Rov9 cells with PrPSc precipitated from brain homogenates 
using silicon dioxide 
Silicon dioxide (SiO2) has been reported to bind and precipitate resistant prion protein 
(Rees et al., 2009). Therefore, it was used here to concentrate PrPSc from brain 
homogenates. Brain homogenates (10 or 20 % (w/v)) were prepared by mixing 50:50 
with D-PBS. Then, 50 µl of each diluted brain homogenate was mixed with 25 µl of 20 % 
(w/v) SiO2 slurry in PBS (cat. no. 637238, Sigma). Samples were sealed and incubated 
with rotation for 3 h at room temperature. Then, samples were centrifuged for 10 
minutes at 400 x g. Supernatants were collected for further analysis, whereas 
precipitates were re-suspended and washed with in 0.1 % (w/v) SDS. Then, samples 
were centrifuged again at 400 x g for 3 minutes. Supernatants were collected for further 
analysis. Each pellet was then re-suspended in 1 % (w/v) SDS and vortexed for 
2 minutes. Next, samples were centrifuged at 400 x g for 2 minutes and supernatants 
containing PrPSc were collected.  
In order to exchange the buffer from 1 % (w/v) SDS to D-PBS that is suitable for cell 
culture, samples were precipitated using absolute methanol (MeOH). Briefly, the PrPSc 
solution was mixed with ice-cold MeOH in 5:1 ratio and incubated for 1.5 h at -20 °C. 
Then, samples were centrifuged at 21 000 x g for 30 minutes at RT. Supernatants were 
discarded and protein pellets were re-suspended in D-PBS. For short term storage, 
samples were kept at 4 °C, whereas for long term storage, samples were kept at -20 °C. 
10 or 20 µl of these SiO2 extracted products were added per 1 ml of OPTI MEM complete 
with 1 µg/ml doxycycline on cells and incubated for 72 h at 37 °C, 5 % CO2. After 72 h, 
media was discarded and fresh OPTI MEM complete with 1 µg/ml doxycycline was added 
on cells and incubated in the same conditions for further 48 h. Cells were then passaged 
and incubated for another 5 days in OPTI MEM complete with 1 µg/ml doxycycline. After 
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5 days, half of the cells were lysed, PK digested and analysed on western blotting, 
whereas the other half was seeded on a cell culture dish and grown further.  
2.7.5.3 Inoculation of Rov9 cells with PrPSc precipitated from brain homogenates 
using NaPTA  
Sodium phosphotungistic acid (NaPTA) has been reported to bind misfolded PrPSc and 
allows the purification and concentration PrPSc from brain homogenates (Safar et al., 
1998). In order to precipitate PrPSc from 10 % brain homogenates SSBP1, PG1207/03 
(VRQ/VRQ genotypes), PG1361/05 (ARQ/VRQ) were digested with PK at 50 µg/ml for 
1 h at 37 °C. Digestion was stopped by freezing the samples at -80 °C for 5 minutes. 
Then, samples were warmed to RT. 4 % (w/v) NaPTA solution (cat. no. P6395, Sigma) 
was prepared, pre-warmed at 37 °C and added to PK digested samples to a final NaPTA 
concentration 0.3 % (v/v). Samples were incubated for 30 minutes at 37 °C and then 
centrifuged for 30 minutes at 20 000 x g. Supernatants were removed and pellets were 
re-suspended in D-PBS. For short term storage, samples were kept at 4 °C, whereas for 
longer storage samples were kept at -20 °C.  
30 µl of NaPTA precipitated PrPSc were added per 1 ml of OPTI MEM complete with 
1 µg/ml doxycycline and incubated for 72 h at 37 °C, 5 % CO2. Then, scrapie inoculas 
were discarded and fresh OPTI MEM complete with 1 µg/ml doxycycline was added on 
the cells and incubation at 37 °C, 5 % CO2 was performed for another 48 h. After that 
time (120 h post infection, 5 dpi) cells were collected, frozen and stored until further 
notice at -80 °C. This experiment was interrupted by sudden facility closure due to 
Covid-19 pandemic. When possible, cells were retrieved from -80 °C storage and 
analysed further.  
2.7.6 BCA assay 
For protein content estimation in cell lysates, PierceTM BCA Protein Assay Kit was 
performed as described in company protocols for a microplate procedure (ThermoFisher 
Scientific). Briefly, BSA standards at concentrations 2000 – 0 µg/ml were prepared in 
lysis buffer. Each standard and sample in duplicate (25 µl) were added into wells (Nunc-
Immuno Maxisorp ELISA 96 well plate; ThermoFisher Scientific). Next, 200 µl of BCA 
Working Reagent was added per well and plates were incubated for 30 minutes at 37 °C. 
After the incubation plates were read at 595 nm (FLUOstar, BMG Labtech). Blank 
absorbance values (lysis buffer only) were subtracted from each measurement and 
average values were calculated for each sample and standard. Then, values were plotted 
against concentration and the amount of protein in samples was read from the curve. 
2.7.7 PrPres concentration from cell lysates  
500 µg of protein from each protein lysate was digested with 20 µg/ml of PK for 1 h at 
37 °C. The digestion was stopped by freezing at -80 °C for 5 minutes. After thawing, 
samples were centrifuged for 1 h at 20 000 x g. Supernatant was removed and PrPres 
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pellets were re-suspended in 15 µl of PBS. 5 µl of 4 x LDS Sample Buffer (cat. no. 
NP0008, Invitrogen) with 5 % (v/v) β-mercaptoethanol was added and samples were 
boiled for 10 minutes at 100 °C. Then, SDS-PAGE, western blotting and 
immunodetection with SHA31 antibodies were performed as described previously 
(2.4.6, 2.4.7).  
2.7.8 The detection of PrPres in cell lysates using serial PMCA  
For the first round of PMCA, 10 µl of each cell lysate were mixed with 90 µl of TSE 
negative brain homogenate B16 (VRQ/VRQ). For negative control, 10 µl of lysis buffer 
instead of cell lysate were mixed with 90 µl of B16. For a positive control, scrapie 
PG1361/05 (ARQ/VRQ) diluted 1/10 diluted in lysis buffer was used. Each condition was 
run in triplicates. Samples were amplified for 24 h with 40 seconds of sonication and 29 
minutes 20 seconds incubation at 37 °C cycles with power set to 180 – 200 W (S-4000 
Misonix, Ultrasonic Liquid Processors). Then, samples were diluted 1/3 into fresh B16 
and amplified for another 24 h. Five rounds of PMCA were performed. All amplification 
products were stored at -20 °C for further analysis. The dotblot and western blot 
analysis was performed as previously described. 
2.7.9 Preventing infections of Rov9 cells with recombinant PrPs 
rVRQ, rRRQ, rKRQ, rPRQ and rARR were concentrated and dialysed prior to each 
experiment as described in chapter 2.3.4. In addition, Bradford assay was performed 
to estimate the protein content before every protein use (2.3.3). 50 or 250 nM of each 
recombinant protein was mixed with heated and sonicated 10 % SSBP1 brain 
homogenate (VRQ/VRQ) in OPTI MEM media with or without 1 µg/ml doxycycline. 
Brain/media/rPrP mixture was incubated for 1 h at 37 °C and added on the cells on the 
infection day. rPrP was kept on the cells after each cells subculture.  
2.7.10 Curing Rov9 PrPres infections with recombinant PrPs 
Persistently infected with SSBP1 (VRQ/VRQ) cells were seeded on the 12 well plate with 
density 0.1 x 106 cells per well with or without 250 nM of each rPrPs. Cell were incubated 
in OPTI MEM complete with 1 µg/ml doxycycline for 4 days at 37 °C, 5 % CO2 humidified 
incubator. After 4 days, cells were washed 2 x with PBS and 500 µl of lysis buffer was 
added. Cells were lysed on the plate for 10 minutes, lysates were collected and 
centrifuged for 5 minutes at 400 x g. Supernatants were collected and stored at -20 °C 
for further analysis. 
2.7.11 Data analysis 
The densitometry for all western blots was measured in ImageJ using the gel analysis 
tool (Schneider, Rasband and Eliceiri, 2012). Where possible data distribution was 
established using normality tests. According to the values distribution, equivalent 
statistical tests were used in order to analyse the data.  
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Chapter 3: The production of rPrP mutants at 




TSE diseases have been recognised since the first description of scrapie in 1853 but, 
they still lack any successful therapeutic (Stockman, 1913; Forloni et al., 2013). Many 
agents have been tested in both in vitro and in vivo with few then being assessed in 
clinical trials. Amongst them are drugs, antibodies, peptides but also recombinant prion 
proteins. All of these target cellular PrP, PrPSc or the protein misfolding process (Trevitt 
and Collinge, 2006). 
In ovine PrP three common polymorphisms at 136, 154 and 171 positions have been 
recognised as having serious impact on scrapie development. The paradigm is that VRQ 
are the most susceptible to classical scrapie and ARR the most resistant (DEFRA, 2001). 
This research will focus on using recombinant ovine PrP with variations at position 136 
as a therapeutic agent for prion disease. Previous research demonstrated that 
recombinant ovine PrP with valine (VRQ) acted as a better inhibitor in vitro for various 
prion diseases isolates than PrP with alanine (ARQ) at 136 position (Workman, Maddison 
and Gough, 2017). Moreover, it was also tested whether ARR also inhibit the in vitro 
amplification of isolates. The research showed that the rARR was the least potent 
inhibitor with the highest IC50 value compared to VRQ, ARQ and hamster recombinant 
PrPs (Workman, Maddison and Gough, 2017). The first aim of this research was to obtain 




3.2.1 Availability of rPrP mutants  
Within the study, valine at position 136 in rVRQ was mutated into the other 18 amino 
acids. Clones of nine rVRQ mutants within the expression vector pET22b(+) were 
available at the outset of the study: IRQ, FRQ, NRQ, SRQ, RRQ, CRQ, LRQ, YRQ and 
HRQ. For these clones, the presence of the specific mutation was confirmed by Sanger 
Sequencing. The other 9 recombinant prion protein clones (KRQ, GRQ, WRQ, QRQ, PRQ, 
TRQ, DRQ, ERQ and MRQ) were produced by site directed mutagenesis during this study. 
3.2.2 Inverse PCR for making recombinant prion proteins 
Firstly, inverse PCR was carried out with positive samples (with the DNA of interest) and 
compared to negative samples (no template). DNA for 8 samples was confirmed as 
positive on the agarose gel (producing a band of ~6 kb), while there was no PCR product 
for one sample, rQRQ (Figure 3.2.1). Furthermore, the forward primer for QRQ (1) 
with mutation codon CAG did not work in different amplification temperatures in the 
inverse PCR (Figure 3.2.2, A), therefore a new forward primer for rQRQ with a CAA 
codon to mutate position 136 to glutamine (rPrP-For-Q(2)) was designed. Inverse PCR 
was performed with the rPrP-For-Q(2) primer and annealing temperatures in the range 
58 – 60 °C were tested. In all mentioned temperatures, PCR product was positive 
(Figure 3.2.2, B). All clone variants were produced and Sanger sequenced to confirm 




Figure 3.2.1. Inverse PCR amplification of site directed PrP mutants. Template vector 
(pet22b(+)) containing the Prnp gene for rVRQ was amplified by inverse PCR (annealing 
temperature 61 °C) using primers to mutate the equivalent codon at position 136 in 
ovine PrP. DNA products were assessed for a band at 6.2 kb on 1 % agarose gel. For 
some negative samples, bands were visible on the gel and could suggest primers 
dimerization or samples contaminants. M – DNA marker, 1 – KRQ, 2 – GRQ, 3 – WRQ, 
4 – QRQ, 5 – PRQ, 6 – TRQ, 7 – DRQ, 8 – ERQ, 9 – MRQ, N – the equivalent negative 
samples. 
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Figure 3.2.2. Gradient inverse PCR amplification of rQRQ with rPrP-For-Q(1) primer 
(A) and rPrP-For-Q(2) primer (B). Template vector (pet22b(+)) containing the Prnp 
gene for rVRQ was amplified by gradient inverse PCR to mutate the codon at position 
136 in ovine PrP. The annealing temperatures A – 50-63 °C using primer rPrP-For-Q(1) 
and B – 58-60 °C using the primer rPrP-For-Q(2) were tested. DNA products were 
assessed for a band at 6.2 kb on 1 % agarose gel. M – DNA marker, 1 – 14 – different 
annealing temperatures, N – equivalent negative control (no DNA template). 
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3.2.3 Purification of recombinant prion proteins 
Recombinant prion proteins were expressed and purified. Bacteria were grown and 
purified using FPLC using purified by immobilised metal affinity chromatography (IMAC) 
taking advantage of the metal binding properties of the PrP octapeptide repeat region. 
Eluted FPLC fractions were analysed by SDS-PAGE and gels stained with Instant Blue 
(Figure 3.2.3).  
 
 
Figure 3.2.3. Representative SDS-PAGE gel analysis of rVRQ, rRRQ and rERQ (~23 
kDa) purification fractions. 15 µl of each fraction were analysed on the gel stained with 
Instant Blue. A – rVRQ, B – rRRQ, C – rERQ, 25 – 37 eluted fractions. A 24 kDa marker 
is indicated on the left side of each gel. 
For eluate fractions containing purified rPrP were pooled and stored at -80 °C with 
addition of 20 % sucrose. Overall, from 1 L of bacterial culture, from 10 – 15 ml of pure 
rPrP were collected with concentration range being from 0.3 to 0.5 mg/ml. 
3.2.4 Dialysis of recombinant prion proteins 
Before use, the concentrations of thawed rPrP stocks were analysed by Bradford Assay 
to re-estimate protein content. When concentrations were below 0.5 mg/ml, rPrPs were 
concentrated using PierceTM Protein Concentrator PES with 10 kDa molecular weight cut 
off. All rPrPs were then dialysed and protein bands were analysed on SDS-PAGE gels. 
For rIRQ, rFRQ, rNRQ, rSRQ, rRRQ, rCRQ, rLRQ, rYRQ and rHRQ only dialysed fractions 
were analysed on the gel (Figure 3.2.4, A), whereas for rVRQ, rKRQ, rGRQ, rWRQ, 
rQRQ, rPRQ, rTRQ, rDRQ, rERQ, rMRQ purified non-dialysed and dialysed proteins were 
analysed (Figure 3.2.4, B). Purity of dialysed PrPs was estimated by densitometry 
analysis using ImageJ.  
C 27 28 29 30 31 32 33 34 35 36 37A 25 26 27 28 29 30 31 32 33 34 28 29 30 31 32 33 34 35 36 37B
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Figure 3.2.4. Examples of purity analysis and the effects of dialysis on recombinant 
rPrPs. A – dialysed rIRQ, rFRQ, rNRQ, rSRQ, rRRQ, rCRQ, rLRQ, rYRQ and rHRQ. B – 
non-dialysed (-) and dialysed (+) rVRQ, rKRQ, rGRQ, rWRQ, rQRQ, rPRQ, rTRQ, rDRQ, 
rERQ and rMRQ. Each rPrP was purified, fractions were pooled together, concentrated, 
where necessary, and dialysed for 1 h with PBS with 10 % sucrose, 0.25 M imidazole 
and then 1 h with PBS only. 15 µl of each fraction were analysed on the gel stained with 
Instant Blue. A 25 kDa marker is indicated on the left side of each gel. The purity of 
each rPrP was calculated using the ImageJ densitometry tool: the density of entire gel 
lane for each rPrP was measured and compared to the main band density. The 
percentage of protein purity was calculated from obtained in the software values.  
The representative purity for dialysed rPrPs calculated according to the SDS-PAGE gels 
analysis (Figure 3.2.4) is as follows rIRQ: 38 %, rFRQ: 48 %, rNRQ: 59 %, rSRQ: 36 
%, rRRQ: 38 %, rCRQ: 46 %, rLRQ: 64 %, rYRQ: 43 %, rHRQ: 43 %, rVRQ: 60 %, 
rKRQ: 56 %, rGRQ: 76 %, rWRQ: 72 %, rQRQ: 66 %, rPRQ: 50 %, rTRQ: 78 %, rDRQ: 
77 %, rERQ: 62 % and rMRQ: 69 %. In addition, dialysis caused the reduction of protein 
concentration by around 30-40 %. Moreover, different batches of recombinant proteins 
needed to be made and the process was consistent. This included re-purification and/or 
re-dialysis. All dialysed rPrPs were stored at 4 °C until use. 
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The change from alanine to valine at 136 position seems to have significant impact on 
the inhibition of misfolding process for prion diseases isolates (Workman, 2017; 
Workman, Maddison and Gough, 2017). To investigate whether other amino acid 
substitutions at this position in the prion protein will possess greater inhibitor properties 
to rVRQ, the codon for valine at 136 was mutated into other amino acids. While some 
of the recombinant proteins were previously made within the research group (IRQ, FRQ, 
NRQ, SRQ, RRQ, CRQ, LRQ, YRQ and HRQ), the others were produced during this study 
using site directed mutagenesis. This method allowed the successful mutation and 
production of the other recombinant prion proteins (KRQ, GRQ, WRQ, QRQ, PRQ, TRQ, 
DRQ, ERQ, MRQ). To my knowledge and to date, mutation of 136 position of ovine PrP 
into other amino acids was performed for the first time. rARQ (alanine136) was not 
produced and analysed in this study as it was previously determined as less potent than 
rVRQ inhibitor (Workman, 2017; Workman, Maddison and Gough, 2017). In contrast, 
rVRQ which was also analysed previously, was used as a control in this study.  
The purification of cellular PrP from brain (Turk et al., 1988; Pan, Stahl and Prusiner, 
1992; Pergami, Jaffe and Safar, 1996) usually resulted in low protein recovery: up to 
20 % of total PrPC from brains and low yield (Pan, Stahl and Prusiner, 1992; Pergami, 
Jaffe and Safar, 1996). Therefore, PrP brain isolation protocols were replaced with 
recombinant protein production systems. In this research, we used the NovaBlue DE3 
E. coli organism to produce recombinant ovine PrP. This protein expression system is 
highly accessible and produces a relatively high quantity of bacteria expressing 
recombinant protein in a short period of time (Rosano and Ceccarelli, 2014).  
In this research, recombinant ovine PrP was purified exploiting the ability of the 
octapeptide repeats within the prion protein sequence to bind metals. This allowed the 
purification of the prion protein that does not include any additional affinity tags in 
a one-step purification (Rezaei et al., 2000; Yin, Zheng and Tien, 2003). Purification of 
recombinant prion protein based on metal affinity of octapeptide repeats was firstly 
described by Razaei’s group and produced stable and monomeric PrP (Rezaei et al., 
2000). Here, we used Sepharose columns charged with copper ions that display the 
strongest affinity to PrP compared to nickel, cobalt or zinc (Pan, Stahl and Prusiner, 
1992). Recovery of the recombinant prion protein was maximised by the use of urea to 
solubilise inclusion bodies. In addition, the FPLC was also carried out under denaturing 
conditions. Previously, in order to obtain recombinant PrP, different tags were added to 
the protein sequence. First of all, production of hamster or human prion protein with 
glutathione S-transferase (GST) tag was described (Weiss et al., 1995; Völkel, 
Blankenfeldt and Schomburg, 1998; Corsaro et al., 2002). The addition of GST tag 
increased the solubility and stability of rPrP. Moreover, purification of human PrP 
fragment (90-231) was possible in native conditions. In this case, PrP did not 
accumulate within inclusion bodies but was expressed in the cytosolic fractions of 
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bacterial cells, therefore was accessible with native purification conditions (Corsaro et 
al., 2002). However, addition of the GST tag caused problems with isolation of the PrP 
or the obtained product was unstable (Weiss et al., 1995). Addition of GST tag added 
extra steps to the procedure with one being addition of detergents like Triton X-100 to 
increase the protein-tag complex solubility (Bell et al., 2013). Moreover, a 26 kDa GST 
tag has a propensity to dimerize, that could affect the properties of PrP (Kimple, Brill 
and Pasker, 2013). Alternatively, a poly-histidine tag has been attached to either C- or 
N-terminus of bovine or human PrP. The PrP was then purified using denaturing 
conditions on purification columns charged with Ni2+ ions (Negro et al., 1997; Jackson 
et al., 1999; Shin et al., 2008). Again, addition of the poly-histidine tag can alter the 
properties of the rPrP. 
After the purification, only the purest PrP fractions were pooled together and kept for 
further analysis. The method used here is consistent with the previous research, where 
recombinant ovine VRQ, ARQ, ARR and hamster PrP were purified (Workman, 2017). 
Additionally, all recombinant proteins in this research were produced using the same 
methodology. After purification, dialysis was performed to remove the imidazoles and 
sucrose from the final PrP pool. It was previously found that the presence of imidazoles 
has interfered with the in vitro amplification of bovine and ovine BSE but not with 
classical scrapie (Workman, 2017). In this research, each rPrP was dialysed in order to 
remove the co-eluted proteins and imidazoles from the buffer so that the rPrP produced 
in this research were consistent with previous analysis of rPrP inhibition during PMCA 
(Workman, 2017). Analysis of the purity of the recombinant proteins demonstrated that 
it was contaminated with relatively low amounts of smaller PrP fragments or co-eluting 
bacterial proteins (Mehlhorn et al., 1996). However, the rVRQ produced in this research 
had the same degree of inhibition as the one reported by Workman et al. (Workman, 
Maddison and Gough, 2017). This suggest that the presence of minor co-eluted protein 
did not affect the PrP inhibition properties.  
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Chapter 4: Quantification of the ability of rPrP 




The importance of successful development of therapeutic agents for prion diseases 
increased after the BSE outbreak in the UK that resulted in a new prion disease – vCJD 
(Will et al., 1996). The pace of prion research accelerated after the development of 
PMCA, a method that allows in effective in vitro replication of prions, assisting in the 
development of diagnostics and also providing a model to screen for potential 
therapeutics (Saborio, Permanne and Soto, 2001). It has been described that the in 
vitro produced disease associated PrP displayed similar characteristics to that isolated 
from diseased brains, like protease resistance, detergent resistance and infectivity 
(Saborio, Permanne and Soto, 2001; Shikiya and Bartz, 2011). PMCA allows to study of 
inhibition mechanisms for prion conversion in more detail and can be used in preliminary 
screening of inhibitory mechanisms of PrPres formation. However, this method could not 
completely replace the cell culture models that are slower but an excellent, valuable and 
viable tool for screening prion diseases therapeutic compounds in the cellular context 
(Skinner et al., 2015; Moda, Bolognesi and Legname, 2019). The limitations of cell 
culture are the limited number of natural prion isolated that can be used to infect cells 
and in contrast, PMCA has been shown to amplify most prion isolates (Moda, Bolognesi 
and Legname, 2019). In therapeutic agents screening, PMCA has been used in a few 
cases. Barret et al., studied the effect of quinacrine and tetracycline on 263K scrapie 
hamster brain homogenate amplification in healthy hamster brain homogenate using 
PMCA. In this work, both molecules reduced the formation of PrPres in the in vitro 
amplification (Barret et al., 2003). Furthermore, another research used PMCA as a tool 
for investigating the inhibition of CWD with quinacrine (Bian, Kang and Telling, 2014). 
PMCA was also used for inhibition effect study of an iron tetrapyrrole – Fe(III)-TMPyP 
(Fe(III)-meso-tetra(N-methyl-4-pyridyl)porphine). This potential therapeutic reagent 
was found to inhibit the cell-free amplification of mouse 22L and Dawson isolate scrapie 
strain (Massignan et al., 2016).  
Since the interaction between PrPC and PrPSc is a crucial part for creating disease 
associated prion aggregates, it has been investigated what the impact is of any 
interruptions of this process (Seelig, Goodman and Skinner, 2016). The use of 
recombinant prion proteins in inhibition research is not a new concept. Moreover, both, 
heterologous and homologous PrPs were used in various studies. It was firstly 
determined in scrapie infected MNB cells (mouse neuroblastoma) that the expression of 
heterologous (hamster) PrP interfered with production and aggregation of PrPres (Priola 
et al., 1994). Later on, Horiuchi and co-workers using a different approach, cell free 
conversion assay, and demonstrated that hamster prion protein could interfere with 
mice PrPSc formation (Horiuchi et al., 2000). Furthermore, expression of rabbit PrP was 
shown to stop the conversion to PrPres in scrapie infected MNB cells (Vorberg et al., 
2003). In the research of Yuan and co-workers, heterologous (mouse, bank vole and 
bovine) and homologous PrP were screened for their inhibitory capabilities of iCJD 
amplification during PMCA. They found out that the heterologous PrPs inhibition was 
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much less efficient than homologous (Yuan et al., 2013). The use of homologous PrP in 
inhibitory PMCA also was presented by Workman. He has investigated how addition of 
different variants of recombinant ovine PrP slowed down the PMCA process of different 
scrapie isolates. The results showed that the inhibition efficacy changed with the 
genotype of rPrP used (Workman, 2017; Workman, Maddison and Gough, 2017).  
There has also been successful in vivo research in using recombinant hamster PrP in 
a scrapie mouse model. Animals were inoculated with RML-Chandler scrapie isolate and 
additionally rhamPrP was also administered into animals. The result of this study showed 
that the rhamPrP treatment not only delayed the onset of disease symptoms like loss of 
motor function but also increased the animal survival time (Skinner et al., 2015). In 
addition, another study confirmed the previous research that mice infected with RML-
Chandler strain and treated with high doses (0.7 mg/ml) of rhamPrP significantly 
increased the animal survival and delayed the symptoms onset. In addition, animals 
that were treated with high dose of heterologous recombinant PrP showed less PrPres 
deposits in the brain in comparison to animals treated with low dose (0.35 mg/ml) or 
without rhamPrP (Seelig, Goodman and Skinner, 2016).  
A proposed inhibition mechanisms suggests that homologous PrP binding to the resistant 
PrPSc blocks the possible structural binding sites for PrPC (Yuan et al., 2013). 
Furthermore, heterologous rPrP inhibition showed that recombinant PrP binding 
destabilises aggregates and no seed for further amplification were produced (Jarrett and 
Lansburry, 1993). An additional in vivo mechanism suggests that the presence of 
heterologous prion protein stimulated an immune response and this event resulted in 
a decrease of PrPSc production (Skinner et al., 2015).  
In this study, we investigated how the change of a single amino acid at position 136 in 
ovine PrP affected its ability to inhibit prion replication. Previously, it was determined 
that amongst rhamPrP, rARQ, rVRQ and rARR, rVRQ showed the highest inhibition 
(Workman, 2017). Here, rVRQ and 18 rPrPs with mutations at position 136 were tested 
for their ability to inhibit the replication of scrapie isolate PG1361/05 (ARQ/VRQ). It was 
demonstrated before that this particular classical scrapie isolate was easily amplified 
within one PMCA round (24 h), therefore it is an effective model for screening rPrP 
inhibition (Workman, 2017). Each rPrP was first tested at 100 nM, which is around the 
previously reported IC50 value for rVRQ. Then, rPrPs with more effective inhibition 
properties than rVRQ were characterised by calculating IC50 values. This value is an 
indicator of inhibitory efficacy and reports the concentration of rPrP at which the 




4.2.1 rVRQ as a PrPSc replication inhibitor  
rVRQ (recombinant prion protein valine136) was tested in PMCA as a scrapie PG1361/05 
ARQ/VRQ inhibitor. A range of rVRQ concentrations (1200 – 50 nM) were added into 
PMCA. Firstly, PK digested 1200 rVRQ inhibition and no inhibition products were 
analysed on western blot in order to see the characteristic for the scrapie triple band 
pattern (Figure 4.2.1, B). In addition, also an amplified and PK digested TSE negative 
sample was analysed by western blot and no signal was produced. Next, inhibition 
samples and control samples were analysed on dotblots (Figure 4.2.1, A). For 
reference, additional no inhibition and designated 100 % inhibition (1200 nM rVRQ, the 
low signals were likely to be from the PrPSc seeded into the PMCA reaction) controls 
were included in each experiment. In addition, to assess the PK digestion efficacy, PrPC 
controls were displayed on each dotblot. All dotblots images were analysed using the 
ImageJ software. First of all, the average background value was calculated from density 
measures of all 1200 nM rVRQ repeats. Then, the average background value was 
subtracted from all other values. For each experiment, IC50 value was calculated 
according to signal intensities for each inhibitory sample to no inhibition samples 
(Figure 4.2.2). The calculated IC50 values for three repeat experiments were 115 nM, 
89 nM and 139 nM. The average IC50 value for rVRQ calculated from three independent 




Figure 4.2.1. Representative analysis of rVRQ inhibition of ovine scrapie ARQ/VRQ 
PG1361/05. A – representative dotblot analysis. 2.5 µl of each sample was loaded on 
the nitrocellulose membrane in duplicate. Experiment was performed three times, each 
including triplicates analysis as shown here. Additional of 1200 nM rVRQ and ‘no 
inhibition’ controls were included. B – representative western blot showing almost 
complete inhibition of scrapie ARQ/VRQ amplification with 1200 nM rVRQ in comparison 
to ‘no inhibition’ samples. Western blots show the characteristic triple band pattern for 
scrapie. PrPC – TSE negative brain substrate only control. Molecular weight is indicated 
on the left side on the blot (kDa). 20 µl of PK digested amplified products were analysed 
per reaction.  
 
 
Figure 4.2.2. Representative data for rVRQ inhibition. Graph displays the percent of 
control versus logarithmic concentration of rVRQ for classical scrapie strain ARQ/VRQ 
(PG1361/05). Range of rVRQ concentrations (1200 – 50 nM) were tested. 1200 nM rVRQ 
was treated as a blot background control, therefore was not displayed on the graph. 
The IC50 value calculated from this data was 89 nM. The mean IC50 value calculated 






















4.2.2 Screening of rVRQ mutants for prion replication inhibition properties 
In order to investigate whether the 136 position mutants inhibit the scrapie ARQ/VRQ 
(PG1361/05) amplification more or less than rVRQ, rPrPs were tested at 100 nM and 
compared to rVRQ at 100 nM. In addition, 1200 nM rVRQ was included in each 
experiment as a 100 % inhibition control. Therefore, the density values for 1200 nM 
rVRQ were subtracted from each blot. Also, PrPC controls (no PrPSc seed added to the 
PMCA) were displayed on each dotblot as a PK digestion controls. Each sample was 
performed in quadruplicate (Figure 4.2.3, A). The density of each sample was 
measured using ImageJ software. Then, the percent of no inhibition control was 
calculated for samples. Next, the average signal as a percent of the uninhibited sample 
for each rPrP type from each experiment was calculated. And these values were 
calculated in at least two independent experiments. For rIRQ, rFRQ and rNRQ one batch 
of protein was tested in two independent experiments. In this case, the result showed 
that 100 nM of rIRQ, rFRQ and rNRQ inhibits the amplification of scrapie ARQ/VRQ 
(PG1361/05) less effectively or at the same level as rVRQ (Figure 4.2.3, B). Statistical 
analysis using one-way non-parametric ANOVA – Kruskal-Wallis test (H=48.28, p<0.05) 
followed by Dunn’s multiple comparisons test showed no significant differences between 
these groups (IRQ p value>0.9999, FRQ p value>0.9999, NRQ p value=0.4882). 
Therefore, these rPrPs were not analysed further.  
 
Figure 4.2.3. Effect of 100 nM rVRQ, rIRQ, rFRQ and rNRQ on scrapie ARQ/VRQ 
PG1361/05 amplification. A – representative dotblot comparing 100 nM rIRQ, rFRQ and 
rNRQ to 100 nM rVRQ. 2.5 µl of each sample were added on the dotblot in duplicate. 
Each control was run in quadruplicates. PrPC was included on the dotblot as a PK 
digestion control. 1200 nM rVRQ was included as a 100 % inhibition control. B – plot 
displays the mean percent of the signal compared to the no inhibition control values for 
100 nM inhibition using rIRQ, rFRQ and rNRQ within two experiments in comparison to 
rVRQ at the same concentration. The data for 100 nM of rPrP was compared to 100 nM 
rVRQ and statistical Kruskal-Wallis test followed by Dunn’s multiple comparison test 
were performed in GraphPad Prism 8. There were no significant statistic differences 
(H=48.28, p value>0.05) reported between 100 nM rVRQ and 100 nM IRQ (p>0.9999), 
FRQ (p>0.9999) and NRQ (p=0.4882). 1200 nM rVRQ was treated as a background 
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control for each experiment and is not displayed on the graph. PrPC – TSE negative brain 
substrate only was used in PMCA. 
For rSRQ, rRRQ, rCRQ, rLRQ, rYRQ and rHRQ, four independent experiments were 
performed and two batches of rPrPs were used. The analysis (Figure 4.2.4) showed 
that 100 nM rSRQ and rHRQ did not inhibited the scrapie PrPSc amplification better that 
100 nM rVRQ. On the other hand, 100 nM of rRRQ (p<0.0001), rCRQ (p=0.0012), rLRQ 
(p<0.0001) and rYRQ (p=0.0039) displayed higher inhibition than 100 nM rVRQ. These 
differences were reported as statistically different using the Kruskal-Wallis followed by 
Dunn’s multiple comparison test. Kruskal-Wallis statistic was calculated separately for 
rSRQ, rRRQ, rCRQ (H=135.4, p<0.05) and rLRQ, rYRQ, rHRQ (H=134.1, p<0.05). 
Therefore, these recombinant proteins were analysed further. rHRQ was not reported as 
significantly different but as the trend suggested it may display more effective inhibition, 




Figure 4.2.4. Effect on 100 nM rVRQ, rSRQ, rRRQ, rCRQ, rLRQ, rYRQ, rHRQ on 
ARQ/VRQ scrapie PG1361/05 amplification. A, C – representative dotblots comparing 
100 nM of rPrPs to 100 nM rVRQ. 2.5 µl of each sample were added on the dotblot in 
duplicate. Each control was run in quadruplicates. PrPC was included on the dotblot as 
a PK digestion control. 1200 nM rVRQ was included as a 100 % inhibition control. B, D 
– plots display the mean percent of signal compared to the no inhibition control values 
for 100 nM inhibition of rPrPs for four experiments in comparison to rVRQ at the same 
concentration. 1200 nM rVRQ was treated as a background control for each experiment 
and is not displayed on the graph. The data for 100 nM of rPrP was compared to 100 
nM rVRQ and statistical Kruskal-Wallis test followed by Dunn’s multiple comparison test 
were performed in GraphPad Prism 8. Kruskal-Wallis statistics were calculated 
separately for experiments rSRQ, rRRQ, rCRQ (H=135.4, p<0.05) and rLRQ, rYRQ, 
rHRQ (H=134.1, p<0.05). Significant differences (p value<0.05) are reported between 
100 nM rVRQ and 100 nM RRQ (****, p value<0.0001), CRQ (**, p value=0.0012), 
LRQ (****, p value<0.0001) and YRQ (**, p value=0.0039). 1200 nM rVRQ was treated 
as a background control for each experiment and is not displayed on the graph. * - 
p0.05; ** - p0.01; *** - p0.001; **** - p0.0001. PrPC – TSE negative brain 
substrate. 
Recombinant proteins with K, G, W, Q, P, T, D, E, M at 136 position, one batch of each 
protein were similarly tested in two independent experiments. Kruskal-Wallis statistics 
were calculated separately for rKRQ, rGRQ, rWRQ (H=63.29, p<0.05), rQRQ, rPRQ, 
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rWRQ (H=49.88, p<0.05) and rDRQ, rERQ, rMRQ (H=64.58, p<0.05). Analysis showed 
(Figure 4.2.5) that rGRQ, rWRQ, rQRQ, rTRQ, rDRQ and rMRQ displayed similar or 
lower inhibition at 100 nM when compared to 100 nM rVRQ. In addition, the variations 
between rPrPs replicates were very high. For these reasons, recombinant prion proteins 
with glycine (G), tryptophan (W), glutamine (Q), threonine (T), aspartic acid (D) and 
methionine (M) were not analysed further. rKRQ, rPRQ and rERQ showed higher 
inhibition when compared to rVRQ and the statistical Kruskall-Wallis test followed by 
Dunn’s multiple comparison test showed statistically significant differences between 
these groups (rKRQ p value=0.0399, rPRQ p value=0.0059 and rERQ p value=0.0428). 
Consequently, rKRQ, rPRQ and rERQ were analysed further.  
To conclude, all the produced rPrPs were tested at 100 nM level and compared to 100 
nM rVRQ. Amongst them, rPrPs having arginine, cysteine, leucine, tyrosine, histidine, 
lysine, proline and glutamic acid displayed enhanced inhibition compared to valine and 




Figure 4.2.5. Effect of 100 nM rVRQ and 100 nM of mutants produced by site directed 
mutagenesis on ARQ/VRQ scrapie PG1361/05 amplification. A, C, E – representative 
dotblots comparing 100 nM of each rPrP to 100 nM rVRQ. 2.5 µl of each sample were 
added on the dotblot in duplicate. Each control was run in quadruplicates. PrPC was 
included on the dotblot as a PK digestion control. 1200 nM rVRQ was included as 
a 100 % inhibition control. B, D, E – plots display the mean signal as a percentage of 
the no inhibition control values for 100 nM inhibition of rPrPs for two experiments in 
comparison to rVRQ at the same concentration. The data for 100 nM of rPrP was 
compared to 100 nM rVRQ using statistical Kruskal-Wallis test followed by Dunn’s 
multiple comparison test in GraphPad Prism 8. Kruskal-Wallis statistics were calculated 
seperetely for rKRQ, rGRQ, rWRQ (H=63.29, p<0.05), rQRQ, rPRQ, rWRQ (H=49.88, 
p<0.05) and rDRQ, rERQ, rMRQ (H=64.58, p<0.05). Significant differences (p>0.05) 
are reported between 100 nM rVRQ and 100 nM KRQ (*, p=0.0399), rPRQ (**, 
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p=0.0059), rERQ (*, p=0.0428). 1200 nM rVRQ was treated as a background control 
for each experiment and is not displayed on the graphs. * - p0.05; ** - p0.01; *** - 
p0.001; **** - p0.0001; PrPC – TSE negative brain substrate. 
4.2.3 IC50 value determination for rPrPs with potentially enhanced inhibition 
properties compared to rVRQ 
Eight rPrPs were chosen for dose response experiments. A range of rPrPs concentrations 
were added into PMCA reactions, where scrapie ARQ/VRQ PG1361/05 isolate was 
amplified. For rRRQ, rCRQ, rLRQ, rYRQ and rHRQ, 1200 – 12.5 nM of each rPrP were 
added, whereas for rKRQ, rPRQ and rERQ 100 – 0.25 nM were added into PMCA. Each 
experiment consisted of 4 replicates. PK digested PMCA products were analysed on 
dotblot as previously described. 1200 nM of rVRQ was included in each experiment 
as a 100 % inhibition control. In addition, PrPC control was included in order to assess 
the PK digestion efficiency. Addition of 1200 and 800 nM of each rPrP, inhibited the 
amplification to 100 % (data not shown) therefore, further repeats consisted only of 
values 400 – 12.5 nM (Figure 4.2.6) or 100 – 0.25 nM (Figure 4.2.8) of each rPrP. 
For each experiment, IC50 value was calculated according to signal intensities for each 
inhibitory sample to no inhibition samples (Figure 4.2.7). The IC50 values calculated 
for rRRQ were 16 and 1 nM. The data reproducibility for rCRQ, rLRQ, rYRQ, rHRQ was 
poor. For example, rCRQ seemed to inhibit the scrapie in vitro amplification in 100 % 
at concentrations 400 nM but from this point variations between replicates were high as 
were the differences between experiments, IC50 vales calculated from two independent 
experiments were 112 nM and 11 nM. rLRQ was found to stop the scrapie isolate 
amplification at 400 nM but further inhibitor dilutions resulted in lack of reproducibility 
between experiments, the calculated IC50 values were 17 nM and 1 nM. For rYRQ and 
rHRQ, densitometry analysis over two independent experiments revealed IC50 values 
were 45 nM and 78 nM for rYRQ and 90 nM and 69 nM for rHRQ.  
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Figure 4.2.6. Representative dotblots showing the dose response inhibition of 
ARQ/VRQ scrapie PG1361/05 with rRRQ (A), CRQ (B), rLRQ (C), rYRQ (D), rHRQ (E). 
2.5 µl of each sample was added on the dotblot in duplicate. Each control was run in 
quadruplicates. 1200 nM rVRQ was used as a 100 % inhibition control. PrPC – TSE 









































































Figure 4.2.7. Representative plots displaying percent of uninhibited versus logarithmic 
concentration for rRRQ (A), rCRQ (B), rLRQ (C), rYRQ (D), rHRQ (E) inhibition of 
scrapie ARQ/VRQ PG1361/05. From these graphs IC50 values were calculated for each 
rPrPs as 16 nM for rRRQ, 11 nM for CRQ, 1 nM for LRQ, 78 nM for YRQ and 69 nM for 
HRQ. These rPrPs were tested in 400 – 12.5 nM concentration range. 1200 nM rVRQ 
was used as a blots background control and it was not displayed on the graphs.  
For rKRQ, rPRQ and rERQ over the range of concentrations from 100 to 0.25 nM (Figure 
4.2.8) IC50 values were calculated as follows rKRQ – 2 nM, rPRQ – 2 nM and rERQ – 
95 nM in the first experiment (Figure 4.2.9). In addition, for rKRQ second calculated 
IC50 value was 1 nM, what together with the first experiment gave average IC50 value 
2 nM for rKRQ. For rPRQ second experiment, we could not calculate the IC50 values, 
however based on dotblot and graphs analysis the IC50 value was below 20 nM. In 
addition, only one experiment for rERQ inhibition was performed and due to its hight 
IC50 value this rPrP was not variations between replicated was not analysed further.  
Additionally, inhibition of rRRQ was also tested in the range 100 to 0.001 nM with 
ARQ/VRQ scrapie isolate (data not shown). However, 100 nM of rRRQ still showed the 
100 % inhibition of scrapie amplification, the lowest inhibitor concentrations showed no 
inhibition that could be related to the difficulty of accurately measure this amount of 
protein. On the other hand, IC50 was calculated from the experiment and was 15 nM. 
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This, together with two other IC50 values that were calculated for rRRQ (16 nM, 1 nM, 
15 nM) gave an average IC50 value for rRRQ – 11 nM.  
To conclude, from eight rPrPs where IC50 values were calculated, all displayed values 
lower than rVRQ as predicted from the initial screens using 100 nM rPrP. Three proteins, 
rRRQ, rKRQ and rPRQ, were chosen for further analysis as they displayed the lowest 
IC50 values (Table 4.2.1). 
 
Figure 4.2.8. Inhibition of scrapie ARQ/VRQ PG1361/05 with 100 – 0.25 nM of rKRQ 
(A), rPRQ (B) and rERQ (C). 2.5 µl of each sample were added on the dotblot in 
duplicate. Each control was run in quadruplicates. 1200 nM rVRQ was used as a 100 % 













































Figure 4.2.9. Representative plots displaying percent of uninhibited versus logarithmic 
concentration for rKRQ (A), rPRQ (B) and rERQ (C) inhibition of scrapie ARQ/VRQ 
PG1361/05. IC50 value was calculated for each rPrPs as 2 nM for rKRQ, 2 nM for PRQ 
and 95 nM for ERQ. These rPrPs were tested in 100 – 0.25 nM concentration range. 




Table 4.2.1. IC50 values comparison for rVRQ mutants. 
rPrP mutant IC50 (1) IC50 (2) 
rVRQ Average: 114 nM1 
rRRQ2 16 nM 1 nM 
rCRQ 112 nM 11 nM 
rLRQ 17 nM 1 nM 
rYRQ 45 nM 78 nM 
rHRQ 90 nM 69 nM 
rKRQ 2 nM 1 nM 
rPRQ 2 nM <20 nM3 
rERQ 95 nM NA4 
1Average IC50 value for rVRQ was calculated from three 
independent experiments  
2Also, third experiment was performed, where IC50 = 15 nM 
(100 – 0.001 nM) 
3For experiment where we could not calculate the IC50 values, 
an estimated value was reported based on dotblots and 
graphs 




4.2.4 rRRQ, rKRQ and rPRQ analysis at lower concentrations 
In order to assess whether the rKRQ and rPRQ are inhibiting the scrapie ARQ/VRQ 
amplification more efficiently than rRRQ, the inhibitors were compared at 10, 5 and 
1 nM (Figure 4.2.10, A, C). When analysing these data, in order to pass the normality 
tests, one value for 10 nM rRRQ had to be excluded from data (second replicate, second 
repeat). The experiment showed that when looking at 10 nM and 5 nM inhibition, rRRQ 
was more efficient than rKRQ. The differences at these concentrations were analysed 
using the statistical mixed-effects model (two-way ANOVA with missing values) followed 
by Sidak’s multiple comparisons test (F=29.28, p<0.05). The results showed that rRRQ 
inhibited amplification of PG1361/05 scrapie ARQ/VRQ significantly better than rKRQ at 
10 nM and 5 nM (p values < 0.0001). In contrast, there was no statistically significant 
difference when comparing these two proteins at 1 nM level (Figure 4.2.10, B). 
Furthermore, rPRQ was compared to rRRQ (Figure 4.2.10, D). Data from this 
experiment passed the normality tests, therefore the statistical analysis using two-way 
ANOVA with Sidak’s multiple comparison was performed (F=2.053, p<0.05). The test 
showed that rRRQ and rPRQ were not statistically different between at 10 and 5 nM 
(p>0.05). In contrast, rRRQ appeared to have a higher inhibition level at 1 nM than 
rPRQ (p value =0.0170). In addition, rPRQ results were very variable at this 
concentration, so that it was hard to fully predict the inhibition efficacy at 1 nM. 





Figure 4.2.10. Inhibition of rRRQ in compare to rKRQ (A, B) and rPRQ (C, D) at 10, 5 
and 1 nM of scrapie ARQ/VRQ PG1361/05. A, C – representative dotblots showing the 
direct comparison of rRRQ and rKRQ (A) and rRRQ and rPRQ (C) at 10, 5 and 1 nM. 
2.5 µl of each sample were added on the dotblot in duplicate. Each control was run in 
quadruplicates. 1200 nM rVRQ was used as a 100 % inhibition control. PrPC – TSE 
negative brain homogenate. B, C – graphs display comparison of rRRQ to rKRQ and 
rRRQ to rPRQ at 10, 5 and 1 nM concentration. The data for rKRQ and rRRQ were 
analysed using mixed-effects model (two-way ANOVA for missing values) and Sidak’s 
multiple comparisons test (F=29.28, p<0.05). The test showed that rRRQ at 10 nM and 
5 nM inhibit amplification of scrapie significantly better that rKRQ at the same 
concentrations (‘****’ - p values <0.0001). For 1 nM comparison there was no 
significant statistical difference between rRRQ and rKRQ (p value = 0.2954). For rRRQ 
and rPRQ comparison, two-way ANOVA with Sidak’s multiple comparisons test were 
used (F=2.053, p<0.05) and the significant difference was only at 1 nM level (‘*’, 
p value =0.0170). Both, 10 and 5 nM of rPRQ and rRRQ has similar impact on scrapie 




Protein misfolding cyclic amplification provides a tool for investigating the misfolding 
process of prion protein (Saborio, Permanne and Soto, 2001). In this research, PMCA 
was modified and in addition to template (PrPSc) and substrate (PrPC), homologous, full 
length, ovine recombinant PrP was added. The difference between recombinant PrP 
produced in bacteria (E. coli) and brain derived PrPC is that the recombinant PrP does 
not undergo any posttranslational modifications, therefore, it lacks the N-glycans and 
GPI anchor (Kim et al., 2009; Yuan et al., 2013). Previously, Workman and colleagues 
tested recombinant ovine prion proteins: rVRQ, rARQ (alanine136, arginine154, 
glutamine171) and rARR (alanine136, arginine154, glutamine171). They have calculated the 
IC50 for these recombinant proteins inhibiting the scrapie ARQ/VRQ isolate PG1361/05 
and calculated average IC50 values 122 nM for rVRQ, 228 nM for rARQ and 505 nM for 
rARR when analysing the products on dotblot. In addition, the same samples were 
analysed on western blots and showed the IC50 values 85 nM for rVRQ, 200 nM for 
rARQ and 515 nM for rARR (Workman, 2017; Workman, Maddison and Gough, 2017). 
In both methods, the result showed that rVRQ was the most potent inhibitor. As the 
dotblot is a higher throughput assay we therefore decided to conduct only dotblots for 
the inhibition analysis in the current study. In addition, Workman et al. also tested 
heterologous PrP (rhamPrP) in this scrapie inhibition model. This version of rPrP had 
IC50 value of 181 nM (dot blot analysis), which showed that this rPrP also acted as an 
inhibitor of scrapie ARQ/VRQ amplification in vitro. Moreover, reported IC50 value for 
rhamPrP was lower than for tested rARQ or rARR in the same research (Workman, 
2017). The data produced in the current study confirmed that recombinant ovine rVRQ 
can inhibit scrapie ARQ/VRQ isolate PG1361/05 prion protein amplification in vitro. The 
average calculated IC50 value for rVRQ was 114 nM, correlating with the 122 nM value 
previously obtained for the same PG1361/05 (ARQ/VRQ) scrapie isolate (Workman, 
2017).  
All eighteen rPrPs were first compared at 100 nM to 100 nM rVRQ (all variants excluding 
ARQ), which is around its IC50 value. At this stage, it was found that rRRQ, rCRQ, rLRQ, 
rYRQ, rHRQ, rKRQ, rPRQ and rERQ inhibited the amplification of scrapie isolate 
(PG1361/05, ARQ/VRQ) better than rVRQ. In order to analyse them further, PMCA 
including a range of rPrP concentrations was performed. At this point, IC50 values for 
rCRQ (122 and 11 nM) varied between the repeats, whereas IC50 calculated for rYRQ 
(45 and 78 nM), rHRQ (90 and 69 nM) and ERQ (95 nM) were high in compare to other 
tested rPrPs. For these reasons, rCRQ, rYRQ, rHRQ and ERQ were not analysed further 
in the current study. Additionally, for some rPrP it was challenging to accurately estimate 
IC50 values. The tested concentrations did not allow to produce full sigmoidal curve and 
usually the curves did not reach the top plataur. Therefore, IC50 values were calculated 
beyond the range of tested concentration. At this stage, four of the tested recombinants 
showed significantly higher inhibition in in vitro amplification of ovine scrapie PG1361/05 
than rVRQ and the data was reproducible between experiments. These were rRRQ, rLRQ, 
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rKRQ and rPRQ, with arginine, leucine, lysine and proline at 136 position, respectively. 
Additionally, third experiment for IC50 values calculations was performed for rRRQ and 
involved range of concentrations from 100 nM to 0.001 nM. The calculated IC50 was 15 
nM and confirmed that rRRQ was one of the strongest inhibitor for PG1361/05 
amplification. The average IC50 value calculated from three independent experiments 
for rRRQ was 11 nM. In addition, two IC50 values for rKRQ were calculated and gave 
an average value 2 nM (1 nM and 2 nM). The rRRQ, rKRQ and rPRQ were then directly 
compared in the same experiments at lower concentrations (10, 5 and 1 nM) and it was 
found that the differences between them in inhibition of scrapie ARQ/VRQ PG1361/05 
amplification were very similar. This could suggest that rRRQ and rKRQ gave similar 
levels of inhibition in PMCA, whereas rPRQ inhibiton degree. It has to be taken into 
account that the statistical differences between rPRQ and rRRQ at 1 nM could also be 
explained by rRRQ variability between experiments. At this point, rLRQ was not analysed 
in direct comparison at lower concentrations and it was decided to proceed and analyse 
rRRQ, rKRQ and rPRQ further.  
Inhibition of PK resistant prion formation using both homologous and heterologous prion 
protein has been reported previously. Yuan and co-workers compared homologous 
(human PrP) and heterologous (mouse, bank vole and bovine) recombinant prion 
protein inhibition in human prion protein amplification during PMCA. They found that the 
addition of homologous human rPrP was more effective than the heterologous (Yuan et 
al., 2013). Moreover, in vitro research by Priola and colleagues used the model of scrapie 
infected mouse neuroblastoma – MNB – cell line. They showed that the addition of 
heterologous prion protein inhibits resistant PrP formation and accumulation (Priola et 
al., 1994). In addition, Skinner et al., used an in vivo model, where scrapie infected 
mice were treated with two different levels (high and low dose) of recombinant hamster 
PrP. The heterologous protein was injected (for high dose 31.5 µg, 15.75 µg for low 
dose) together with the scrapie dose intracerebrally and also orally on the following day 
(70 µg for high dose, 35 µg for low dose). After 108 days post infection, brain and spleen 
tissue staining showed that all animals were infected with scrapie and addition of 
heterologous recombinant PrP did not prevent the disease progression, although 
addition of high dose treatment reduced the amount of PrPSc accumulation in analysed 
tissues. Furthermore, when the experiment was finished (452 days post infection), 50 % 
of animals with high dose treatment still not developed any clinical symptoms in 
compare to low dose treatment and mock infected animals (Skinner et al., 2015). 
Overall, the current research and described examples showed that usage of rPrPs could 
inhibit the prion replication in vitro and in vivo. 
Within the literature, multiple mutations and polymorphisms have been recognised in 
the Prnp gene. In the ovine PrP, codons 136, 154 and 171 play very important roles in 
disease development and as mentioned before, some of the genotypes are scrapie 
susceptible (like VRQ) or resistant (like ARR) (Goldmann, 2008). From the range of rPrP 
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variants at codon 136 tested in the current study, rRRQ, rKRQ and rPRQ were the most 
effective inhibitors of in vitro scrapie replication and all were more effective than natural 
variants. Whilst none of the most effective variants have been reported in the nature, 
tyrosine at position 136 was found in both scrapie affected and healthy sheep 
populations in Greece, Iran, Turkey and China at low frequencies (Billinis et al., 2004; 
Alvarez et al., 2011; Guan et al., 2011; Frootan et al., 2012; Meydan et al., 2012). First 
reports about presence of T at 136 position came from Greece, where 216 sheep from 
different country regions and flocks were screened for PrP genotypes. It was described 
that the possibility of scrapie development in sheep with genotype ARQ/TRQ was at the 
same level as for animals with ARQ/ARQ. Moreover, ARQ/TRQ heterozygotes showed 
lower risk of scrapie than animals with VRQ/VRQ (Billinis et al., 2004). So far, it is the 
only published research that describe the presence of T136 in scrapie affected animals. 
Furthermore, in Chinese healthy Hu sheep from two country regions T was also found 
at 136 position. The researchers screened 180 animals in which the highest frequency 
allele was A136, whereas T136 had the lowest frequency in this group. In addition, new 
low frequency genotypes were reported: ARQ/TRK, ARQ/TRR and TRR/TRQ (Guan et al., 
2011). Additionally, ARQ/TRQ, TRQ/TRQ, TRQ/ARR and TRQ/VRQ genotypes were 
reported at low frequencies across different breeds in both Turkey and Iran (Alvarez et 
al., 2011; Frootan et al., 2012). Because of its rare presence, association of mentioned 
genotypes with scrapie is hard to determine (Goldmann et al., 2005). Amongst the 
published data, only Billinis et al. reported T136 in scrapie affected sheep, therefore any 
conclusions regarding its impact on disease resistance/susceptibility cannot be predicted 
(Billinis et al., 2004). Moreover, any outcomes need to be treated with caution and more 
genotypes distribution screening in sheep populations needs to be analysed (Billinis et 
al., 2004; Goldmann et al., 2005; Meydan et al., 2012). This is important in planning 
new breeding strategies that help to eliminate genotypes prone to scrapie in sheep 
(Goldmann et al., 2005). In addition, in the majority of these sheep populations ARQ 
was the most frequent allele and in some breeds and VRQ (the most scrapie susceptible 
genotype) was not found (Billinis et al., 2004; Goldmann, 2008; Alvarez et al., 2011; 
Guan et al., 2011; Frootan et al., 2012; Meydan et al., 2012). In the current research, 
it was investigated how the substitution from V to T changed the inhibition of scrapie in 
in vitro amplification. We found that the rTRQ was a less effective inhibitor than rVRQ. 
Apart from commonly and less known polymorphisms described at 136 position, also 
137 and 138 positions display amino acid changes (Goldmann et al., 2005). These 
substitutions include changes from M to T and S to R, respectively. Similarly, it is hard 
to determine the impact of these changes on disease appearance because of their low 
frequency in sheep populations (Goldmann et al., 2005; Saunders et al., 2006). 
However, one study showed that the presence of tyrosine at 137 position together with 
the ARQ/ARQ and ARQ/AHQ genotypes had a protective effect when sheep were 
challenged experimentally with scrapie or BSE (Vaccari et al., 2007).  
 112 
Chapter 5: Assessment of rPrP 136 codon mutants 
as inhibitors of replication of distinct prion strains 




Protein misfolding diseases are characterised by the presence of disease specific protein 
aggregates. These proteins differs in secondary and tertiary structure without any 
changes within the protein sequences (Soto, 2001). One of the most important features 
of misfolded proteins aggregates is that they consist of β-sheets rich structures (Moore, 
Taubner and Priola, 2009). Based on that, a potential molecule could bind to these 
elements and reduce the further processes of fibrils formation. This would potentially 
decrease or even stop the disease development pace. To date, no successful therapeutic 
agents targeting either specific protein aggregates or any amyloid compounds present 
in brain tissue have progressed to the clinic. Furthermore, any therapeutic approaches 
towards prions diseases could be further tested for the application to other protein 
misfolding (Panegyres and Armari, 2013; Thompson et al., 2013). Several studies have 
described PMDs as diseases with co-occurrence of different misfolded proteins within 
the tissue of the same patient (Katorcha et al., 2017). For example, α-synuclein deposits 
were detected in sCJD, fCJD and iCJD patients and scrapie (Haïk et al., 2000, 2002; 
Vital et al., 2009; Kovacs et al., 2011). Therefore, potential successful therapeutics 
could not only slow down the misfolding process of each protein, they could inhibit and 
reverse the misfolding and aggregation processes for multiple proteins and also prevent 
any cross seeding of misfolding proteins (Soto and Estrada, 2005).  
The interactions of PrP and other proteins that misfold could play an important role in 
the pathogenesis of PMDs (Han et al., 2006). It has been described that the cell 
membrane localised PrPC interacted with β-sheet rich conformers like Aβ, yeast 
produced PrP or β-peptides. Furthermore, these interactions were inhibited by the use 
of PrP and Aβ oligomer specific antibody (A11) (Kayed et al., 2003; Resenberger et al., 
2011). These findings showed that PrPC could potentially interact with β-sheet rich 
structures within misfolded proteins like Aβ, α-syn or tau (Resenberger et al., 2011). In 
addition to that, studies showed that PrPC exhibited high affinity for binding synthetic 
amyloid β (1-42) oligomers and low affinity for binding the Aβ monomers (Laurén et al., 
2009; Bove-Fenderson et al., 2017). Moreover, PrPC regions responsible for PrP – Aβ 
interactions have been mapped. Chen et al., found that the deletion of PrPC N-terminal 
region (either residues 23-90 or 92-110) resulted in total loss of human PrP and human 
Aβ binding (Chen, Yadav and Surewicz, 2010). The later research confirmed the 
importance of N-terminal part of PrP in Aβ oligomers binding (Nieznanski et al., 2014). 
In contrast, the highly structured C-terminus of cellular prion protein was not reported 
to be involved in any interactions of PrP and Aβ oligomer, however research performed 
by Bove-Fenderson and co-workers indicated the involvement of both C- and N-terminus 
of PrP as necessary (Chen, Yadav and Surewicz, 2010; Bove-Fenderson et al., 2017). 
Since there is evidence indicating that PrP can interact with misfolded Aβ research into 
the development of therapeutic towards their dependency were carried out. It was 
shown that full length human PrP (PrP23-231) and a C-terminus truncated version 
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inhibited the fibrillization of amyloid β, when investigated by ThT fluorescence. In 
contrast, N-terminally truncated PrP had no inhibition effect on amyloid 
β oligomerisation (Nieznanski et al., 2012).  
Multiple studies showed that the amyloid β aggregates could bind to PrPC resulting in 
decreased levels of amyloid oligomerisation, however not much is known about the 
relation of α-syn and tau with prion protein and some research showed conflicted 
outcomes (Corbett et al., 2020). Ferreira and co-workers communicated that α-syn 
could interact with PrPC. They reported PrP as an important linker between α-synuclein 
oligomers and their synaptic toxicity. Moreover, it was found that PrP/α-synuclein 
interaction is regulated by a member (Fyn kinase) of Src tyrosine kinase family (SFK) 
that are commonly found within neurons (Um and Strittmatter, 2013; Ferreira et al., 
2017). Additionally, the same Fyn kinase was associated with PrPC mediated Aβ toxicity 
(Um et al., 2012; Um and Strittmatter, 2013). The toxic effects of α-synuclein oligomers 
in synaptic structures were inhibited by inactivation by a PrPC specific antibody targeting 
the 93-109 region of PrPC (Ferreira et al., 2017). Also, recently published work showed 
α-synuclein soluble aggregates bind to PrP but the affinity of that process depended on 
an aggregation form. Furthermore, the binding affinity for α-synuclein soluble 
aggregates was similar to Aβ soluble aggregates. On the other hand, work from La Vitola 
and colleagues revealed neither binding nor any interactions between the PrPC and α-
synuclein oligomers (La Vitola et al., 2019).  
The third most common protein found in protein misfolding diseases is tau. It was found 
that recombinant full length tau protein is capable of forming tau-PrP complexes in in 
vitro research. Moreover, the binding affinity was dependent on the number of 
octapeptide repeats within the recombinant prion protein (Wang et al., 2008). These 
findings suggested that PrP could moderate some of the tau aggregates damaging 
effects on synaptic functions (Hu et al., 2018; Ondrejcak et al., 2018). These outcomes 
were supported by the most recent work by Corbett, where soluble tau aggregates were 
bound to PrP, however with less affinity than the soluble aggregates of Aβ or α-synuclein 
(Corbett et al., 2020). In addition, co-immunoprecipitation studies revealed that 
recombinant tau protein could not only interact with native PrPC but also PrPSc derived 
from 263K scrapie strain (Han et al., 2006).  
PrP as a protein might exhibit disaggregating properties (Nieznanski et al., 2014). On 
this basis along with the reported interaction of PrPC with other misfolded proteins, it 
could be hypothesised that PrP could provide a potential therapeutic of not only TSE but 
also other protein misfolding diseases (Nieznanska et al., 2018). As stated, it has been 
shown that PrP inhibits the Aβ oligomers formation. However, no studies investigating 
its possible inhibitions of formation α-synuclein or tau oligomers have been reported. In 
the current study, our main focus was on testing recombinant prion proteins (rRRQ, 
rKRQ and rPRQ) in a spectrum of ruminant TSEs. This involved classical ovine scrapie, 
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bovine BSE and ovine BSE isolates. In addition, the rPrPs were also used to investigate 
possible inhibitions mechanisms of α-synuclein fibril formation during PMCA.   
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5.2 Results 
5.2.1 Optimisation of scrapie, bovine and ovine BSE isolate amplification 
In order to analyse whether the rPrP mutants can act as an inhibitor for other prion 
disease isolates, amplification conditions for each isolate were tested and optimised. 
Isolates of ovine scrapie PG1207/03 (VRQ/VRQ) and PG1499/02 (AHQ/VRQ) were found 
to amplify over 4 rounds in VRQ/VRQ, whereas bovine BSE (SE1945/0035) amplified in 
bovine brain substrate over 5 rounds (Figure 5.2.1, B). In addition, PG1361/05 
(ARQ/VRQ) was found to amplify consistently over 4 rounds in VRQ/VRQ substrate, and 
round 5 reactions were used as a control that should be inhibited by the rPrPs (Figure 
5.2.1, A).  
 
Figure 5.2.1. Representative western blots and dotblots of ovine scrapie and bovine 
BSE isolate amplification in serial PMCA. A – amplification of scrapie PG1361/05 
(ARQ/VRQ) isolate over PMCA rounds 1, 4 and 5. This ovine isolate was amplified in 
VRQ/VRQ brain substrate. Samples show characteristic triple band pattern for scrapie. 
Molecular weight markers (kDa) are indicated on the left side on the blot. 20 µl of 
amplified, PK digested products were analysed per lane. Duplicates PMCA reactions were 
analysed on western blot. B – amplification of ovine scrapie isolates PG1361/05 
(ARQ/VRQ), PG1207/03 (VRQ/VRQ), PG1499/02 (AHQ/VRQ) isolates and bovine BSE 
(SE1945/0035) over PMCA rounds. Ovine scrapie isolates were amplified in VRQ/VRQ 
substrate, whereas the bovine BSE was amplified in bovine brain. 0.5 µl of 10 % brain 
homogenate of PG1361/05 and PG1207/03 was added into round 1. For scrapie 
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PG1499/02 and bovine BSE (SE1945/035), 5 µl of 10 % brain homogenates were added 
into round 1 of PMCA. After each round, PMCA products were PK digested and 2.5 µl of 
each sample in duplicate were added on the dotblot.   
Moreover, ovine BSE – PG1693 (ARQ/ARQ) isolate – was amplified using VRQ/VRQ 
substrate only and also the method described previously where two different substrates 
are being used: for rounds 1, 3 and 5, AHQ/AHQ substrate, and for rounds 2 and 4, 
VRQ/VRQ (Taema et al., 2012). The ovine BSE amplified better using the latter 
procedure (Figure 5.2.2), therefore this method was applied for inhibitor testing. 
Furthermore, also BSE-like scrapie, CH1641 isolates J3011 (AHQ/AHQ) and J2935 
(ARQ/AHQ) were amplified in AHQ/AHQ substrate but over 5 rounds of PMCA but there 
was no amplification product (data not shown). Therefore, these isolates were not 
analysed further.  
 
Figure 5.2.2. Amplification of ovine BSE – PG1693/03 (ARQ/ARQ) over 5 PMCA rounds. 
Top row shows amplification of ovine BSE in VRQ/VRQ substrate only. Bottom row shows 
amplification of ovine BSE in two different substrates: AHQ/AHQ for rounds 1, 3, 5 and 
VRQ/VRQ for rounds 2 and 5. For each PMCA, 5 µl of 10 % ovine BSE brain homogenate 
was added into round 1 of PMCA. After each round, PMCA products were PK digested 
and 2.5 µl of each sample was added on the dotblot in duplicate.  
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5.2.2 Optimisation of round 5 ovine scrapie PG1361/05 inhibition with rRRQ 
In order to analyse the inhibition of round 5 of serial PMCA amplifications, the control 
ovine scrapie isolate PG1361/05 (ARQ/VRQ) was inhibited with rRRQ. Different amounts 
of scrapie spike from round 4 of PMCA were added into round 5 and amplified as 
described before. The amounts were 30, 15, 7.5 and 3.75 µl of round 4 product into 70, 
85, 92.5 and 96.25 µl of TSE negative VRQ/VRQ brain, respectively. In addition, 100 
nM of rRRQ was added into each reaction and products were PK digested. The higher 
concentration of rRRQ (9 x greater than reported average IC50 value) was chosen 
because it was hypothetisezed that higher inhibitor concentrations could act as stronger 
inhibitors of different prion strains and prion diseases amplification. This idea was also 
based on and supported by previous research where higher than IC50 concentrations of 
rVRQ was used to inhibit across prion disease isolates in 100 % (Workman, Maddison 
and Gough, 2017). The experiment was performed in triplicates (Figure 5.2.3, A). The 
dotblot analysis showed that addition of 30 µl of round 4 scrapie spike was the most 
efficient method, in which both the amplification and inhibition of round 5 with 100 nM 
rRRQ was clearly visible. Moreover, addition of 30 µl of round 4 allowed to compare all 
isolates regardless the variability of amplification efficiency for different disease isolates. 
Therefore, a dilution of 3:7 of round 4 spike into round 5 was used in further 
experiments.  
A second optimisation step involved adding 30 µl of round 4 PrPSc (PG1361/05, ARQ/VRQ 
scrapie) but with a range of rRRQ concentrations (100, 200 and 400 nM) (Figure 5.2.3, 
B). These samples were compared to uninhibited control. The experiment was 
performed in triplicate. The densitometry analysis showed that all used rRRQ 
concentrations inhibited the round 5 amplification of ovine scrapie ARQ/VRQ PG1361/05 
by around 70 % when compared to non-inhibited. Moreover, there were no inhibition 
differences in PrPSc signal between 100, 200 and 400 nM of rRRQ. This result suggested 
that 100 nM of rRRQ might have inhibited round 5 amplification of control scrapie isolate 
by 100 % and the sample signal on the dotblot came from the amount of PrPSc spike 
added into round 5. Therefore, it was established what negative control should be used 
for these experiments. Samples in which 30 µl of round 4 scrapie PG1361/05 was mixed 
with 70 µl of negative brain homogenate (VRQ/VRQ, brain 16) was kept at -20 °C for 
the period of amplification (24 h). These samples were compared to amplified controls 
and then all samples were PK digested and analysed on the dotblot (Figure 5.2.3, C). 
The result showed that samples with no amplification gave high PrPSc positive signal on 
the dotblot indicating that the amount of amplified PrPSc after 4 rounds of PMCA for 
ovine scrapie (PG1361/05) could be detected. It was decided to use the non-inhibited 
and non-amplified samples as a background control for inhibition with rPrPs of serial 
PMCA experiments. When this was applied, both dotblots with either different amounts 
of round 4 spike going to round 5 or different amounts of rRRQ going into round 5, rRRQ 
inhibited the round 4 to round 5 amplification of ovine ARQ/VRQ PG1361/05 scrapie in 
100 % when analysed in additional experiments on the same blots (data not shown).  
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Figure 5.2.3. Dotblots showing the amplification and inhibition result of different 
amount of round 4 PrPSc of ovine scrapie PG1361/05 (ARQ/VRQ) and different 
concentrations of rRRQ added in round 5 of PMCA. A – 30, 15, 7.5 and 3.75 µl of round 
4 PrPSc was added into 70, 85, 92.5 and 96.25 µl of negative brain homogenate 
(VRQ/VRQ, brain 16), respectively. The samples were amplified with or without addition 
of 100 nM rRRQ for 24 h. B – dotblot shows amplification of round 4 scrapie PG1361/05 
(ARQ/VRQ) PrPSc, where 30 µl of round 4 spike was mixed with 70 µl of negative brain 
(VRQ/VRQ, brain 16). Amplification was performed with and without 100, 200 and 400 
nM of rRRQ. C – representative dotblot shows the signal level for non-inhibited and non-
amplified samples with 30 µl of R4 ARQ/VRQ scrapie PrPSc going into 70 µl of negative 
brain homogenate (VRQ/VRQ, brain 16). During the amplification time, non-amplified 
samples were stored at -20 °C. 2.5 µl of PK digested products were analysed on dotblot. 
Experiment was performed in triplicate. PrPC – negative brain homogenate, R4 – 
round 4; 
  
30 µl of round 4 PrPSc, no inhibition
30 µl of round 4 PrPSc, 100 nM rRRQ
15 µl of round 4 PrPSc, no inhibition
15 µl of round 4 PrPSc, 100 nM rRRQ
7.5 µl of round 4 PrPSc, no inhibition
7.5 µl of round 4 PrPSc, 100 nM rRRQ
3.75 µl of round 4 PrPSc, no inhibition
3.75 µl of round 4 PrPSc, 100 nM rRRQ
PrPC
ReplicateA
30 µl of round 4 PrPSc, no inhibition
30 µl of round 4 PrPSc, 100 nM rRRQ
30 µl of round 4 PrPSc, 200 nM rRRQ




30 µl of R4 PrPSc, no inhibition, no amplification
C Replicate
 120 
5.2.3 Optimization of the amount of rPrP inhibiting the round 5 of ovine scrapie 
ARQ/VRQ PG1361/05 amplification 
It was previously established that 400 nM of rVRQ added into serial PMCA inhibited the 
classical ovine scrapie, bovine and ovine BSE isolates to 100 % (Workman, Maddison 
and Gough, 2017). Therefore, we applied the same approach for screening other 
recombinant prion proteins with the classical ovine scrapie isolate PG1361/05 
(ARQ/VRQ). Accordingly, 400 nM of rVRQ or 100 nM of rRRQ, rKRQ and rPRQ were 
added into round 5 of PMCA and seed from round 4 PrPSc was added into VRQ/VRQ 
negative brain homogenate at ratio 3:7 and amplified. Furthermore, no amplification/no 
inhibition samples were included in the analysis and its average signal was used as a 
dotblot background control (Figure 5.2.4, A). The data from the dotblot were analysed 
in two different ways. Firstly, each rPrP was compared to no inhibition samples. 
Secondly, the potential differences between rPRQ and other rPrP levels of inhibiton at 
100 nM were compared. The result showed that on average 400 nM rVRQ inhibited the 
round 5 scrapie amplification by 96 %, 100 nM of rRRQ by 100 %, 100 nM rKRQ by 88 
% and 100 nM of rPRQ by 55 % (Figure 5.2.4, B). These data were then statistically 
analysed using the Tukey’s multiple comparisons test (F=27.47, p<0.05). The analysis 
showed that the differences between 400 nM rVRQ and No inhibition (p<0.0001), 100 
nM rRRQ and No inhibition (p<0.0001), 100 nM KRQ and No inhibition (p<0.0001) and 
rPRQ and No inhibition (p=0.0004) were statistically significant. In addition, some 
significant differences between rPrPs efficacy were also present. 400 nM rVRQ 
(p=0.0103), 100 nM rRRQ (p=0.0047) and 100 nM rKRQ (p=0.0491) inhibited 
amplification of ovine scrapie significantly better than 100 nM rPRQ (Figure 5.2.4, C). 
Moreover, there were no statistically significant differences between level of inhibition 
of the scrapie isolate between 400 nM rVRQ and 100 nM rRRQ (p=0.9974) or 100 nM 
rKRQ (p=0.9591). These results suggest that addition of 100 rRRQ and rKRQ inhibited 
the amplification of scrapie isolate PG1361/05 (ARQ/VRQ) at a similar to 400 nM rVRQ. 
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Figure 5.2.4. Inhibition of round 5 of serial PMCA ovine scrapie ARQ/VRQ PG1361/05 
with 400 nM rVRQ, 100 nM rRRQ, rKRQ and rPRQ. A – representative dotblot shows 
inhibition pattern for 400 nM rVRQ, 100 nM rRRQ, rKRQ and rPRQ in comparison to no 
inhibition samples. Round 5 amplification samples signals subtracted with no inhibition 
and no amplification samples. 2.5 µl of PK digested products were analysed on the 
dotblot. B – graph shows the percent inhibition for 400 nM rVRQ, 100 nM rRRQ, rKRQ, 
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rPRQ in round 5 of PMCA for ovine scrapie ARQ/VRQ PG1361/05 compared to no inhibitor 
being present. The percent of inhibition was displayed on the graphs as it showed the 
power of each tested rPrP in compare to controls in a better way. According to one-way 
ANOVA followed by Tukey’s multiple comparisons test (F=27.47, p<0.05), significant 
statistical differences (p<0.0001) were reported on the graphs between each rPrP and 
No inhibition sample: 400 nM rVRQ (‘****’, p<0.0001), 100 nM rRRQ (‘****’, 
p<0.0001), 100 nM rKRQ (‘****’, p<0.0001) and rPRQ (‘***’, p=0.0004). C – graph 
shows the percent inhibition for 400 nM rVRQ, 100 nM rRRQ, rKRQ, rPRQ in round 5 of 
PMCA for ovine scrapie ARQ/VRQ PG1361/05 compared to no inhibitor being present. 
Here, statistical differences in the inhibition response levels between rPrP are indicated. 
Based on Tukey’s multiple comparisons test (p<0.0001), statistical differences are 
reported between 400 nM rVRQ and rPRQ (‘*’, p=0.0103), 100 nM rRRQ and rPRQ (‘**’, 
p=0.0047) and 100 nM KRQ and rPRQ (‘*’, p=0.0491). * - p0.05; ** - p0.01; *** - 
p0.001; **** - p0.0001; 
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5.2.4 Ovine scrapie, bovine BSE and ovine BSE isolate inhibition 
The addition of 100 nM of rRRQ into round 5 PMCA inhibited the scrapie amplification in 
100 %. Because of the fact that the recorded IC50 values for tested rPrPs were lower 
than 50 nM and for some lower than 20 nM, it was decided to change the concentration 
of rPrPs in PMCA to 50 nM and investigate its effect. Moreover, other tested rPrPs 
presented less efficacy when only round 5 was inhibited, therefore we tested whether 
addition of 50 nM of rPrPs into every PMCA round could improve their performance. 
Furthermore, it was investigated if rRRQ, rKRQ and rPRQ also inhibit other prion isolates, 
when 50 nM of each rPrP were added to every PMCA round. All prion isolates were 
amplified for up to round 5 and the rounds with the most consistent amplification for no 
inhibition samples were analysed. Inhibited with recombinant PrP samples were 
compared to non-inhibited but amplified samples. Non-amplified samples were prepared 
at the same time as other samples but stored at -20 °C for the PMCA running time. 
Round 5 was chosen for analysis of classical ovine scrapie isolates and a bovine BSE 
isolate and round 4 was analysed for ovine BSE (Figure 5.2.5). These rounds showed 
the most consistent amplification of no inhibition samples, therefore could be analysed 






Figure 5.2.5. Representative dotblots for serial PMCA round 5 (classical scrapie and 
bovine BSE isolates) and round 4 (ovine BSE) shows inhibition with 50 nM of each rRRQ, 
rKRQ and rPRQ. A – inhibition of round 5 of PMCA with 50 nM rRRQ, rKRQ and rPRQ for 
classical scrapie isolates PG1361/05 (ARQ/VRQ), PG1207/03 (VRQ/VRQ) and 
PG1499/02 (AHQ/VRQ). 50 nM of rRRQ, rKRQ and rPRQ was added into every PMCA 
round. B – inhibition of PMCA round 5 of bovine BSE (SE1945/0035) and round 4 of 
ovine BSE (PG1693/03). 50 nM of rRRQ, rKRQ and rPRQ was added into every PMCA 
round. PMCA products were PK digested and 2.5 µl was analysed on the dotblot in 
duplicates.  
During densitometry analysis, the average signal for no inhibition/no amplification 
samples was subtracted from the densitometry signals for other samples in ImageJ. 
Analysis (Figure 5.2.6) of round 5 of scrapie isolates showed that on average rRRQ 
inhibited the scrapie isolates PG1361/05 (ARQ/VRQ), PG1207/03 (VRQ/VRQ) and 
PG1499/02 (AHQ/VRQ) by 99 %, 90 % and 82 %, respectively. Furthermore, rRRQ also 
showed high inhibition for both bovine (SE1945/0035) and ovine BSE (PG1693/03, 
ARQ/ARQ) with average inhibition of 98 % and 64 %, respectively. rKRQ inhibited 
scrapie isolates PG1361/05, PG1207/03 and PG1499/02 in 100 %, 97 % and 57 %, 
respectively, and round 5 of bovine BSE was inhibited by 81 % and ovine BSE by 60 %. 
rPRQ inhibition has been found to be at levels 84 %, 40 % and 46 % for round 5 of 
scrapie isolates PG1361/05, PG1207/03 and PG1499/02, respectively, and for round 5 
of bovine BSE by 68 % and round 4 of ovine BSE by only 18 %. From these results, 






























inhibitor across different prion diseases isolates with a mean of 87 %. This was followed 
by rKRQ (79 %) and rPRQ (52 %). Additionally, two-way ANOVA (F=2.44, p<0.05) with 
Dunnett’s multiple comparison test was performed on this data in order to compare 
differences between for each rPrP within isolates. The statistically significant differences 
were reported for rRRQ between control scrapie PG1361/05 and ovine BSE isolate 
(PG1693/03) (p=0.0253) and for rPRQ between scrapie PG1361/05 and scrapie 
PG1207/03 (p=0.0036) and ovine BSE PG1693/03 (p=0.001). When rKRQ was 
analysed, no statistically significant differences in inhibition were found between scrapie 
PG1361/05 and other tested isolates (p>0.05). This outcome suggested that from the 
pool of tested rPrPs, rKRQ was the best inhibitor among all tested isolates derived from 
different TSEs and its response didn’t differ significantly between isolates. However, 
high standard deviations for rPrP could suggest that both rRRQ and rKRQ showed similar 
inhibtion rates among tested prion diseases isolates.  
 
Figure 5.2.6. Percent of inhibition for rRRQ, rKRQ and rPRQ in round 5 of PMCA for 
ovine scrapie isolates PG1361/05 (ARQ/VRQ), PG1207/03 (VRQ/VRQ), PG1499/02 
(AHQ/VRQ), bovine BSE (SE1945/0035) and round 4 of ovine BSE (PG1693/03). The 
background signals of non-amplified, non-inhibited samples were subtracted from blots. 
The densitometry values for other samples were obtained from dotblots and the percent 
of inhibition was calculated using the non-inhibited control. Graph shows the data from 
three replicates per rPrP. Two-way ANOVA (F=2.44, p<0.05) with Dunnett’s multiple 
comparison test was performed. Statistical differences were found for rRRQ between 
scrapie PG1361/05 and ovine BSE PG1693/03 (‘*’, p=0.0253) and rPRQ between control 
scrapie PG1361/05 and scrapie PG1207/03 (‘**’, p=0.0036) and ovine BSE PG1693/03 
(‘***’, p=0.001). * - p0.05; ** - p0.01; *** - p0.001; **** - p0.0001; 
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5.2.5 Inhibition of α-synuclein fibrils formation  
In order to investigate, whether rRRQ, rKRQ or rPRQ could act as an inhibitor for α-
synuclein fibril formation during PMCA, recombinant prion proteins were added at 50 nM 
concentration prior to PMCA. Recombinant α-syn was seeded with healthy control (HC) 
and Parkinson’s Disease patients (PD) samples and compared to samples treated with 
rPrPs. Samples were amplified with 40 seconds of sonication followed by 29 minutes 20 
seconds of incubation at 37 °C (144 cycles). Products were digested with PK (17 µg/ml) 
and analysed on the SDS-PAGE. Signal values were measured in ImageJ and the percent 
of control was calculated. The control for α-synuclein + PD with rPrP was α-synuclein + 
PD only, whereas for α-synuclein + HC with rPrP was compared to α-synuclein + HC. 
Moreover, all samples were amplified in 1 x PBST, therefore rPrP in PBST controls were 
also included in the experiment as further controls. Results showed spontaneous 
fibrillization of recombinant α-syn and recombinant α-syn with healthy control. 
Moreover, misfolding of α-syn seeded with Parkinson’s Disease samples showed similar 
to HC seed product. Furthermore, the addition of 50 nM of rRRQ (Figure 5.2.7) did not 
inhibit the α-synuclein fibril formation in all tested cases (recombinant α-syn on its own, 
seeded with HC and PD samples). The data were compared using statistical one-way 
ANOVA (F=0.1969, p<0.05) with Tukey’s multiple comparisons test, which showed that 
there were no statistically significant differences between any tested groups. In addition, 
also other concentrations – 1 nM and 100 nM of rRRQ – were tested in this experiment 
but showed results similar to 50 nM rRRQ (data not shown). Moreover, rKRQ and rPRQ 
were also tested at 50 nM and displayed no inhibition of α-synuclein fibrils formation 
(data not shown). 
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Figure 5.2.7. Representative SDS-PAGE gel image and graph analysis for 50 nM rRRQ 
inhibition of α-synuclein fibrils formation. A – representative SDS-PAGE gel image 
showing lack of inhibition of α-synuclein fibrils with 50 nM rRRQ. Protein marker was 
indicated on the left site of the gel (kDa). Each sample was digested with PK at 17 µg/ml 
and 15 µl of the product was analysed on the SDS-PAGE. Gel was stained with Instant 
Blue. B - graph shows the percent signal with rRRQ compared to the relevant control 
(shown as 100% signal). The control for α-synuclein with PD and with rRRQ was α-
synuclein with PD only, whereas α-synuclein with HC and rRRQ were compared to α-
synuclein with HC only. Data were analysed using one-way ANOVA (F=0.1969, p<0.05) 
followed by Tukey’s multiple comparisons test and showed no statistical differences 
between groups. α-syn - α-synuclein (no seeding representing de novo formation of 
fibrils); PD – Parkinson’s Disease sample seed; HC – healthy control sample seed; M – 
marker, PBST – phosphate buffer with 0.05 % Tween 20.  
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5.3 Discussion 
This study focused on attempts to inhibit a range of TSE isolates in ruminants and also 
a completely unrelated protein misfolding disease with mutant rPrPs. In the previous 
chapter, it has been shown that amongst all produced recombinant prion proteins, three 
– rRRQ, rKRQ and rPRQ – were identified as demonstrating the greatest potential to 
decrease the in vitro amplification of an ARQ/VRQ classical scrapie isolate. Here, we 
investigated the inhibition impact of these recombinant PrPs on the replication of other 
prion isolates. Besides ovine classical scrapie isolate - PG1361/05 (ARQ/VRQ) – two 
further classical scrapie isolates were used. These were PG1207/03 (VRQ/VRQ) and 
PG1499/02 (AHQ/VRQ). In addition, bovine BSE (SE1945/0035) and ovine BSE 
(PG1693/03, ARQ/ARQ) were tested. First of all, the amplification efficiency of these 
isolates was analysed in various negative brain homogenates. Classical scrapie isolates 
were found to successfully amplify in VRQ/VRQ substrate over 4 rounds of PMCA. 
Moreover, bovine BSE was amplified in bovine substrate, and ovine BSE isolate was 
amplified using a previously established method, where two substrates (AHQ/AHQ and 
VRQ/VRQ) are alternated (Taema et al., 2012). In addition, distinctive experimental 
scrapie isolate samples CH1641 (isolates J3011 and J2935) were amplified over four 
rounds of PMCA but no PrPSc was detected. Therefore, in this research isolate CH1641 
was not analysed further. In comparison to this, Workman et al., found that CH1641 
isolate J2935 amplified over 5 rounds in AHQ/AHQ substrate (Workman, Maddison and 
Gough, 2017). In contrast, CH1641 like scrapie isolates was reported not to amplify 
over 5 or 10 rounds in neither VRQ/VRQ nor AHQ/AHQ substrate (Taema et al., 2012). 
Discrepancies between the studies may be due to differences in amplification condition 
used such as the amplitude or could be due to the subtle effects of using distinct 
sonication machines/horns.  
For PG1361/05, 0.5 µl of PrPSc going into round 1 showed high levels of PrPSc 
amplification. On this basis we hypothesized that the amount of PrPSc going into round 
5 would be high and detectable on dotblot without round 5 amplification. To test that, 
we firstly added various amounts of PG1361/05 round 4 product into round 5 of PMCA 
and performed the amplification. The result showed that the highest PrPSc signal was 
when 3/7 of round 4 was added into round 5. Furthermore, PrPSc amplified even when 
adding only 3.75 µl of round 4 spike. This amount of PrPSc spike resulted in no 
background signals, therefore, would have been ideal for screening inhibitors. But other 
isolates did not amplify as efficiently as this scrapie isolate therefore higher seeding 
volume (3/7) was used. Secondly, different rRRQ concentration were tested with 3/7 
ratio of round 4 into round 5 of PMCA for control classical scrapie PG1361/05. It was 
noticed that there were no differences between used rRRQ concentration. Additionally, 
to test the exact signal of round 4 amplified PrPSc going into round 5 (3/7 ratio), we 
prepared the sample as for non-inhibition control but 24 h amplification was replaced 
by sample storage. The experiments showed that the round 4 PrPSc spike was detectable 
on dotblots and could act as a negative (background) control for dotblots. Furthermore, 
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for some cases, the signal for no amplification, no inhibition controls was higher than 
inhibited samples. This suggested that the amplification was inhbited in 100 % but and 
the signal came from the previous round seed.  
Workman and colleagues established that addition of 400 nM rVRQ inhibited the serial 
amplification of PG1361/05 by 100 %. Primary tests with control isolate PG1361/05 
involved screening 400 nM of rVRQ and compared it to 100 nM rRRQ, rKRQ and rPRQ 
(as they had lower IC50 values than rVRQ). At this point, results showed that there 
were no significant differences in inhibition of ARQ/VRQ scrapie isolate between 400 nM 
rVRQ and 100 rRRQ or rKRQ. Moreover, inhibition with 100 nM rPRQ had lower efficiency 
and larger variability than for the other rPrPs. At this point, the 400 nM rVRQ and 100 
nM rRRQ and rKRQ inhibited the round 5 amplification at the same level showing that 
rRRQ and rKRQ are potentially more efficient inhibitors than rVRQ, as also indicated by 
the relative IC50 values.  
After the optimisation of the serial PMCA conditions for the amplification of each TSE 
isolate, rounds with the most consistent amplification across the experimental repeats 
were chosen for densitometry analysis. Round 5 for every classical scrapie isolate 
(PG1361/05, PG1207/03 and PG1499/02) and bovine BSE (SE1945/0035) were 
analysed, whereas for ovine BSE (PG1693/03) round 4 of PMCA was analysed. As 
a background control, either round 5 or round 4 were prepared the same way as the no 
inhibition control, however, no amplification was carried out and samples were frozen 
for the PMCA duration time. This control showed the exact amount of PrPSc spike going 
into the final round of PMCA and provided the background signal in the blots. 
Additionally, after discussions and consideration it was decided to lower the amount of 
rPrP used in PMCA from 100 nM to 50 nM. The reported IC50 values for rPrPs were lower 
than 20 nM. Basing on the molecular weight and obtained concentration for each rPrP, 
it was possible to include as accurately as possible 50 nM of each PrP. Moreover, for 
some isolates round 5 amplification products had already large amounts of PrPSc what 
could have an impact on the rPrP performance. Therefore, for testing other isolates, 
rPrPs at 50 nM were added into every PMCA round.  
Workman et al., showed that rVRQ acted as a strong inhibitor for various TSE isolates. 
Classical scrapie isolates (PG1361/05 (ARQ/VRQ) and PG1563/02 (VRQ/VRQ)), mouse 
passaged classical scrapie (two G338 scrapie and two Apl338 scrapie isolates, all 
VRQ/VRQ), ovine BSE isolates (PG0392/04 and PG1693/04, both ARQ/ARQ) and bovine 
BSE isolates (SE1929/0729 and SE1945/0035) were tested. In every case, rVRQ at 400 
nM inhibited the prion protein amplification with a mean inhibition of 84 % (Workman, 
2017; Workman, Maddison and Gough, 2017). In the current study, our final tests 
involved using rPrP at 50 nM in every PMCA round. This amount of recombinant protein 
inhibited round 1 of classical scrapie isolate (PG1361/05, ARQ/VRQ) by 100 %. In this 
assay, the mean percent of inhibition for rRRQ (at 100 nM) across all tested TSE isolates 
was 87 % which was marginally higher than previously reported value for rVRQ at 400 
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nM – 84 % (Workman, 2017; Workman, Maddison and Gough, 2017). Furthermore, 
rRRQ inhibited classical scrapie isolates as well as bovine BSE and ovine BSE. rKRQ also 
displayed high mean inhibition value for all tested isolates – 79 %. rKRQ showed similar 
inhibition efficiency for classical ovine scrapie isolates – PG1361/05 and PG1207/03 and 
bovine BSE in comparison to rRRQ. While testing the third recombinant prion protein 
rPRQ, it was found that the variations between replicates and experiments were high 
and the protein had a lower mean percent of inhibition (52 %). In addition, statistical 
analysis for rPrPs for control classical scrapie isolate (PG1361/05) and different TSE 
isolates revealed that rKRQ was the best inhibitor among all tested isolates. It’s percent 
of inhibition did not differ significantly between the control isolate and other TSE 
isolates. This was followed by rRRQ which only displayed the difference between 
PG1361/05 and ovine BSE. In contrast, rRRQ had the highest mean inhibition for all 
isolates from all tested rPrP. On the other hand, rPRQ showed differences in inhibition 
between PG1361/05 and another classical scrapie PG1207/03 and ovine BSE. 
Interestingly, for any of the tested rPrPs no significant differences were reported 
between ovine classical scrapie PG1361/05 and other species TSE – bovine BSE. This 
result confirm the data obtained for rVRQ, which had the same inhibition level for ovine 
scrapie and bovine BSE (Workman, 2017). These data confirm the hypothesis that 
recombinant prion protein could act as an inhibitor for a wide spectrum of animal TSE 
isolates independently from the genotype differences between the recombinant PrPC and 
the seeding PrPSc, and the prion strain being amplified (Workman, 2017).  
It was also investigated whether rPrP could act as inhibitor for an unrelated protein 
misfolding processes. Here, α-syn aggregates were produced according to a PMCA 
method developed by research group member Juan Fernandez Bonfante (personal 
communication). The method can amplify synthetic α -synuclein monomers into fibrils 
either without seed (de novo formation) or after seeding with either PD or healthy brain 
samples. It has been shown that the seeded samples contain distinct fibril conformers 
compared to de novo fibrils (Juan Bonfante, personal communication). An analogous 
method has also been reported and the α-synuclein aggregates shown to display similar 
biochemical and biophysical characteristic as in vivo α-synuclein aggregates (Herva et 
al., 2014). Moreover, commonly known anti-amyloid compounds like CR or curcumin 
have been tested by this method. The PMCA products showed significant decrease in 
ThT positive structures after Congo Red or curcumin treatment. Also, SDS-PAGE results 
were consistent with these findings and less PK-resistant α-synuclein was produced in 
the presence of the inhibitors (Herva et al., 2014). Here, it was tested whether the 
recombinant ovine prion proteins could inhibit the in vitro formation of α-synuclein 
aggregates. Based on the finding by Nieznanski, in which prion protein was described 
as having disaggregating properties, we tested if it inhibits α-synuclein aggregates 
production (Nieznanski et al., 2014). This preliminary outcome showed that in the PMCA 
system, rPrPs did not prevent or decrease the extent of fibril formation. Previously, 
research produced conflicting outcomes regarding the PrP – α-synuclein interactions 
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(Ferreira et al., 2017; La Vitola et al., 2019; Corbett et al., 2020). Furthermore, the 
method of α-synuclein oligomers production was different in each case and none of 
these previous studies involved fibril production by PMCA. One study used 300 seconds 
of shaking every 10 minutes before the ThT fluoresce reading (Corbett et al., 2020). 
Other two studies used either shaking for 6 days at 37 °C or incubation of α-synuclein 
at 37 °C for 48 h without shaking (Ferreira et al., 2017; La Vitola et al., 2019). In 
addition to the different methodologies for fibril production, all three studies produced 
de novo α-synuclein aggregates and reactions were not seeded with Parkinson’s Disease 
samples. Therefore, it is possible that fibrils produced in our research (and between 
studies), could exhibit different features and misfolding pattern for samples seeded with 
HC or PD samples.  
To conclude, three recombinant prion protein produced in this research – rRRQ, rKRQ 
and rPRQ – were found to inhibit various TSE isolates but not the formation of misfolded 
α-synuclein during PMCA.  
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The use of peptides derived from recombinant proteins shows an opportunity to design 
new therapeutics that mimics natural processes (Lau and Dunn, 2018). In addition, 
peptides could be engineered to have higher biological activity, membrane penetration 
and be less toxic than the full-length proteins. Furthermore, peptide production has 
lower cost (Baig et al., 2018). Peptide inhibitors have been used in a range of 
neurodegenerative diseases. For Aβ, β-sheet breakers were described. These 
compounds specifically recognise and bind amyloid β fragments and prevent the 
oligomer and/or fibril formation (Funke and Willbold, 2012). In the Aβ aggregation 
studies, sequence KLVFFA (Aβ residues 16-21) and its modifications were used (Soto et 
al., 1996; Tjernberg et al., 1996; Funke and Willbold, 2012). This peptide is derived 
from the hydrophobic, fibrillogenic fragment of the Aβ N-terminus (Barrow et al., 1992). 
The peptide not only bound to the monomeric full-length protein but also prevented its 
polymerization into fibrils by blocking the formation of β-sheet rich structures (Soto et 
al., 1996; Tjernberg et al., 1996; Nieznanska et al., 2018). Additionally, other research 
investigated how the substitution of any amino acid in the HHQKLVFFAEDVG (Aβ 
residues 13-25) sequence changes the impact on Aβ aggregation. For that purpose, 
overlapping peptides were designed. As a result, the replacement of any amino acid in 
the sequence equivalent to Aβ residues 13-25 with proline resulted not only in better 
peptide solubility but most importantly in significant reduction of fibrils formation (Wood 
et al., 1995). Moreover, a similar approach was used for the inhibition of tau fibrils 
formation. Pir and colleagues used a recombinant tau fragment (residues 258-360) with 
inserted prolines. The tau fibrils formation was investigated in multiple experiments 
involving Thioflavin S fluorescence, atomic force microscopy and N2a cell culture. The 
outcome showed that the modified tau fragment affected the aggregation process in a 
dose-dependent manner (Pir et al., 2019).  
PrPsen to PrPres conversion and PrPres accumulation has been inhibited using prion protein 
derived peptides in cell free conversion assays and MNB scrapie infected cells (Chabry, 
Caughey and Chesebro, 1998; Chabry et al., 1999). Among many overlapping hamster 
and mouse amino acid sequences tested, peptides homologous to the central parts of 
PrP were the most successful and showed the potential for this approach for further 
usage among other prion diseases (Chabry et al., 1999). Moreover, N-terminus PrP 
derived peptides were also found to inhibit the Aβ  fibrils formation and their neurotoxic 
effects on cells (Nieznanski et al., 2012; Fluharty et al., 2013; Nieznanska et al., 2018). 
It was presented that two binding sites (residues 23-31 and 95-105) on the PrPC could 
interact with the Aβ (Chen, Yadav and Surewicz, 2010). Based on that, the PrP fragment 
containing the PrPC residues 23-111 (N1 peptide) was designed and tested. It was found 
that N1 inhibited the oligomers fibrils formation in polymerization assays (Fluharty et 
al., 2013). In addition, further research presented that full length PrP was found to have 
similar effectiveness as the N1 peptide, whereas the C-terminal fragment had no 
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inhibitory activity on Aβ fibril formation (Nieznanski et al., 2012). Moreover, the shortest 
possible molecule with the ability to inhibit amyloid β misfolding was investigated using 
the ThT fluorescence assays and transmission electron microscopy analysis. The two N1 
derived peptides (PrP23-50 and PrP90-112) interfered with amyloid formation, however, 
the process was less effective than for the N1 peptide (Nieznanska et al., 2018). 
In the previous research, synthetic hamster peptides were shown to interact with PrPsen 
and demonstrated inhibitory effect in cell free scrapie conversion assays (Chabry, 
Caughey and Chesebro, 1998). The most successful peptides were highly homologous 
in other species PrP sequences (Chabry et al., 1999). In this research, we propose 
similar mechanisms for ovine prion protein conversion during PMCA and that fragments 
or peptides from ovine PrP can inhibit prion formation. In this chapter, we focused on 
designing and producing ovine PrP derived peptides in order to investigate which part 
of the structure and/or sequence might have an impact on the inhibition of in vitro prion 
protein misfolding. We analysed rVRQ, rRRQ, rKRQ and rPRQ derived peptides of 
different lengths. The sequences of these peptides were carefully designed to include 
the known polymorphisms at positions 136, 154 and 171 in ovine PrP. Peptide design 
included predicted structural analysis in order to select the residues in the protein 
sequence that could be important for β-sheet formation and molecule stabilization. 
Furthermore, the predicted protein structure was used as a tool for predicting the 
various amino acids substitutions on protein structure, function and bindings (Teng et 
al., 2010). Here, models were created for rARQ, rRRQ, rKRQ and rPRQ with focus on 
the amino acid substitutions at position 136 in those recombinant proteins. These four 
recombinant proteins were compared to those previously deposited in Protein Data Bank 
VRQ model (pdb entry 2N53) that showed less efficient inhibition than rRRQ, rKRQ and 




6.2.1 Optimisation of peptides’ solvent concentration in PMCA  
Acetonitrile was used as solvent for all peptide Ov112-144 fragments, as specified by 
the manufacturer. In order to assess any peptide solvents inhibitory effects in PMCA, 
a range of concentrations of acetonitrile was added to PMCA and samples were amplified 
as previously described (Figure 6.2.1). The solvent concentrations required to be 
added in the PMCA reactions were calculated from peptides concentrations. Results were 
compared to samples amplified in PBS. Densitometry analysis showed that 2.7 % of 
acetonitrile, that is an equivalent amount of solvent in 50 µM of peptide, had a significant 
inhibition effect on amplifications of PG1361/05 scrapie (ARQ/VRQ). On average, it 
inhibited the scrapie amplification by 64 %. Furthermore, the 0.05 % and 0.005 % of 
acetonitrile that would correspond to 1 µM and 100 nM peptide concertation, 
respectively, slowed down the prion protein misfolding by 30 %. This result shows that 
there is acetonitrile related inhibition of misfolding of prion protein.  
 
Figure 6.2.1. Solvent impact on scrapie ARQ/VRQ PG1361/05 in vitro amplification. 
Different amounts of acetonitrile and formic acid (HCOOH) were added into PMCA and 
amplified for 24 h. 2.5 µl of PK digested products were analysed on dotblot in duplicate. 
Samples contain specific solvent were compared to samples amplified in PBS. PrPC – 
negative brain homogenate. 
Furthermore, for peptide OvV122-139, manufacturer solubility tests showed that this 
peptide is resuspended in acetonitrile and formic acid (HCOOH). Therefore, different 
concentrations according to peptide concentrations were tested with the highest being 
0.04 % HCOOH, 0.3 % acetonitrile for 50 µM peptide and the lowest - 0.00007 % 
HCOOH, 0.0006 % acetonitrile for 100 nM of peptide OvV122-139. The dotblot analysis 
showed that the mixture of formic acid and acetonitrile had no impact on the ovine 
2.7 % acetonitrile
0.04 % HCOOH, 0.3 % acetonitrile





0.0007 % HCOOH, 0.006 % acetonitrile
Replicate
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scrapie prion protein misfolding during the PMCA. Additionally, OvR, OvK and OvP122-
139 were resuspended in water and their solvent impact on PMCA was not assessed.  
6.2.2 Peptides inhibition of ovine scrapie PG1361/05 amplification 
rRRQ derived peptides (OvR112-144 and OvR122-139) were screened at concentrations 
of 50 µM, 1 µM and 100 nM and compared to 50 nM rRRQ and no inhibition controls 
(Figure 6.2.2). 50 µM of peptide was equivalent to 2.7 % of acetonitrile in the PMCA 
reaction, therefore PrPC in 2.7 % of acetonitrile was also analysed. For each peptide 
concentration, non-inhibited control with equivalent solvent concentration was studied. 
So that, 50 nM rRRQ, 50 µM, 1 µM and 100 nM of OvR122-139 were compared to 
PG1361/05 amplification in PBS. Then, 50 µM of OvR112-144 was compared to 
PG1361/05 amplification with 2.7 % acetonitrile, 1 µM of OvR112-144 was compared to 
PG1361/05 amplification with 0.05 % acetonitrile and 100 nM of OvR112-144 to 
PG1361/05 amplification in 0.005 % acetonitrile. Data shows that the addition of 2.7 % 
acetonitrile already inhibited the amplification of PG1361/05, therefore it is difficult to 
investigate the inhibition of 50 µM of OvR112-144 peptide, which contain 2.7 % 
acetonitrile. In such case, any PrPSc signal decrease came from solvent rather than 
peptide derived inhibition. PMCA samples containing 1 µM and 100 nM of this peptide 
did not inhibit amplification. On the other hand, 50 µM of OvR122-139 inhibited the 
misfolding on average by 30 %, whereas 1 µM and 100 nM had no inhibitory effect.  
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Figure 6.2.2. Representative dotblot shows inhibition of ovine scrapie PG1361/05 
(ARQ/VRQ) with rRRQ and OvR peptides. 50 nM rRRQ, 50 µM, 1 µM and 100 nM of 
OvR122-139 were compared to PG1361/05 amplified in PBS. PrPC amplified in PBS was 
included as a PK digestion control. 50 µM OvR112-144 was compared to PG1361/05 
amplified in the presence of 2.7 % acetonitrile and PrPC in 2.7 % acetonitrile was 
included as a digestion control. 1 µM of OvR112-144 was compared to PG1361/05 
amplified with addition of 0.05 % acetonitrile. 100 nM of OvR112-144 was compared to 
PG1361/05 amplified in 0.005 % of acetonitrile. Amplification products were PK digested 
and 2.5 µl of each sample were added on the dotblot in duplicate. PrPC – negative brain 
homogenate. 
Possible inhibition of OvR122-139, PMCA with higher concentrations of this peptide (50 
– 150 µM) was investigated (Figure 6.2.3). The results showed again that there was 
around 30-40 % of signal decrease for 50 µM of that peptide in compare to non-
inhibition samples, however higher concentrations showed no inhibition. Based on this, 
we concluded that there is no significant OvR122-139 inhibition of ovine scrapie 
PG1361/05. The 30-40 % signal decrease for 50 µM peptide on the dotblot could be 
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Figure 6.2.3. Representative dotblot showing the inhibition of ovine scrapie PG1361/05 
(ARQ/VRQ) with 50 nM rRRQ and 50 – 150 µM of OvR122-139 peptide. This peptide was 
re-suspended in water and further dilutions were made in PBS. All inhibition samples 
were compared to no inhibition control – PG1361/05 that was also diluted in PBS. PrPC 
(negative brain homogenate) was included as a background control and to assess PK 
digestion efficacy. All samples were PK digested and 2.5 µl of each sample was added 
on dotblot in duplicate.  
Further peptides were also tested for rVRQ, rKRQ and rPRQ. The longer peptide for each 
mutation (OvV112-144, OvK112-144, OvP112-144) and a randomised peptide (OvRND) 
were tested at 1 µM and 100 nM. 50 µM was not assessed further as this resulted in an 
acetonitrile concentration of 2.7 % that interfered with PMCA. In addition, the shorter 
peptides OvK122-139 and OvP122-139 were analysed at 50 µM, 1 µM and 100 nM as 
they were resuspended in water and then diluted in PBS. In addition, OvV122-139 was 
resuspended in formic acid and acetonitrile, and these concentrations of solvents were 
not affecting misfolding in vitro. In all cases, there was no peptide inhibition of scrapie 
ARQ/VRQ PG1361/05 (Appendix). 
The peptide that consists of three ovine polymorphic positions 136, 154 and 171 was 
designed with R at 136 position (OvR130-173) was also produced. There was no 
suggested solvent from the manufacturer, therefore the overall peptide net charge was 
calculated using the online calculator pepcalc to be 1.1 at pH 7 (Lear and Cobb, 2016). 
The value suggested good water solubility, therefore the peptide was resuspended in 
ultrapure water and further dilutions were performed in PBS. The range of peptide 
concentrations (50 µM – 1 nM) were added into PMCA reactions (Figure 6.2.4). The 
dotblot analysis showed that OvR130-173 had no inhibitory effect on amplification of 




















Figure 6.2.4. Representative dotblot determining the inhibition of ovine scrapie 
ARQ/VRQ (PG1361/05) with 50 nM rRRQ and range of concentrations (50 µM – 1 nM) 
OvR130-173). The peptide included all three polymorphic positions in ovine PrP and 
included arginine at 136 and 154 position and glutamine at 171 position (RRQ). Peptide 
was re-suspended in water and further dilutions were made in PBS. All inhibition 
samples were compared to no inhibition control – PG1361/05 that was also diluted in 
PBS. PrPC (native brain homogenate) was included as a background control and to test 
PK digestion efficacy. All samples were PK digested and 2.5 µl of each sample was added 
on dotblot in duplicate. 
In summary, the various peptides derived from rVRQ, rRRQ, rKRQ and rPRQ and 



















6.2.3 Structural overview of the rPrP mutants  
6.2.3.1 Structure of ovine PrP with valine at 136 position 
As a model the wild-type ovine PrP (accession code: 2N53) with valine136, arginine154 
and glutamine171 was taken from the Protein Data Bank (PDB), entry 2N53 (Figure 
6.2.5, B) (Munoz-Montesino et al., 2016). The structure analysis in PyMOL showed 3 
α-helices within the core PrP structure (Figure 6.2.5, A). During the PyMOL analysis of 
the 2N53 entry those helices were reported at positions:  α-helix 1: 146-156, α-helix 2: 
174-194 and α-helix 3: 202-232. In addition, there is one anti-parallel β-sheet present 
in the structure (131-134 and 162-165), however it was not shown in the images 
generated by the pdb files downloaded from the website.  
 
Figure 6.2.5. The most-representative model of the PrP structure (A) and sequence 
(B) of the 2N53 protein bank database entry. A – structure of ovine prion protein with 
valine at 136 position (pink) was generated using 2N53 .pdb file and PyMOL (version 
0.99). The model contains residues 92 (S) – 234 (S) of ovine prion protein and does not 
contain the poly-his tag. 1st α-helix is indicated in red, 2nd α-helix – blue, 3rd α-helix – 
yellow. B – ovine prion protein amino acid sequence. Valine (pink), arginine (green) and 
glutamine (grey) are marked as known polymorphic positions 136, 154 and 171, 
respectively. Also, the displayed on A sequence was underlined.  
Moreover, it was also investigated how the valine position at 136 varies between 
different NMR model ensembles. From different models’ alignment (Figure 6.2.6, A) it 
was noticed that the N-terminus of the ovine PrP was highly flexible and presented large 
variations between NMR coordinates. Moreover, these variations between models 
existed until residue 131 (tyrosine), at which the models started to create a more 
organised amino acid chain with similar coordinates for each NMR entry. After a closer 
look at the 136 position region (Figure 6.2.6, B), it was observed that the positions 
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around 136 valine might have different NMR coordinates in different NMR models 
suggesting flexibility.  
 
 
Figure 6.2.6. NMR ensembles of solution models of ovine prion protein with valine at 
136 position (2N53 PDB entry). A – whole prion protein structure. B – close-up view of 
the 136 position region. The valine136 has been marked in pink and is indicated in arrows. 
6.2.3.2 Comparison of PrP models of different species 
In order to better understand whether the effective therapeutic for prion disease could 
work among other species, the similarities in prion protein sequences were investigated. 
Prion protein sequences are highly conserved between mammalian species. The protein 
sequences for ovine (P23907), bovine (P10279), human (P04156), mouse (P04925) and 
hamster PrP (P04273) from UniProt database were compared using ClustalW (Higgins, 
Thompson and Gibson, 1996; The UniProt Consortium, 2019). The degree of homology 
between species could be an indicator of using a potential therapeutic for TSEs across 
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species. For all species, alanine was present at 136 position (ovine position) (Figure 
6.2.7, A). Moreover, the sequences comparison showed that ovine PrP shared 70 % 
sequence alignment with bovine, 89 % with human, 83 % with mouse and 85 % with 
hamster PrP. The lower percent of similarity between ovine and bovine PrP was a result 
of an additional octapeptide repeat in bovine PrP. In addition, to visualise the PrP 
structures, PDB entries for ovine (2N53), bovine (1DWY), hamster (1B10), mouse 
(1XYX), and human (1QLX) were used (James et al., 1997; Zahn et al., 2000; Lopez 
Garcia et al., 2002; Gossert et al., 2005; Munoz-Montesino et al., 2016). The deposited 
database entry for ovine PrP included the ARQ variant, the partial alignment between 
full ovine PrP (P23907) and Protein Data Bank entry for ovine PrP (2N53) was performed 
(Figure 6.2.7, B). The pdb entry contained a shorter sequence, that started with 
a poly-his tag and did not contain the octapeptide repeats within the N-terminal protein 
end. The first amino acid that was common for pdb and Uniport entry was N103. The 
similarity between full ovine PrP and 2N53 was 86 %, however this analysis included 
the whole N-terminus of full-length protein and poly-his tag of 2N53 followed by residues 
not common in ovine PrP in these models. Additionally, when ovine PrP fragment 103 
(N) – 234 (S) fragment and 2N53 sequence were compared, the sequences similarities 
were at 99 % with differences being at 136 position (A/V) and 171 position (R/Q), which 
are natural polymorphisms observed previously (Belt et al., 1995; Goldmann, 2008). 
Moreover, sequences for all other full-length PrP were aligned to pdb entries. The 
similarities were 99 %, 99 %, 100 % and 100 % for bovine, human, mouse and hamster 
sequences, respectively (data not shown). For bovine data, only one aa substitution was 
found at position 131 (A/S), whereas in human data two positions 21 (L/G) and 22 
(C/S). For human sequence, the differences at 21 and 22 residues are within the signal 
peptide that is being cleaved during the protein processing. Therefore, the presence of 
different amino acids at these positions could be an experiment variation rather than 
commonly found differences in protein sequence. Furthermore, in other species, alanine 
is presented naturally at the 136 position (as numbered in ovine sequence), but the 
ovine rPrP with alanine at this position was a less effective inhibitor than VRQ. Therefore, 
only structures that have valine at 136 were analysed.  
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Figure 6.2.7. Prion protein sequences alignment. A – full-length PrP alignment for ovine 
(P23907), bovine (P10279), human (P04156), hamster (P04273) and mouse (P04925) 
performed in ClustalW. Alanine at equivalent to 136 position in ovine PrP is marked 
with a red box. In all other species analysed, alanine is present at this position. The 
similarities between ovine and other species are: 70 %, 89 %, 83 % and 85 % for 
bovine, human, mouse and hamster, respectively. B – representative sequence 
alignment for full length PrP (P23907) and pdb entry (2N53) sequence for ovine PrP. 
The similarity of these two sequences was 86 %. The differences included include the 
presence of poly-his tag in 2N53 sequence and two amino acids substitutions: A/V136 
and R/Q171. Position 136 is indicated in red box. Analysis performed using ClustalW.  
The ovine PrP structure with valine at 136 position (2N53) was compared in PyMOL to 
other PrP of mammalian species (Figure 6.2.8). The structures alignment was only 
partial and did not include the whole flexible N-terminus. The structural analysis showed 
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that all compared PrPs contained three α-helices in the 3-D model. It was noticed that 
the valine136 in ovine PrP was directed inside the protein chain, whereas for other 
proteins with alanine, this amino acid residue was directed to the outside of the 
molecular structure. Additionally, there were no large differences within the structure’s 
alignment between PrPs.  
 
 
Figure 6.2.8. Ovine PrP (PDB entry 2N53, pink) superposition with bovine (1DWY), 
human (1QLX), mouse (1XYX) and hamster PrP (1B10) (all cyan). Valine at 136 position 
in ovine PrP is indicated on the images as A, whereas alanine in other models is indicated 
as B. All models were compared in PyMOL.  
 
6.2.3.3 rPrP variants structural comparison  
In order to generate the pdb files for PrP mutants at position 136, a web server - 
Dynamut – was used (Rodrigues, Pires and Ascher, 2018). Firstly, to investigate the 
differences between ARQ and VRQ, a structural model for ARQ was generated in 
Dynamut server (Rodrigues, Pires and Ascher, 2018). Using the pdb files obtained from 
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Dynamut distance lengths between carbons in both alanine and valine at 136 position 
to other amino acid were measured. Alanine is a short amino acid with a side chain 
methyl group attached to the central carbon. In comparison to alanine, the valine side 
chain contains an isopropyl group attached to central carbon (Hastings et al., 2016). 
PyMOL analysis allowed comparison of the 3-D models of both VRQ and ARQ and 
measurement of the distances between the closest amino acid side chains (Figure 
6.2.9). It was identified that the closest side chains to both valine and alanine at 136 
position were leucine at 141 position. Using Dynamut interatomic interactions file and 
PyMOL measurement tool, the distances were measured from C5 or C5’ of leucine at 
141 position to C3, C4 and C4’. The distances were as follows: ~3.6, 3.7 and 3.9 
Ångstroms (Å), respectively. According to the software analysis there could be some 
interactions between these carbon atoms like hydrophobic bonds. In compare to this, 
only one possible interaction was mapped between C5 or C5’ of leucine and C3 in 







Figure 6.2.9. VRQ and ARQ structure comparison. A – Alignment of VRQ (valine at 136 
position, pink) and ARQ (alanine at 136 position, cyan) 3-D models. B – Distances and 
possible interactions mapped between 136 position valine (V)/alanine (A) (green) and 
leucine (L) (grey) atoms at 141 position. The interatomic interactions files were 
generated using Dynamut and distances were measured using PyMOL tool 
‘measurement’. There are 3 possible interactions between valine carbons (C3, C4, C4’) 
and C5 or C5’ of leucine at 141 position (lengths: ~3.6, 3.7 and 3.9 Å), whereas only 
one interaction between alanine C3 and leucine was mapped (length ~3.5 Å). Oxygen 
atoms are indicated in red, nitrogen atoms are blue.  
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Next, the structure of VRQ was compared to structure with R at 136 position (RRQ). 
Arginine contains a three-carbon chain that ends with a guanidino group (Hastings et 
al., 2016). The arginine carbon chain is longer than the previously analysed alanine or 
valine carbon chains. Again, whole 3-D models were compared between these two 
proteins and atoms interactions. Interatomic interactions were analysed using the 
Dynamut generated files (Figure 6.2.10) and then uploaded into PyMOL. The analysis 
revealed one potential linkage between arginine C4 and carbonyl group in S138. In 
addition, four interactions between C5 or C5’ of L141 and carbonyl group, C3, C4 and C5 
of arginine were shown. These could involve hydrophobic, hydrogen bonds or other 
undefined connections. In addition, the distances between these atoms varied from ~3.4 
to ~3.7 Å. More atomic interactions were determined with arginine136 than valine136. 
 148 
 
Figure 6.2.10. RRQ (cyan) and VRQ (pink) structures comparison (A) and mapped 
arginine (R) interactions with serine (S) at 138 position and leucine (L) at 141 position 
(B) in a protein amino acid chain. A first interaction (black) was mapped between 
carbonyl in arginine and C5 (or C5’) of leucine at 141 position (~3.7 Å). A second 
interaction (black) was outlined between the C4 of arginine136 and carbonyl group of 
serine at 138 position (~3.7 Å). Analysis also showed interactions (blue) between C3 
and C4 of arginine136 and C5 (or C5’) of leucine at 141 position (3.7 Å and 3.6 Å, 
respectively). In addition, a linkage (red) was created between C5 of arginine136 and C5 
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(or C5’) of leucine141 with distance measured 3.4 Å. Oxygen atoms are indicated in red, 
nitrogen atoms are blue.  
Similarly to VRQ and RRQ, structures for KRQ and PRQ were also analysed (Figure 
6.2.11 and Figure 6.2.12). Firstly, the whole PrP chains alignment was looked at. 
Since VRQ differs from KRQ and PRQ by only one amino acid, the protein 3-D models 
were aligned with only exemption of the analysed amino acid at 136 position. Then, the 
possible interactions between amino acids were analysed. It was found that lysine136 
C3, C4 and C5 potentially created hydrophobic bonds with leucine141 C5 or C5’. The 
measured distances between atoms were ~3.4, 3.9 and 3.5 Å, respectively. In 
comparison, proline136 atoms C4 and C5 also created interactions: two with C5 (or C5’) 
of leucine141 (~3.4 and 4.4 Å, respectively) and one between C4 of P136 and glutamine163 
C4 with a distance of ~4 Å.  
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Figure 6.2.11. Structural differences between VRQ (pink) and KRQ (cyan). A – whole 
PrP structure alignment for VRQ/KRQ. B – atomic interactions with K136. Structural 
analysis using Dynamut and PyMOL revealed three possible hydrophobic interactions for 
KRQ between C5 (or C5’) of leucine141 and C3, C4 and C5 carbon atoms in lysine with 
distance lengths ~3.4, 3.9 and 3.5 Å, respectively. Oxygen atoms are indicated in red, 
nitrogen atoms are blue.  
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Figure 6.2.12. Structural differences between VRQ (pink) and PRQ (cyan). A – whole 
PrP structure alignment for VRQ/PRQ. B – atomic interactions with P136 (green). 
Structural analysis using Dynamut and PyMOL revealed two possible hydrophobic 
contacts for proline136 C3, C4 with C5 (or C5’) of leucine141 (~3.4 and 4.4 Å) and one 
interaction of proline C4 with C4 of glutamine163 (Q) (distance measured ~4 Å). Oxygen 
atoms are indicated in red, nitrogen atoms are blue. 
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6.2.3.4 Protein surface analysis for prion proteins with valine, arginine, lysine and 
proline at 136 position  
The charge distribution on the molecules globular part surface was analysed, in 
particular the region around the position 136. The PYMOL generated images showed 
that the electrostatic potential around the analysed position differed between PrPs. VRQ, 
RRQ and KRQ images showed a positively charged (blue) region, whereas the proline 
within the PRQ had a charge lower than that for the other analysed proteins which was 
close to 0 kT/e (white) due to it missing a second basic residue. Furthermore, the 
surfaces coloured by electrostatic potential of the molecules are shown (Figure 6.2.13, 
A) with a schematic representation of the secondary PrP structure (Figure 6.2.13, B). 
It was noticed that on the opposite site of position 136 in each analysed protein, 
a structural ‘pocket’ was present. This space was made by amino acids residues 209-
216 (MERVVEQM) from the 3rd α-helix. It was clear that for RRQ and KRQ, the arginine 
and lysine long side chains went into that pocket, whereas the valine and proline side 
chains were not large enough to fill this space.  
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Figure 6.2.13. Electrostatic surface representation for the globular part of VRQ, RRQ, 
KRQ and PRQ. A – position 136 in all proteins was marked with a black circle. For RRQ 
and KRQ, position 136 was enlarged for better visualisation. The longer amino acids at 
136 position were displayed in green (RRQ and KRQ), whereas shorter amino acid sticks 
are not visible on the protein surface. Red – negative charge, blue – positive charge, 
white – uncharged. B – Positioning of structural parts of PrP globular domains (VRQ as 
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an example). The displayed position was the same for all shown proteins. Position 136 




The study has demonstrated that recombinant PrPs could act as inhibitors for in vitro 
prion protein amplification. Here, this was expanded to investigate the shortest possible 
fragment of the most potent rPrPs that could inhibit the in vitro amplification of prion 
protein misfolding. For this purpose, we tested rRRQ, rKRQ, rPRQ and rVRQ derived 
peptides with different lengths. All tested peptides consisted of the amino acid at 136 
position in ovine PrP. Moreover, the 33 amino acids long peptides also contained the 
hydrophobic sequence AGAAAAGA, which had been reported to be essential for the 
inhibitory effects of hamster PrP derived peptides on PrPsen conversion into PrPres in cell-
free conversion assay (Chabry, Caughey and Chesebro, 1998). In addition, peptides 
without the hydrophobic sequence (18 amino acids long) were designed and produced. 
Both, 33 (Ov112-144) and 18 amino acids long (Ov122-139) ovine PrP derived peptides 
were equivalent to hamster derived peptides previously presented in the literature 
(hamster 109-141 and 119-136, respectively) (Chabry, Caughey and Chesebro, 1998) 
where the ovine position 136 is equivalent to position 133 in the hamster PrP sequence. 
In addition, a 43 amino acids long peptide was also designed and its sequence included 
all three polymorphic positions within the ovine PrP, 136, 154 and 171, but not the 
hydrophobic sequence. This peptide was produced and designed only for rRRQ. In 
addition, one peptide with randomised amino acids sequence was designed and 
produced as a control. For peptides, powder resuspensions used the buffers 
recommended by the manufacturer. Some were resuspended in water, other buffers 
were checked to determine if they interfered with in vitro prion protein amplification. It 
appeared that the presence of 2.7 % acetonitrile in the samples significantly inhibited 
the in vitro misfolding of ovine scrapie prion protein (ARQ/VRQ, PG1361/05). The 2.7 % 
of acetonitrile is present when using 50 µM OvR112-144, therefore, this was the highest 
concentration of this peptide used. It was shown that 1 µM and 100 nM of OvR112-144 
did not inhibit scrapie prion misfolding. Furthermore, 33 amino acids long peptides with 
other mutations at 136 position (for OvV, OvK and OvP) had no inhibitory effects at 
concentrations 1 µM and 100 nM. When analysing shorter peptides (Ov122-139) only 
OvR122-139 at 50 µM decreased the signal of PMCA amplified PrPSc on dotblots. 
However, higher concentration of this peptide did not affect the PMCA indicating the 
peptide did not consistently inhibit prion replication. In addition, the 50 nM of the rRRQ 
did not inhibit the PMCA reaction as previously described. This could suggest that were 
some problems with either PMCA process or with the recombinant rRRQ. For the other 
shorter peptides (Ov122-139) there were no inhibitory effects on ovine scrapie 
misfolding. Additionally, the longer peptide OvR130-173 was tested at concentrations 
of 50 µM – 1 nM and there was no peptide inhibition effects on the ovine PrP misfolding.  
Chabry et al., showed that the synthetic hamster peptides inhibited the conversion of 
PrPsen in cell-free conversion assay. Moreover, the researchers tested a range of different 
peptides lengths and clearly stated that the peptides derived from the central part of 
hamster PrP had the highest inhibitory rate. In addition to that, they also showed that 
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the presence of the highly hydrophobic sequence AGAAAAGA was essential for inhibition 
of the PrPres formation and the IC50 increased as the number of hydrophobic amino acid 
residues in the sequence decreased (Chabry, Caughey and Chesebro, 1998). To support 
this, the AGAAAAGA sequence has been described as highly amyloidogenic and crucial 
for the conversion of PrPC into PrPres (Gasset et al., 1992; Hölscher, Delius and Bürkle, 
1998). The inability of our peptides to inhibit the prion protein misfolding could be due 
to the methodology used for prion conversion. Chabry et al., used cell-free conversion 
assay, which differs from PMCA. In cell-free conversion assays, recombinant cellular PrP 
is incubated with PrPSc that has been purified and denatured by guanidine hydrochloride 
(Gdn-HCl), whereas in our PMCA model both PrPC and PrPSc were derived from whole 
brain homogenates. In addition, in PMCA sonication and incubation steps were used, 
whereas in cell-free conversion assays recombinant PrP and PrPSc required only an 
incubation step (Kocisko et al., 1994; Saborio, Permanne and Soto, 2001). Moreover, 
PrPSc formation using PMCA generated greater amounts of misfolded PrP and the 
formation was highly efficient in comparison to the cell-free conversion assay. 
Furthermore, the generated PrPSc in PMCA shares biochemical properties of PrPSc 
isolated from TSE infected brains (Saborio, Permanne and Soto, 2001). The inhibition 
of PMCA misfolding could possibly require the presence of whole recombinant prion 
protein and/or both its C- and N-terminus. To support this hypothesis, Yuan et al., tested 
the conversion of human PrPSc during PMCA. Similar to current research, his group 
showed that the full-length human recombinant PrP was able to inhibit the in vitro 
misfolding of human iCJD brain derived PrPSc. Moreover, the inhibition depended on the 
rPrP dose used and the inhibition mechanism involved the recombinant prion protein C- 
and N-termini regions (Yuan et al., 2013).  
The differences in the protein sequences and structures between rPrPs from different 
species were investigated to assess the stability and flexibility of 136 region, which 
seems to have a significant impact on the inhibitory efficacy of rPrPs. The structure of 
rVRQ ovine PrP (residues 92-234) was analysed and shown the presence of 3 α-helices 
(α-helix 1: 146-156, α-helix 2: 174-194 and α-helix 3: 202-233) within the core PrP. 
The presence of valine136, arginine154 and glutamine171 were confirmed in the ovine PrP 
sequence. Moreover, multiple NMR ensembles were analysed for region 136. It was 
shown that N-terminal part of protein was highly flexible and presented large variations 
between NMR ensembles. These variations existed until tyrosine131, from which models 
created a more ordered structure, however the NMR coordinates for position 136 
differed between entries. Therefore, it was hypothesised that region 136 is flexible. 
Additionally, sequences and structures of PrP from distinct species were examined. The 
potential similarities of PrP whole sequence/structure and/or 136 region between 
species could help to determine whether ovine PrP could act as a universal prion 
replication inhibitor. For this purpose, the full length mature ovine PrP with an ARR 
variant was compared to bovine, hamster, mouse and human PrP (Goldmann et al., 
1990). Slight differences in the sequence were noticed and also reported previously 
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(Groschup, Harmeyer and Pfaff, 1997; Baral et al., 2015). First of all, the bovine PrP 
sequence was longer (264 amino acids) than the other species PrP because of additional 
octapeptide repeats within the N-terminus (Yoshimoto et al., 1992). Additionally, the 
lengths of other tested PrPs were 254 aa (mouse and hamster) and 253 aa (human) 
(Oesch et al., 1985; Kretzschmar et al., 1986). Moreover, ovine prion protein has three 
highly polymorphic positions: 136, 154 and 171 (Belt et al., 1995; Goldmann, 2008). 
Furthermore, the differences between PrP sequences were single amino acid 
substitutions alongside the sequence chain (Groschup, Harmeyer and Pfaff, 1997). 
Overall, the found differences between analysed PrP sequences resulted in the ovine PrP 
similarity to bovine in 70 %, human in 89 %, mouse in 83 % and hamster in 85 %. 
Previous data from the multiple sequences alignment for prion mammalian prion 
proteins confirmed the high protein sequence homology between species, however the 
exact percentage value could differ between bioinformatic tools (Groschup, Harmeyer 
and Pfaff, 1997). As indicated from the sequence analysis, the presence of alanine at 
the equivalent to ovine 136 position is a common feature between species. In the 
current research, structures for different species and ovine prion proteins were 
compared. The NMR files that were used during the structural analysis (from protein 
data bank files) contained the globular, C-terminus part of the protein. All analysed PrP 
structures contained three α-helices, where for ovine these included residues 146-156 
(α-helix 1), 174-194 (α-helix 2) and 202-232 (α-helix 3). These results were similar to 
reported previously by Haire and co-workers (Haire et al., 2004). Moreover, the NMR 
coordinates for other species α-helices were similar to ovine PrP, however the region 
121-135 in ovine and equivalent residues in other species was the most disordered part 
of the C-terminus (Pastore and Zagari, 2007). Moreover, the 129-131 region structurally 
created β-sheet (Haire et al., 2004; Pastore and Zagari, 2007). In contrast to analysis 
of PrP in other species, the β-sheet was not marked on the ovine PrP entry but this was 
due to the focus on the ovine α-helices structures (Munoz-Montesino et al., 2016). The 
similarity between different species PrP could indicate that recombinant ovine PrP could 
be used as an universal therapeutic that can bind and mimic the PrP.   
Tested in the current research ovine PrP mutants at 136 position showed different 
inhibition performance in PMCA. Therefore, the main aim of the structural analysis was 
to compare the rPrP versions. The analysis could give an insight on why some of the 
amino acid substitutions at 136 position showed the differences in inhibition of prion 
protein misfolding. In order to analyse the implemented changes at position 136 in ovine 
PrP and its effects on protein structure. rPrP structures were generated using Dynamut 
server and analysed in PyMOL. First of all, the two natural variants: VRQ and ARQ were 
compared. Alanine in comparison to valine is a shorter amino acid (Hastings et al., 
2016). The length of each amino acid at 136 position could result in differences in 
formation of atomic interactions between different amino acids within the protein chain. 
As observed, both alanine and valine side chains could form some interactions with side 
chains of lysine141, however valine side chains could form three, whereas according to 
 158 
software analysis, alanine could form only one connection. Furthermore, comparison of 
ovine natural variants: ARQ, VRQ and ARR was performed in previous research. The 
authors looked at the whole molecule and noticed that position 136 as well as the other 
polymorphic residues in ovine PrP, were on the protein surface and exposed to water 
and other solvents and of course were accessible to interact with other proteins or other 
PrP molecules. Moreover, it was described that in the VRQ, an additional hydrogen bond 
between N162 side chain and R139 stabilised the molecule more in comparison to ARQ 
(Eghiaian et al., 2004). In addition, we also tested the number of possible interactions 
for the best inhibitory PrPs: RRQ, KRQ, PRQ. R and K have longer amino acids. As the 
analysis revealed, R chain atoms were shown to form different interactions with L141 and 
Ser138. These could include hydrophobic and hydrogen bonds. For KRQ hydrophobic 
interactions were shown only for L141 atoms. In addition, to that, proline atoms were 
found to interact with L141 and Q163. Among all the analysed structures R136 atoms 
created the most interatomic bonds. We could speculate that the greater number of 
connections between atoms could increase the protein stability. This would indicate that 
VRQ, RRQ, KRQ, PRQ had more stable structures around residue 136 compared to ARQ 
and this increased stability may present a more stable interaction region for binding to 
PrPC and/or PrPSc during prion conversion and enhance inhibition. The distances of atoms 
forming connections were also estimated, however these only indicated the distance for 
formed bonds rather than analysis of differences between the distances between atoms. 
Furthermore, the amino acids variations could change the electrostatic potential of the 
PrP surfaces and this could influence their interaction with PrPC and/or PrPSc during prion 
conversion (Baral et al., 2015). In the current research, the changes of the surface 
electrostatic potential due to amino acid change were observed. In compare to VRQ 
(positive charge), PRQ neutralised the charge, whereas R and K, as charged amino 
acids, maintained the positive charge of proteins region. These slight variations in 
charge distribution on the PrP surface could modify the protein’s features like binding 
properties or even already discussed interatomic interactions (Baral et al., 2015). 
Furthermore, the presence of proline in the amino acids chain could lower the flexibility 
of the protein backbone and therefore affects the formation of protein secondary 
structures and increase protein stability (Choi and Mayo, 2006). In addition, the 
structural ‘pocket’ was observed on the opposite site of position 136 in ovine PrP. This 
space was created by amino acids contained within α-helix 2. Data also indicated that 
introduction of the longer amino acids at position 136 in ovine PrP did not implement 
further changes within the whole structure.  
The change of the single amino acids in ovine PrP resulted in significant changes of the 
inhibition process of in vitro prion protein misfolding. Here, it was shown that even large 
fragments of the rPrPs failed to inhibit prion replication and only full-length protein was 
effective. Preliminary structural analysis revealed new insights on these prion protein 
variants. The amino acids changes could influence some local changes in terms of 
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domain stability and surface charge which could trigger the change in the whole protein 
properties including the inhibition efficacy (Baral et al., 2015).  
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Chapter 7: Infections and treatment model of 




Cell cultures provide an extremely model for various physiological and disease 
associated processes. They are incredibly practical for screening for and testing 
candidate therapeutic compounds for various diseases, including TSEs (Kocisko and 
Caughey, 2006a). For prion diseases, cell culture experiments could also deliver details 
about the conversion mechanisms of PrPC into PrPres and PrPres transmission between 
cells (Solassol, Crozet and Lehmann, 2003). In addition, metabolism of both resistant 
and cellular PrP have been analysed in in vitro cell culture experiments (Caughey et al., 
1999). For now, only a very limited number of cells lines have been described as 
permissive to prion from natural TSE isolates (Vilette et al., 2001; Solassol, Crozet and 
Lehmann, 2003; Courageot et al., 2008). Therefore it was hypothesised that the 
amplification of prions in cells could require additional, unknown factors (Courageot et 
al., 2008). Previously, RK13 cell line (rabbit epithelial kidney cells) derived Rov9 cells 
were described as permissive to natural scrapie isolates due to a lack of endogenous 
PrPC and the presence of doxycycline induced ovine PrPC (VRQ equivalent) (Vilette et 
al., 2001; Neale et al., 2010). The Rov9 cells not only successfully replicated the 
resistant PrP from infectious inoculas but also stably infected over time and multiple 
passages (Vilette et al., 2001). In addition, RK13 cells were also engineered into 
expressing bank vole and mouse PrPC and propagated both voles and mouse prions 
(Courageot et al., 2008).  
In addition, research using cell lines has included screening for agents that inhibit PrPres 
infection. Potential inhibitors of PrP conversion have been identified including PPS, 
Congo Red, quinacrine and mefloquine, and a range of monoclonal antibodies (Caughey 
and Race, 1992; Caughey and Raymond, 1993; Doh-ura, Iwaki and Caughey, 2000; 
Birkett et al., 2001; Peretz et al., 2001; Beringue et al., 2004; Kocisko and Caughey, 
2006b; Bian, Kang and Telling, 2014). Interestingly, the potential drugs were screened 
in experiments that either cured persistently infected cells or prevented initial cell 
infections (Beringue et al., 2004). Furthermore, a library of 2000 potential drugs and 
natural products were screened in RML scrapie infected ScN2 cells in order to identify 
new therapeutic candidates for TSEs (Kocisko et al., 2003). In addition, the effects of 
recombinant prion proteins and PrP derived peptides on PrPres aggregation was 
investigated in cells persistently infected with TSE agent. Priola et al., studied how the 
co-expression of heterologous (hamster) PrP affect the PrPres accumulation in scrapie 
infected MNB cells. They found that the presence of recombinant pion protein expressed 
by the murine cells significantly interfered with PrPC conversion in those cells (Priola et 
al., 1994). Later, other research showed promising results with using recombinant prion 
proteins and its fragments to cure cells infected with PrPres (Chabry et al., 1999; Yuan 
et al., 2013).  
Here, Rov9 cells expressing the VRQ ovine prion protein after induction with doxycycline 
were used as the model to screen various classical scrapie isolates for their ability to 
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infect the cells. For these tests, 5 scrapie isolates/strains were used: SSBP1 (VRQ/VRQ), 
PG1361/05 (ARQ/VRQ), PG1207/03 (VRQ/VRQ), PG1212/03 (VRQ/VRQ) and 
PG1517/01 (VRQ/VRQ). In addition, we tested infection efficiencies with both brain 
homogenates and purified PrPSc. Once, an infection model was established, the ability 
to prevent infections and cure persistently infected cells with rPrPs was determined. 
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7.2 Results  
7.2.1 Presence of PrPC in induced Rov9 cells  
The level of PrPC in Rov9 cells was determined with and without induction with 1 µg/ml 
doxycycline. For this purpose, the Rov9 cells were seeded on 12 well plate with the 
density 0.1 x 106 cells per well and grown for 48 h after which cells were induced with 
1 µg/ml doxycycline for 48 h. The result showed that only the doxycycline induced cells 
displayed detectable ovine PrPC after detection with SHA31 antibodies on western blots 
(Figure 7.2.1, A).  
In addition, the PK concentration used for digestion of PrPC was optimised (Figure 
7.2.1, B). 40 µg of total protein content was digested with 0.01, 0.05 and 0.1 mg/ml 
of PK. Induced and digested samples were compared to non-induced, digested samples 
on the western blot. The result showed that 0.01 mg/ml of PK was sufficient to fully 
digest the ovine PrPC.  
 
Figure 7.2.1. Rov9 cells produce ovine PrPC after induction with 1 µg/ml doxycycline. 
A – Rov9 cells lysates with and without doxycycline treatment, 40 µg of total protein 
content was mixed with 4 x sample buffer and analysed on western blot. 
B – optimisation of proteinase K concentrations to digest the ovine PrPC from Rov9 cells. 
Lysates containing 40 µg of protein from induced and non-induced cells were digested 
with 0.01, 0.05 and 0.1 mg/ml of PK and 20 µl of each sample was analysed on the 
western blot. Protein markers are indicated on the left side of the blot. Dox – 
doxycycline, PK – proteinase K; 
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7.2.2 Analysis of PrPSc in brain homogenates and PMCA products used as inocula 
In order to assess the amount of PrPSc in the scrapie brain homogenates, 10 % brains 
of SSBP1 (VRQ/VRQ), PG1361/05 (ARQ/VRQ), PG1207/03 (VRQ/VRQ), PG1212/03 
(VRQ/VRQ) and PG1517/01 (VRQ/VRQ) were digested with 100 µg/ml of PK and 
analysed on western blot (Figure 7.2.2). The result showed that for all samples the 
characteristic 3 band pattern for classical ovine scrapie was produced. The analysis of 
SSBP1 scrapie showed the lowest level of PrPSc in the 10 % brain homogenate. In 
addition, 5 rounds of PMCA were performed for all the scrapie brain homogenates in 
VRQ/VRQ substrate (TSE negative brain homogenate 16). For PG1207/03, PG1212/03, 
PG1517/01 and PG1361/05 round 1 and 5 of serial PMCA was analysed. In all cases, 
the amplification of PrPSc was successful and showed high amount of PrPSc in round 1 
and 5 PMCA products. For SSBP1, both round 1 and round 5 were analysed, however 
this scrapie brain showed no detectable on western blotting levels of PrPSc after round 
1 (data not shown). Moreover, PMCA round 5 analysis showed that SSBP1 isolate 
amplified. These results demonstrated that all tested scrapie isolates amplified in 
VRQ/VRQ substrate and so should be able to replicate in the Rov9 cells.  
 
Figure 7.2.2. PrPSc levels in scrapie 10 % brain homogenates and PMCA products. This 
was determined for SSBP1 (VRQ/VRQ), PG1361/05 (ARQ/VRQ), PG1207/03 (VRQ/VRQ), 
PG1212/03 (VRQ/VRQ) and PG1517/01 (VRQ/VRQ). For round 1 of PMCA, 10 µl of each 
10 % brain was amplified in 90 µl of TSE negative brain homogenate (B16) over 24 h. 
Round 2-5 were prepared by 1/3 dilution of previous round products in TSE negative 
brain homogenate (B16). Scrapie 10 % brain homogenates and PMCA products were 
digested with 100 µg/ml of proteinase K and 15 µl of each sample was analysed on the 
western blot. Protein marker is indicated on the left side of the blot. 
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7.2.3 Optimisation of Rov9 cell infection with brain homogenates 
7.2.3.1 Infections with 1/500 diluted 10 % brain homogenates 
The first attempt involved infection with 1/500 diluted 10 % brain homogenates (2 µl of 
10 % brain per 1 ml of cell culture media) of PG1361/05 (ARQ/VRQ), SSBP1 (VRQ/VRQ) 
and PG1207/03 (VRQ/VRQ). This method was used because it previously showed 
successful Rov9 cells infection and allowed to reduce the impact of detergents contained 
within brain homogenates on the cells. In addition, to test the impact of PMCA and brain 
homogenate buffer on cells, equivalent volumes of PMCA and brain homogenate buffer 
were also added to the cells. Moreover, all samples were applied to non-induced and 
induced cells. The results showed that the presence of doxycycline for 48 h in cell media 
induced the ovine PrPC in Rov9 cells, and this was fully digested with 5 µg/ml of PK 
(Figure 7.2.3, A). In contrast, the Rov9 cells that were not induced with doxycycline 
showed no PrPC band on western blot for all samples (Figure 7.2.3, B). Furthermore, 
the addition of brain homogenate or PMCA buffer and scrapie brain homogenates 




Figure 7.2.3. Infection of Rov9 cells with 1/500 diluted scrapie isolates. 
A - representative western blot shows presence of PrPC in Rov9 cells induced with 
1 µg/ml doxycycline for 48 h. The PrPC is fully digested with 5 µg/ml of PK. B – western 
blots show that there is no PrPC in non-induced cells. Cells were lysed at two different 
timepoints: 3 (72 h) and 5 (120 h) days post infection (dpi). In samples inoculated with 
media, PMCA (conversion) buffer, brain homogenate (BH) buffer, B16 (VRQ/VRQ) or 
scrapie samples SSBP1 (VRQ/VRQ), PG1361/05 (ARQ/VRQ) or PG1207/03 (VRQ/VRQ), 
PrPSc was not detected. 20 µl of each cell lysate was analysed. Dpi – days post infection, 
PK – proteinase K, dox – doxycycline; 
Furthermore, the induced cells were inoculated with scrapie isolates (SSBP1 (VRQ/VRQ), 
PG1361/05 (ARQ/VRQ) and PG1207/03 (VRQ/VRQ)) and analysed 3-, 5-, 16- and 32-
days post infection. Only representative result for SSBP1 infection is shown (Figure 
7.2.4). The outcome showed that the cells were not infected with any of the scrapie 
isolates at any point during the experiment. In addition, around 20 µg of total protein 
was loaded on the gel for 3 and 5 dpi, whereas for 16 and 32 dpi (3rd and 5th passage) 
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for latter timepoints clearly demonstrated that the cells were not infected with any 
scrapie isolate. Moreover, the controls with brain homogenate and conversion buffer 
had no impact on PrPC induction or protein content (not shown).  
 
Figure 7.2.4. Infection of Rov9 cells with SSBP1. Representative western blot showing 
no PrPres in cell lysates after inoculation with scrapie isolate SSBP1 (VRQ/VRQ) after 3-
, 5-, 16- (3rd passage) and 32-days (5th passage) post infection. Rov9 cells were induced 
with 1 µg/ml of doxycycline and non-digested cell lysates were compared to samples 
digested with 5 µg/ml proteinase K. For 3 and 5 dpi samples, 20 µg of total protein, and 
for 16 and 32 dpi 60-100 µg of total protein was used for western blot analysis. Protein 
markers are indicated on the left side of the image. PK – proteinase K, dox – doxycycline, 
dpi – days post infection.  
7.2.3.2 Infections with 1/40 diluted brain homogenates 
Another infection trial, in which 1/40 diluted brain homogenates (25 µl of 10 % brain 
per 1 ml of media) were added on the cells was performed. After 3 dpi, it was noted 
that the majority of cells that were exposed to 1/40 dilution of brain homogenate and 
conversion buffer were dead. In addition, incubation with negative brain homogenate 
(B16, VRQ/VRQ) and scrapie isolate PG1361/05 (ARQ/VRQ) also resulted in noticeable 
cell loss in comparison to media control cells, therefore these were not analysed further. 
Furthermore, SSBP1 and PG1207/03 scrapie incubated samples survived the infection, 
however with some cell loss for SSBP1 isolate and were analysed on western blots 
(Figure 7.2.5, A, B). In cells incubated with SSBP1 scrapie, no PrPSc was detected in 
samples from 5 until 17 dpi (passage 2). For ovine scrapie VRQ/VRQ (PG1207/03), 
a very faint scrapie triplet band was recorded on the western blot at timepoint 5 dpi. 
Therefore, these cells were passaged further until 5th passage (82 dpi), however at all 
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Figure 7.2.5. Representative western blots showing the effect of infections with ovine 
scrapie SSBP1 (VRQ/VRQ) and PG1207/03 (VRQ/VRQ) (1/40, 25 µl of 10 % brain in 
1 ml of media) in comparison to media control (dox induced Rov9 cells). A – western 
blot shows the analysis of cell lysates collected 5 days post infection. Triple band pattern 
after infection with PG1207/07 is indicated with arrows on the right side of the blot. 30 
µg of total protein content was analysed on western blot. B – western blot shows the 
analysis of cell lysates collected after passage 2 (17 days post infection). 100 µg of total 
protein content was digested with 5 µg/ml of PK and analysed on western blot. Rov9 
cells were induced with 1 µg/ml of doxycycline and infected with 1/40 diluted scrapie 
SSB1 and PG1207/03 brain homogenates. Protein marker is indicated on the left side 
of each blot. PK – proteinase K; dpi – days post infection;  
7.2.3.3 Optimisation of PrPres detection in cell lysates 
To further investigate the potential presence of cell infection in samples inoculated with 
1/40 (25 µl of scrapie in 1 ml of media) of 10 % scrapie brains (PG1207/03 and SSBP1) 
two different approaches were tested to detect PrPSc: PMCA (Figure 7.2.6, A, B) and 
protein concentration by centrifugation (Figure 7.2.6, C). Firstly, 5 rounds PMCA 
experiment was used. PMCA was performed on cell lysates for the cells inoculated with 
media, PG1207/03 and SSBP1 and samples taken at 120 h post infection (5 dpi) and 
passage 1 (10 dpi). Briefly, 10 µl of each cell lysate was mixed with 90 µl of 10 % 
negative brain homogenate (B16) and amplified for 5 rounds. PMCA products were 
digested with PK and analysed firstly on dotblot (15 µg/ml PK) and then positive samples 
and representatives of negative samples were analysed on western blot (50 and 100 
µg/ml PK). For an amplification positive control, 10 % brain homogenate PG1361/05 
(ARQ/VRQ) was used and for a negative control 10 % negative brain homogenate was 
used (B16) without seed. Each sample was amplified in triplicate. Dotblot analysis 
showed the presence of PrPres in cell culture lysates after 120 h post infection and 1st 
passage for cells infected with PG1207/03. On the other hand, there was no PrPres signal 
from SSBP1 infected samples in either 120 h post infection or 1st passage. Control 
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scrapie isolate (PG1361/05, ARQ/VRQ) amplified in the VRQ/VRQ brain (B16) in the 
presence of lysis buffer, and PrPC only showed no signal. On western blot, PMCA products 
were digested with 50 (data not shown) and 100 µg/ml of PK. Data confirmed dotblot 
analysis that only PG1207/03 infection derived cell lysates (both 120 h post infection 
and 1st passage) amplified during PMCA.  
A second approach to analyse cell lysates for PrPres used digestion with 20 µg/ml PK and 
concentration of 500 µg of total protein content. In this approach, all samples available 
to date were analysed for cells inoculated with 1/40 (25 µl of 10 % brain in 1 ml of 
media) SSBP1 and PG1207/03 (both VRQ/VRQ). Results showed the presence of PrPres 
in samples infected only with 10 % PG1207/03 brain homogenate (Figure 7.2.6, C). 
Interestingly, the highest signal came from samples collected 72 h (3 dpi) and 120 h 
post infection (5 dpi), after which signal dropped significantly down to undetectable 
levels in passage 3 (24 dpi) samples. This could indicate that the detected of PrPres with 
both PMCA and concentration protocols came from the scrapie inoculum rather than 




Figure 7.2.6. Infection of Rov9 cells analysed by amplification or concentration of PrPSc 
in cell lysates. Analysis of the presence of PrPres using two approaches: PMCA (A, B) 
and concentration by centrifugation (C) for samples infected with 1/40 of 10 % brain 
homogenates for PG1207/03 (VRQ/VRQ), SSBP1 (VRQ/VRQ) and cells in OPTI MEM 
media with 1 µg/ml doxycycline as a control. PMCA experiment was designed for 
samples from 120 h (5 days) post infection and 1st passage (10 days post infection). 
PMCA was performed over 5 rounds and products were digested with 15 µg/ml (A) and 
100 µg/ml (B) PK. 2.5 µl of each PK digested sample replicates was added on the dotblot 
(A) or 20 µl was added on the western blot (B). 10 % scrapie brain PG1361/05 
(ARQ/VRQ) was used as an amplification control and PrPC as a digestion control. On 
western blot (B) all samples with positive signal for PrPres in dotblots were analysed 
alongside representatives of samples where there was no PrPres detection on the dotblot. 
Samples replicates in A are indicated above the dotblot. C – second approach for 
detection of PrPres in cell lysates used the concentration of 500 µg of total protein 
content. 500 µg of total protein was digested with PK (20 µg/ml) and concentrated by 
centrifugation and analysed on western blot. Samples from 72 h post infection (3 days 
post infection), 120 h (5 days post infection), 1st passage (10 dpi), 2nd passage (17 dpi), 
3rd passage (24 dpi) were analysed. 1, 2, 3 – sample replicates, h p.i. – hours post 
infection, dpi – days post infection.  
 171 
It was also investigated, if higher levels of protein needed to be concentrated in order 
to detect PrPres from cell lysates. For this purpose, 1000 µg of total protein at passage 
4 (61 dpi) and 5 (82 dpi) of cells infected with scrapie isolate PG1207/03 (VRQ/VRQ) 
samples was used. Western blot analysis showed no PrPres in cell lysates (data not 
shown). 
Overall, the protocol using concentration of 500 µg of total protein content was used for 
further experiments.  
7.2.3.4 Optimisation of brain homogenate dilutions and treatment before 
inoculation on cells 
Firstly, the maximum amount of brain that could be used for cell infection but not affect 
cells survival, was determined. For this purpose, 10 % brain homogenates SSBP1, 
PG1207/03, PG1212/03 and PG1517/01 (all VRQ/VRQ) were used and kept on the cells 
for 3 days (72 h). During microscopic examination of the cells (data not shown), it was 
found that the addition of 25 µl per 1 ml of media (1/40 brain/media ratio) of 10 % 
brains PG1207/03, PG1212/03 and PG1517/01 did not affect the cell survival. Therefore, 
this amount of brain was used for further infections for PG1207/03, PG1212/03 and 
PG1517/01. However, addition of 25 µl (per 1 ml of media) of 10 % SSBP1 reduced the 
cells survival, whereas the 12.5 µl per 1 ml of media (1/80 brain/media ratio) did not 
cause any cell loss (data not shown). Therefore, for cell infections with 10 % SSBP1, 
12.5 µl of 10 % brain was used in 1 ml of OPTI MEM media (1/80). Moreover, the 1/40 
dilutions of both brain homogenate and conversion buffer in cell culture media resulted 
in noticeably cell loss (data not shown).  
Secondly, it was investigated whether brain homogenate pre-treatments like heating 
for 20 minutes at 80 °C followed by 2 minutes sonication increased the infection rates 
(Vilette et al., 2001). For this purpose, 10 % SSBP1, PG1207/03, PG1212/03 and 
PG1517/01 brain homogenates were heated and sonicated and the brains were added 
on the cells with dilutions 1/40 (25 µl per 1 ml of media) for PG1207/03, PG1212/03 
and PG1517/01 and 1/80 (12.5 µl of brain per 1 ml of media) for 10 % SSBP1. As 
a comparison, cells were also infected with the same dilution of unprocessed brains. The 
treated cells were observed under microscope after 3 days and passaged after 5 days 




Figure 7.2.7. Rov9 cells infection with heated and sonicated and unmodified 10 % 
scrapie brain homogenate. Scrapie PG1207/03, PG1212/03 and PG1517/01 (all 
VRQ/VRQ) were used and cells were inoculated with 25 µl of 10 % brain per 1 ml of 
media (1/40). A – passage 1 (11 dpi) and passage 4 (38 dpi) cell lysate analysis. All 
Rov9 cells were induced with 1 µg/ml doxycycline for 48 h and infected with brain 
samples heated for 20 minutes at 80 °C and sonicated for 2 minutes or unmodified 
scrapie brain homogenates. 500 µg of total protein content was digested with 20 µg/ml 
PK and analysed on the western blot for each sample. B – passage 1 (11 dpi) for non-
induced (-) and induced (+) Rov9 cells. Cells were infected with brain homogenate 
heated for 20 minutes at 80 °C and sonicated for 2 minutes for PG1207/03 and 
PG1517/01 scrapie. For each sample, 500 µg of protein content was digested with 20 
µg/ml PK and analysed on the western blot. Alongside, 20 µl of 10 % scrapie brains 
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digested with 100 µg/ml PK were run for signal comparison. Protein markers are 
indicated on the left side of each blot. Dox – doxycycline; 
For cells infected with brain homogenates PG1207/03 and PG1517/01 there were no 
differences in PrPres detection was observed in cells infection after passage 1 (11 dpi) 
when comparing using the heated and sonicated brain or unmodified brain (Figure 
7.2.7, A). However, higher levels of PrPres were detected in cells infected with heated 
and sonicated PG1212/03 rather than unmodified brain in passage 1 samples (11 dpi) 
(Figure 7.2.7, A). The cells infection for all three scrapie isolates was not stable and 
after analysis of passage 2 (17 dpi), 3 (31 dpi) (data not shown) and 4 (38 dpi) no PrPres 
was detected on the western blot in any of the tested samples (Figure 7.2.7, A). In 
addition, because of its poor performance in cell infection assays, isolate PG1212/03 
was not used in further experiments.  
The loss of PrPres signal over multiple cell passages suggested that the PrPres could came 
from the original inoculum rather than from the infected cells or could be only transiently 
replicating in the cells. In order to investigate that issue, non-induced and induced cells 
were infected with heated and sonicated PG1207/03 and PG1517/01 scrapie brain 
homogenates. The cell lysates were analysed after passage 1 (11 dpi) and showed the 
presence of PrPres in cells not induced with doxycycline for both scrapie isolates (Figure 
7.2.7, B) indicating the PrPSc is from the original inoculum and this is diluted out and 
no longer detected by passage 2.  
For infections with 1/80 dilution of SSPP1 (12.5 µl of 10 % brain per 1 ml of media), 
heated and sonicated or unmodified brains were used. For heated and sonicated 
infections, brain homogenates were added on non-induced and induced cells. Here, after 
1st passage (12 dpi) PrPres was detected only in samples induced with doxycycline 
(Figure 7.2.8, A). This could suggest that the resistant PrP signal came from replication 
within the infected cells rather than the scrapie inoculum. Moreover, PrPres was not 
detected during passage 2 (19 dpi) and 3 (26 dpi), however it was detected on western 
blot in later passages (passage 4 (34 dpi), 5 (41 dpi) and 6 (47 dpi)). Similarly, only 
induced cells were infected with unmodified brain SSBP1 at a 1/80 scrapie:media ratio 
in comparison to non-induced cells. The western blots showed the presence of PrPres at 
passage 1 (17 dpi), 2 (24 dpi), 4 (46 dpi), 5 (53 dpi) and 6 (59 dpi). There was no PrPres 
in sample after passage 3 (38 dpi) probably due to PrPres pellet loss during the 
concentration procedure (Figure 7.2.8, B). Overall, the persistent infection of Rov9 
cells with scrapie brain homogenate SSBP1 was demonstrated. However, inoculation 
with PG1207/03 and PG1517/01 scrapie did not result in prion replication within the 




Figure 7.2.8. Rov9 cell infections with heated and sonicated and unprocessed 10 % 
SSBP1 scrapie brain homogenate (VRQ/VRQ). Cells were infected with 12.5 µl of 10 % 
brain homogenate per 1 ml of media (1/80 dilution). A – passage 1 – 6 (12 – 47 dpi) of 
induced and non-induced cells inoculated with heated and sonicated SSBP1 brain. B – 
passage 1 – 6 (17 – 59 dpi) of induced cells infected with unprocessed SSBP1 brain. 
500 µg of total protein from samples were digested with 20 µg/ml PK and analysed on 
western blots. Protein markers are indicated on the left side of each blot. 10 % SSBP1 
brain was digested with 100 µg/ml PK and 20 µl of the digestion product was analysed 
on the western as a control. Dox – doxycycline;  
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7.2.3.5 Rov9 cell morphology and phenotypes 
When infected with SSBP1 10 % brain homogenate, Rov9 cells were observed under 
a light microscope. The morphology of these cells was compared to independent Rov9 
cells permanently infected with SSBP1 (Dr Fiona Houston, Roslin Institute) and also 
uninduced but cultured in the presence of SSBP1 Rov9 cells (Figure 7.2.9). 
Accumulation of large or small vacuoles was observed in the SSBP1 infected Rov9 cells 
produced in this study. No accumulation of vacuoles was observed in uninfected, 
induced cells that were grew in OPTI MEM complete media. Also, less accumulation of 
vacuoles was observed in cell obtained from the Roslin Institute.  
 
Figure 7.2.9. Representative Rov9 light microscopy images showing vacuole 
accumulation in Rov9 cells infected with SSBP1 (VRQ/VRQ). Infected cells were either 
produced in the present study or were obtained from the Roslin Institute. Representative 
vacuole accumulation was marked on images with black arrows. Scale bars were 
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7.2.3.6 Protease resistance of PrPSc in Rov9 cells infected with SSBP1  
The protease resistance of PrPres produced in SSBP1 infected Rov9 cells was tested. 
Lysates from passage 9 for infected cells produced in the present study and those 
obtained from the Roslin Institute were digested with a range of PK concentrations 
(Figure 7.2.10). The PrPres was resistant to at least 100 µg/ml of PK (passage 9 – 65 
dpi). The absence of PrPres bands in the sample digested with 20 µg/ml of PK was very 
likely a result of losing the PrPres pellet during the experiment procedure. In addition, 
the band pattern for infected cells were similar for both sources of infected cells. The 
bands for di- , mono- and un-glycosylated bands of PrPres had similar sizes and both 
samples had additional lower molecular weight bands.  
 
Figure 7.2.10. Proteinase K resistance of PrPres isolated from Rov9 cells infected with 
scrapie isolate SSBP1 (VRQ/VRQ) (passage 9 – 65 dpi). 500 µg of total protein amount 
for non-induced and induced cells was digested with 20, 50 or 100 µg/ml of PK and 
analysed on the western blot. 20 µl of 10 % SSBP1 brain homogenate was digested with 
100 µg/ml and analysed on the western blot. Two sources of infected cells were used, 
one produced in the present study and one from The Roslin Institute. Protein marker is 




7.2.4 Inoculation of Rov9 cells with SiO2 precipitated PrPSc 
7.2.4.1 SiO2 binding fractions analysis 
Following initial failed attempts to infect Rov9 cells with brain homogenate, the PrPSc 
inoculum was concentrated and purified on SiO2 before application to cells (Rees et al., 
2009). 25 µl of 10 % brain homogenate for each isolate was used for SiO2 capture. In 
order to estimate the amount of PrPSc bound to SiO2 slurry, fractions after binding 
(‘bind’), washing and elution (‘final’) were collected and analysed (Figure 7.2.11). 
Fractions ‘bind’, ‘wash’ and ‘final’ for SSBP1 (VRQ/VRQ) and B16 (VRQ/VRQ) were 
analysed with and without PK digestion, whereas ‘final’ fractions for PG1361/05 
(ARQ/VRQ) and PG1207/03 (VRQ/VRQ) were only analysed as PK digested products. 
For all scrapie isolates and despite the low signal for SSBP1, PrPSc was present in the 
‘final’ fractions. Moreover, B16 derived PrPC was also found to bind to SiO2 slurry and 
was present in the ‘final’ fraction and was full digested with PK (50 µg/ml). 
 
Figure 7.2.11. Levels of PrPSc in different SiO2 precipitation fractions. Scrapie SSBP1 
(VRQ/VRQ), PG1361/05 (ARQ/VRQ), PG1207/03 (VRQ/VRQ) and TSE negative brain 
homogenate B16 (VRQ/VRQ) were mixed with SiO2 and incubated at RT. After 
centrifugation the ‘bind’ fraction was collected and analysed. SiO2 slurry was washed 
(‘wash’ fraction) and also analysed. ‘Final’ fraction was collected in 1 % SDS, 
precipitated in MeOH and resuspended in PBS. Fractions were digested with 50 µg/ml 
of PK and 20 µl of each product was analysed on western blot. Protein markers are 
indicated on the left side of the blots. 
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7.2.4.2 Inoculation of Rov9 cells with SiO2 precipitated PrPSc and PrPC 
10 or 20 µl of SiO2 and MeOH precipitated PrPSc or PrPC was added to Rov9 cells per well 
and kept for 3 days. Firstly, no cell loses or toxic effects on cells were observed during 
and after incubation with PrPC or PrPSc. The Rov9 cells looked healthy and viable. After 
first passage (10 dpi) no PrPres was observed in samples from cells treated with either 
10 or 20 µl of SiO2 purified PrPSc (Figure 7.2.12).  
 
Figure 7.2.12. Representative western blots show absence of PrPSc in passage 1 (10 
dpi) in Rov9 cell lysates. 20 µl of PrPC (B16) and 10 or 20 µl of SiO2 purified and MeOH 
precipitated PrPSc from scrapie SSBP1 (VRQ/VRQ), PG1361/05 (ARQ/VRQ) and 
PG1207/03 (VRQ/VRQ) was added in media complete with 1 µg/ml of doxycycline on 
the cells and incubated. 500 µg of total protein was digested with 20 µg/ml PK and 




































7.2.5 Inoculation of Rov9 cells with NaPTA precipitated PrPSc 
Following initial failed attempts to infect Rov9 cells with brain homogenate, the PrPSc 
inoculum was concentrated NaPTA before application to cells (Safar et al., 1998). NaPTA 
precipitated PrPSc from 10 % brain homogenates SSBP1 (VRQ/VRQ), PG1361/05 
(ARQ/VRQ) and PG1207/03 (VRQ/VRQ) was added on Rov9 induced with 1 µg/ml 
doxycycline. PrPres was observed in Rov9 infected with SSBP1 derived PrPSc in passage 
1 samples (17 dpi). Furthermore, the Rov9 cells were persistently infected with SSBP1 
as the presence of PrPres in cell lysates was detected throughout passages (passage 1: 
17 dpi, passage 6: 59 dpi) (Figure 7.2.13). The lack of PrPres in passage 3 (38 dpi) 
was probably due to PrPres pellet loss during the experiment. In contrast, the other 
scrapie isolates did not infect the cells (data not shown). In addition, the Rov9 cells that 
were inoculated with PG1361/05 derived PrPSc died during the first 3 days post infection.  
 
Figure 7.2.13. Rov9 infections with NaPTA precipitated PrPSc from 10 % SSBP1 brain 
homogenate (VRQ/VRQ). 30 µl of NaPTA precipitated SSBP1 PrPSc was added on induced 
cells. 500 µg of total protein count from each cell lysate was digested with 20 µg/ml of 
PK and analysed on western blot. 10 % SSBP1 brain homogenate was digested with 100 
µg/ml of PK and 20 µl was analysed on western blot. Protein markers are indicated on 
the left side of each blot. Passage 1 – 17 dpi, passage 2 – 24 dpi, passage 3 – 38 dpi, 
passage 4 – 46 dpi, passage 5 – 53 dpi, passage 6 – 59 dpi. 
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7.2.6 Preventing infections with SSBP1 derived PrPSc with rPrP 
Having established an infection protocol for infecting Rov9 cells with heat treated and 
sonicated SSBP1, this was used to determine whether rPrPs could inhibit or prevent 
infection. rPrPs were preincubated in media with the 10 % heated and sonicated SSBP1 
brain (VRQ/VRQ). The samples for non-induced cells inoculated with SSBP1 had no PrPres 
detected in any of the passages and experimental repeats. This result showed that the 
PrPres bands on western blots for doxycycline induced samples came from replication in 
infected cells rather than brain inoculum. In addition, passage 1 (11 dpi) was also 
analysed for induced cells where only rPrPs at 250 nM were added. The outcome showed 
no PrPres in cell lysates after 1st passage (data not shown). Furthermore, the PrPres was 
detected in induced cells inoculated with SSBP1 from passage 1 onwards. The scrapie 
10 % brain was included on each blot for signal reference. The addition of 50 nM of 
rRRQ had no effect on prevention of the SSBP1 Rov9 cells infection over two passages, 
therefore rPrPs were only analysed at 250 nM (Figure 7.2.14, A). For no rPrP, 250 nM 
rRRQ and 250 nM rARR, three independent experiment repeats were performed, 
whereas rKRQ, rPRQ and rVRQ were analysed in two experiment repeats. Calculated in 
ImageJ signal value was standardized against average signal for scrapie brains controls. 
The results were standarised against 10 % SSBP1 brain controls because the signal from 
it was more consistent between experiments than no rPrP (inhibition) signal. Following 
this adjustment, one-way ANOVA (F=14.16, p<0.05) followed by Dunnett’s multiple 
comparisons test was carried out and revealed significant differences in PrPres levels 
between rRRQ (p=0.0067), rARR (p=0.0064) and no rPrP in passage 1 samples (Figure 
7.2.14, B). Both rRRQ and rARR significantly inhibited the infection with scrapie SSPB1. 
Moreover, the data for rKRQ, rPRQ and rVRQ (Figure 7.2.14, C) was not analysed 
statistically due to low number of replicates. Preliminary results for rKRQ and rPRQ 
showed that these rPrPs could also inhibited the scrapie infection of Rov9 cells. In 
contrast, rVRQ showed high variations between experiments therefore its role in the 
experiment needs to be further investigated. Additionally, when western blot passage 
2 (18 dpi) data was analysed (data not shown) low infection level was maintained for 
rRRQ and rPRQ, whereas it was variable between repeats for rKRQ, rVRQ and rARR.  
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Figure 7.2.14. Passage 1 analysis for preventing infections of Rov9 cells with rPrPs. 
A - representative western blot shows passage 1 (11 dpi) for Rov9 cells infected with 
SSBP1 in the presence of rRRQ (50 nM or 250 nM), rKRQ, rPRQ, rVRQ, rARR (250 nM). 
10 % SSBP1 brain homogenate was heated for 20 minutes at 80 °C and sonicated for 
2 minutes then mixed with rPrP in OPTI MEM media complete with or without 1 µg/ml 
doxycycline and incubated for 1 h at 37 °C. The inoculum was then added to Rov9 cells. 
500 µg of total protein from passage 1 cell lysates was digested with 20 µg/ml PK and 
analysed on western blot. PK digested 10 % SSBP1 brain homogenate was put on blot 
for signal reference. SSBP1 brain was digested with 100 µg/ml PK and 20 µl was 
analysed on western blot. Protein markers are indicated on the left side of each blot. 
B – graph shows the calculated ratio for each sample signal/the average signal for 
scrapie brain controls for rRRQ and rARR. Displayed data came from three independent 
experiments. One-way ANOVA (F=14.16, p<0.05) with Dunnett’s multiple comparisons 
test showed significant differences between 250 nM rRRQ and rARR and the no rPrP 
control (p values: rRRQ=0.0067, rARR=0.0064). * - p0 .05, ** - p0.01, *** - 
p0.001, **** - p0.0001. C – graph shows the calculated ratio for each sample 
signal/the average signal for scrapie brain controls for rKRQ, rPRQ and rVRQ in compare 
to no rPrP samples. Displayed data came from two independent experiments. Dox – 
doxycycline, 1, 2 – sample replicates.  
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For two experimental repeats samples were analysed up to passage 4 (31 dpi) (Figure 
7.2.15). In these experiments only rRRQ at 50 and 250 nM and rARR at 250 nM were 
studied. These were compared to non-induced and induced cells infected with SSBP1 
scrapie isolate. In non-induced cells, no PrPres was detected, whereas in dox induced 
cells, cells were infected with scrapie SSBP1 and the PrPres was present in cell lysates. 
In addition, in passage 3 (24 dpi) rRRQ at 50 nM had no inhibition effect on preventing 
cells infection, whereas in passage 4 samples showed some effect, however this could 
be sample variation rather than inhibition effect of rRRQ at 50 nM. Moreover, the 
experiments also showed that in passage 3 and 4 both 250 nM of rRRQ and rARR still 
had an impact on reducing the efficiency of the infection with SSBP1.  
 
Figure 7.2.15. Preventing infections of Rov9 cells by treatment with rPrP. rRRQ (at 50 
and 250 nM) and rARR (250 nM) were assessed. Representative western blots show 
passages 3 (24 dpi) and 4 (31 dpi) for Rov9 cells infected with SSBP1 preincubated with 
rPrP. 10 % SSBP1 brain homogenate was heated for 20 minutes at 80 °C and sonicated 
for 2 minutes. Processed brain was mixed with rPrP in OPTI MEM media complete with 
or without 1 µg/ml doxycycline and incubated for 1 h at 37 °C. 500 µg of total protein 
from passage 3 and passage 4 cell lysates was digested with 20 µg/ml PK and analysed 
on western blot. PK digested 10 % SSBP1 brain homogenate was put on blot for 
reference. SSBP1 brain was digested with 100 µg/ml PK and 20 µl was analysed on 
western blot. Protein markers are indicated on the left side of each blot. Dox – 
doxycycline.  
Overall, the infection of Rov9 cells with scrapie isolate SSBP1 (VRQ/VRQ) could be 
inhibited or efficiency reduced using rPrPs at 250 nM when 10 % scrapie brain was 
preincubated with rPrPs before addition on the cells. The preliminary data suggest that 
between all tested rPrPs – rRRQ showed the most promising results. 
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7.2.7 Curing SSBP1 infected Rov9 cells with rPrPs 
Induced Rov9 cells were infected with heated and sonicated SSBP1 brain homogenate 
(VRQ/VRQ) and exhibited stable infection over multiple passages. These persistently 
infected cells were used in four independent curing experiments. The scrapie 10 % brain 
was included on each blot in duplicates for signal reference (Figure 7.2.16, A). PrPres 
levels were estimated by densitometry and the blots were analysed. The ratio of signal 
for each sample versus the average signal for scrapie brain blotting controls was 
calculated. For this data, Kruskal-Wallis test with multiple comparison Dunn’s test 
analysis was carried out (H=6.810, p<0.05) and showed no significant differences 
between samples (p value: rRRQ=0.86, rKRQ>0.99, rPRQ=0.20, rVRQ>0.99, 




Figure 7.2.16. The effect of 250 nM rRRQ, rKRQ, rPRQ, rARR and rVRQ on PrPres levels 
in persistently infected Rov9 cells. A - the blot shows representative result from four 
experiments. Persistently infected Rov9 cells were incubated with 250 nM of each rPrP 
for 4 days. 500 µg of total protein from each cell lysate was digested with 20 µg/ml of 
PK and analysed on western blot. 10 % classical scrapie brain homogenates were 
digested with 100 µg/ml of PK and 20 µl of the product was analysed on the blot as 
a signal reference. Protein marker is indicated on the left side of the blot. B – graph 
shows the calculated ratio for each sample signal/the average signal for scrapie brain 
controls. Displayed data came from four independent experiments. Kruskal-Wallis test 
(H=6.810, p<0.05) with multiple comparisons Dunn’s test showed no significant 
differences between any of the rPrP and the no rPrP control (p values: rRRQ=0.85, 




Rov9 cells are derived from rabbit epithelial kidney cells. The level of endogenous PrPC 
in these cells is very low and they have been used for ovine PrPC plasmid transfection 
(Vilette et al., 2001). As a result, expression of ovine PrPC (VRQ equivalent) could be 
induced by the presence of 1 µg/ml of doxycycline. These cells were used in this study 
to provide a model for infection with ovine scrapie prions.  
First, it was investigated whether cells were producing ovine PrPC. Expression of PrPC in 
the Rov9 cells at the time of exposure to infectious inocula was necessary for successful 
infection with the TSE agent (Paquet, Daude, et al., 2007). Data showed that induction 
with doxycycline resulted in ovine PrPC production and in addition, the PrPC was fully 
digested with PK at 10 µg/ml. In comparison, the non-induced cells had no ovine PrPC 
in the cell lysates (Vilette et al., 2001). In addition, during the cell infection preparation 
procedure, the media was swapped from EMEM to OPTI MEM and cells induced in OPTI 
MEM. It was previously found that the Rov9 cells maintained infection better in OPTI 
MEM and the PrPres signal after infections with TSE agent was 4 x higher (Kocisko et al., 
2005). 
Some cell lines susceptible to prion infection required isolates that have been previously 
passaged in rodents (Clarke and Haig, 1970; Taraboulos et al., 1990; Schatzl et al., 
1997). This was in part due to a species barrier as the cells used for infections usually 
came from rodents (etc. mice) (Vilette et al., 2001). Because of the expression of ovine 
PrPC, Rov9 cells were described as being susceptible to natural ovine TSEs, that were 
not experimentally adapted to rodents (Vilette et al., 2001; Neale et al., 2010). Here, 5 
scrapie isolates: PG1207/03 (VRQ/VRQ), PG1212/03 (VRQ/VRQ), PG1517/01 
(VRQ/VRQ), PG1361/05 (ARQ/VRQ) and SSBP1 (VRQ/VRQ) were used in infection trials. 
Firstly, the levels of PrPSc were determined in 10 % brain homogenates and after 
amplification in VRQ/VRQ substrate. In all samples, 10 % brain homogenate contained 
readily detectable PrPSc on the western blot, however the SSBP1 displayed the lowest 
PrPSc content in comparison to other brain samples. The difference between levels of 
PrPSc in brain homogenates was not expected to have an impact on the Rov9 cells 
infection as it was previously reported that the amount of PrPSc in the scrapie brains did 
not correlate with the de novo PrPres formation (Neale et al., 2010). Therefore, here, we 
analysed the 10 % brains to determine the PrPres band patterns rather than PrPSc level 
estimation. In addition, all tested isolates amplified over 5 rounds of PMCA in VRQ/VRQ 
substrate. For four isolates (PG1207/03, PG1212/03, PG1517/01 and PG1361/05) the 
amplification product was detectable on western blot after only 1 PMCA round. In 
contrast, for SSBP1 scrapie isolate, there was no product detected after rounds 1-4 of 
PMCA, but this was present after round 5. Successful PMCA amplification indicated these 
scrapie isolates will amplify in VRQ/VRQ substrate and so should be able to replicate in 
the Rov9 cells.  
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Preliminary infection experiments involved testing 3 of the scrapie isolates (PG1361/05, 
SSBP1 and PG1207/03). For these, 2 µl of 10 % brain was added per 1 ml of cell culture 
media (1/500 dilution). It was shown previously that the addition of as little as 0.1 µl 
(1/10,000 dilution) of 10 % brain homogenate of mouse passaged 22L isolate was 
enough to infect the RK13 cells expressing mouse PrP. In addition, PrPres was also 
present for infections using 1000- and 100-fold dilutions of inocula (1 µl and 10 µl of 
10 % brain per 1 ml of media, respectively) after three weeks post infection (Arellano-
Anaya et al., 2017). Therefore, as a first attempt in the current study, 500-fold dilution 
of 10 % brain homogenates were used. SSBP1 was used as it was a VRQ/VRQ brain and 
was previously reported as being able to persistently infect Rov9 cells (Neale et al., 
2010). In addition, another VRQ/VRQ scrapie – PG1207/03 – was also chosen along 
with the heterozygotic VRQ isolate (ARQ/VRQ PG1361/05). This latter classical scrapie 
isolate was tested as it was the primary isolate used in the PMCA model for examining 
the efficacy of rPrPs in blocking prion replication. Moreover, it was also previously shown 
that the Rov9 cells could be infected with field cases of scrapie from VRQ/VRQ or VRQ 
heterozygous isolates (Neale et al., 2010). In this experiment, each sample was 
analysed 3 dpi, 5 dpi and then in weekly intervals. Moreover, the impact on possible 
buffers on cells survival and PrPC expression was also tested. The brain homogenates 
had been previously prepared in two different buffers: brain homogenate buffer and 
conversion buffer. Both of these contain detergents such as triton X-100 or NP-40 and 
additionally, conversion buffer contained EDTA, whereas brain homogenate buffer 
sodium deoxycholate. Analysis demonstrated that the addition of either of the buffers 
to the equivalent level present in 1/500 diluted brain inocula had no impact on cell 
survival and PrPC expression. As a further control, TSE negative brain homogenate 
(VRQ/VRQ) was included in cell infections, this did not cause cell death and the brain 
derived PrPC was not detected in non-induced cells. For all 3 scrapie isolates, PrPres was 
not detected at any timepoint (up to 32 dpi – 5th passage) meaning there was no cell 
infections with a 1/500 diluted of 10 % brain homogenates PG1361/05, SSBP1 and 
PG1207/03. At this stage, two possible reasons for the lack of infection were considered. 
Firstly, the cells could be infected but because of the small dose of the infectious inocula, 
a small number of cells could present the PrPres but this was below the limit of detection 
on western blot when analysing up to 100 µg of total protein. This scenario would also 
indicate that transmission between cells was not efficient (Arellano-Anaya et al., 2011). 
Secondly, the amount of PrPSc that is present in the scrapie inoculum was not enough 
to infect the Rov9 cells, whereas this is in contrast to the mouse PrPC expressing RK13 
cells (Arellano-Anaya et al., 2017).  
Next, cell infections using a much higher amount of inocula was carried out. Cells were 
challenged with a 1/40 dilution (25 µl of 10 % brain in 1 ml of media) of isolates (and 
buffers as controls) in media complete. Using 12.5 times more of each inoculum resulted 
in loss of noticeably number of cells for classical scrapie PG1361/05 inocula and buffers 
controls, suggesting that the amount of detergents in the buffers was high and caused 
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cellular death. Rov9 cells that were infected with PG1207/03 and SSBP1 survived the 
infection as observed at 3 dpi timepoint with some cell loss for SSBP1 infections. After 
5 dpi, there was a very faint characteristically triple band pattern for scrapie in cell 
lysates infected with PG1207/03 but not with SSBP1. However, this potential infection 
signal was lost during subsequent passages. No PrPres bands were detected in SSBP1 
treated cells in passage 2. At this point, it was also assessed whether the detection of 
PrPres in cell lysates could be made more sensitive. The analysis of PMCA samples found 
that cell lysates from infections with PG1207/03 (5 dpi and 1st passage) contained PrPres. 
In contrast, no resistant prion signal was detected with SSBP1. In conclusion, this step 
confirmed that there was PrPres present in the cell lysates from PG1207/03 infected Rov9 
cells. In addition, PrPres in cell lysates were concentrated by centrifugation and 500 µg 
of total protein analysed for each sample. Using this approach, it was confirmed that 
PrPres was present in samples at 5 dpi and after 1st passage for PG1207/03. In addition, 
PrPres was also present at 3 dpi timepoint and 2nd passage (24 dpi) of that isolate. The 
level of PrPres decreased between passages suggesting that the infection was not stable 
or that the observed PrPres was from the scrapie inoculum rather than due to de novo 
production in infected Rov9 cells. As the centration of samples before analysis seemed 
to increase sensitivity and was much more rapid than PMCA, this was adopted as the 
standard analysis method. 
Next, processing of brain homogenates before addition on cells was attempted to try 
and improve infection efficacy. The protocol was taken from Vilette et al. and involved 
heating the brain homogenates at 80 °C for 20 minutes and sonicating for 2 minutes 
(Vilette et al., 2001). These steps could potentially create more infectious resistant prion 
oligomers to act as seeds for de novo prion replication, however this step was not usually 
included in TSE cell culture methods (Vilette et al., 2001; Falanga et al., 2006; 
Courageot et al., 2008; Salamat et al., 2011; Arellano-Anaya et al., 2017). This new 
modification resulted in PrPres detection for all tested scrapie isolates (PG1207/03, 
PG1212/03 and PG1517/01) after passage 1. Furthermore, isolates PG1207/03 and 
PG1517/01 also produce PrPres signals without this pre-treatment. Moreover, it appeared 
that cells infected with any of these scrapie isolates was not persistent and the PrPres 
signal was undetectable by passage 4. It was investigated whether the detected PrPres 
came from replication in cells or from the scrapie inoculum. For this purpose, non-
induced and induced with doxycycline Rov9 cells were infected with 1/40 processed 
10 % brain homogenates PG1207/03 and PG1517/01. It was found that for both isolates 
non-induced and induced Rov9 cells had resistant PrP bands. This experiment showed 
that the PrPres detected in cells inoculated for PG1517/01 and PG1207/03 infected 
samples came from scrapie infectious inocula rather than infected cells. This also 
explained the PrPres signal loss over multiple passages, a result of diluting the inocula.  
The approach of processing the brain homogenate before cells infection was also tested 
for SSPB1 brain. Here, it was observed that the addition of 1/40 (brain:media ratio) on 
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the cells resulted in some cell loss. This was not consistent between experiments 
potentially due to factors like usage of different brain aliquots or suboptimal cells 
growth. A 1/80 dilution of 10 % (12.5 µl of 10 % brain in 1 ml of media) SSBP1 was 
found to not reduce the cells survival when a visual investigation was performed after 
3 dpi. In addition, unprocessed and processed SSBP1 homogenate were used to 
inoculate non-induced and induced cells. Here, samples at 3 and 5 dpi samples were 
not analysed as they could produce false positives from the scrapie inoculum signal. 
After 1st passage (11 dpi) the PrPres was detected only in cells expressing the ovine PrP 
and not in the non-induced cells. This result showed that the original inoculum of SSBP1 
was not detected in neither induced nor non-induced cells. In compare the PG1207/03 
and PG1517/01, the 10 % SSBP1 had less PrPSc in the original inoculum. Additionally, 
the amount of SSBP1 brain added on the cells during infections was reduced from 1/40 
(for PG1207 and PG1517/01) to 1/80. Furthermore, PrPres was detected in passage 1 of 
both experiments, and there was more PrPres in cells infected with processed brain 
compared to those challenges with unmodified SSBP1. This suggested that the heating 
and sonicating procedure created more infectious seed for Rov9 cell infection. The 
infection with both processed and non-processed SSBP1 was also stable over 
6 passages. A technical challenge in the assay was that after the concentration of PrPres 
by centrifugation, the resistant PrP pellet was very small and not always visible. This 
resulted in some pellets being lost and no PrPres detected for such samples.  
Because the presence of detergents in brain homogenates reduced the amount of brain 
to media ratio needed for successful infections, it was also investigated whether the use 
of purified PrPSc from brain homogenates improved cell infection. Two PrPSc purification 
methods were used. First, mineral particles were used to precipitate bind PrPSc (Johnson 
et al., 2006; Rees et al., 2009; Jacobson, Kuech and Pedersen, 2013; Horie et al., 
2014). SiO2 was used to purify the PrPSc from SSBP1 (VRQ/VRQ), PG1361/05 
(ARQ/VRQ) and PG1207/03 (VRQ/VRQ) (Rees et al., 2009). In order to assess the 
presence of PrPSc during the purification and in final preparation, each fraction was 
examined on western blot. High levels of PrPSc were detected in both PG1207/03 and 
PG1361/05 isolates in the final fraction. In compare to this, lower level of PrPSc was 
detected in final preparation of SSBP1. The cells treated with SiO2 – purified PrPSc were 
not infected with any of the tested scrapie isolates when passage 1 was analysed. The 
second method used NaPTA precipitation of the PrPSc (Safar et al., 1998). Infection with 
NaPTA precipitated ARQ/VRQ PG1361/05 scrapie isolate resulted in cell death during 
3 dpi. We cannot exclude here the possibility that the purification was not complete, 
and the detergents present in brain homogenate were not completely removed. 
Furthermore, it was also noticed previously that the 1/40 dilution of 10 % brain 
homogenate (25 µl of 10 % brain in 1 ml of media) for PG1361/05 also killed the cells. 
These two results could be an impact of presence of detergents or presence of PrPSc that 
was highly infectious and, as a result, caused cell death. On the other hand, cells 
infected with PrPSc derived from SSBP1 scrapie isolate showed PrPres in first passage 
 189 
samples. The amount of brain used in NaPTA precipitation was higher than in infection 
with 10 % SSBP1 brain homogenates, however, the potential losses of PrPSc during the 
purification procedure cannot be excluded. Consequently, the signal for PrPres was higher 
than for cells infected with 1/80 of SSBP1 brain homogenate. Moreover, this infection 
was stable over 6 passages.  
When applying the model of Rov9 cell infections, a few factors require consideration. 
Firstly, the PRNP genotype of the isolates. Neale and co-workers assessed the 
permissiveness of Rov9 cells to a panel of sheep scrapie from a range of genotypes. In 
these experiments only scrapie isolates from VRQ/VRQ homozygotes and VRQ 
heterozygotes were able to infect the Rov9 cells. In addition to that, not all VRQ homo- 
or heterozygous scrapie sheep brains infected cells (Neale et al., 2010). These outcomes 
suggested that the homology between PrP genotypes between cells and inoculum might 
be required and Rov9 cell infection could depend on PrPC sequence (Sabuncu et al., 
2003; Neale et al., 2010). Secondly, the dilution of brain homogenate should be optimal 
so that it contains sufficient infectious material but at the same time is not toxic for 
cells. In previously reported research, the brains used for cell infections were 
homogenised in sterile PBS or sterile glucose solution (Vilette et al., 2001; Falanga et 
al., 2006; Neale et al., 2010; Stanton et al., 2012). Here, the disadvantage of our prion 
isolates was that the isolates contained detergents and the solutions used for their 
preparation were not classed as sterile. Therefore, we had to investigate different 
brain:media dilutions and observe its effect on cells. Finally, for successful Rov9 cells 
infections with SSBP1 scrapie isolate we used a dilution of 1/80 of a 10% brain 
homogenate in media. This dilution of 10 % SSBP1 brain homogenate was also been 
used previously to persistently infect Rov9 cells (Falanga et al., 2006). In contrast, 
a study using sterile 5 % glucose solution to prepare 10 % (w/v) brain from PG127 
scrapie isolate, applied 1/4 dilution of natural sheep and mouse-passaged 10 % brain 
homogenates on cells (Vilette et al., 2001). Other research used PG127 scrapie isolate 
and found that inoculation with 1/10 dilution of 10 % of brain homogenate was enough 
to infect the Rov9 cells (Salamat et al., 2011). Additionally, successful infections with 
1/40 dilution of PG127 sheep isolate and 1/1000 dilution of 10 % scrapie field isolates 
were described (Paquet, Daude, et al., 2007; Neale et al., 2010). Because our brain 
homogenates could be non-sterile and contain large PrPSc aggregates we processed the 
brain using the heating and sonication steps before adding into cell culture media 
(Vilette et al., 2001). Surprisingly, the processing was not performed in all published 
research even though the infection of Rov9 cells was successful (Falanga et al., 2006; 
Salamat et al., 2011). The other important factor was the incubation time for cells and 
infectious inocula to allow the PrPSc cell uptake. A report suggested that RML derived 
PrPSc was endocytosed in 1 minute from the exposure time in novel and a neuroblastoma 
cell line (Goold et al., 2011). For Rov9 cells, published methods used exposure times 
from 5 to 48 h (Vilette et al., 2001; Falanga et al., 2006; Paquet, Daude, et al., 2007). 
In addition, quantitative analysis showed that in 6 h after infection only 5-10 % of total 
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PrPSc from the inoculum could be taken up by Rov9 cells, whereas when the time was 
increased to 24 h the total uptake was increased to 82 % (Paquet, Daude, et al., 2007). 
To maximise cellular uptake of the infecting prions, the current study allowed inocula to 
be in contact with cells for 72 h.  
Overall, SSBP1 isolate could be used to stably infect Rov9 cells by direct application of 
a 1/80 dilution of the 10 % brain homogenate in the cell media. This could be enhanced 
in terms of the PrPres signal at passage 1 by either pre-treating the inocula by heating 
and sonication or by NaPTA precipitating the inocula. Considering ease of use and 
efficacy, the use of heat treated/sonicated SSBP1 inocula was the optimum method used 
in this study. Additionally, to maximise the cellular uptake of prions, the scrapie 
inoculum was kept on cells for 72 h.  
Once the infection with SSBP1 brain homogenate was established, the PrPres band 
pattern was compared for SSBP1 brain, the infected cells and also an independent 
source of Rov9 cells infected with SSBP1 (a gift from Dr Fiona Houston, Roslin Institute). 
Both infections were analysed at passage 9. The difference in band pattern for PrPres 
from infected Rov9 cells compared to SSBP1 brain homogenate was consistent for 
independent sources of infected cells and demonstrated that Rov9 cells were infected 
and produced de novo PrPres with distinct glycosylation/cleavage profile compared to the 
infecting PrPSc from brain homogenate (Vilette et al., 2001).  
It was noted that the morphology of infected cells was distinct from uninfected cells. In 
infected Rov9 cells the accumulation of vacuoles was observed. These structures were 
present in all SSBP1 infected cells irrespective of the pre-treatment or precipitation of 
the inoculum. The vacuoles presence was also observed in the infected Rov9 cells 
supplied by The Roslin Institute, however with much lower occurrence. These structures 
have not been reported in the literature for Rov9 cell infections. On the other hand, this 
type of vacuole aggregation was found in association with florid plaques in vCJD cases 
(Ironside and Bell, 1997; Takashima et al., 1997; Grigoriev et al., 1999; Armstrong et 
al., 2002). In addition, these structures were also observed in iCJD (dura mater or 
growth hormone cases) (Takashima et al., 1997; Shimizu et al., 1999; Cali et al., 2015). 
Moreover, all the described changes were reported in brain tissue and not epithelial cells 
(Grigoriev et al., 1999; Asante et al., 2006; Cali et al., 2015).  
The main aim of this chapter was to investigate whether the rPrPs have an inhibition 
impact on de novo PrPres formation in Rov9 cells. For this purpose, two experiments 
were designed to determine if rPrPs can prevent infections and whether they can cure 
stably infected cells. In the preventing infection experiment, the three potentially best 
inhibitors for in vitro PrPSc amplification were used: rRRQ, rKRQ, rPRQ. In addition, also 
natural variants – rVRQ and rARR were tested. rARR was shown to be the least potent 
inhibitor in previous PMCA experiments, therefore we investigated its effect on PrPres 
accumulation in Rov9 cells as a comparison to the variants that were far more potent 
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inhibitors of PrPSc replication in PMCA (Workman, Maddison and Gough, 2017). In all 
three replicate experiments, the Rov9 cells were persistently infected with SSBP1 and 
the PrPres signal did not come from the inoculum. Furthermore, 50 nM of rRRQ was 
tested but it appeared to have little impact on preventing the infections with SSBP1 over 
multiple passages. Moreover, statistical analysis between no rPrP and 250 nM of rRRQ 
and rARR showed that all these mutants reduced the PrPres amount in cell cultures when 
passage 1 was analysed (11 dpi). Because of the lower number of repeats for rKRQ, 
rPRQ and rVRQ we could not perform the statistical analysis on these rPrP. However 
preliminary data for rKRQ and rPRQ suggest that these could act as potential inhibitors 
for Rov9 cells infection with SSBP1 scrapie. For rVRQ, the results were variable, 
therefore we could potentially argue that the presence of natural variant rVRQ did not 
prevent the infection of Rov9 cells as effectively. Further passages for 250 nM of rRRQ 
and rARR showed that these two rPrP reduced the PrPres level in infected Rov9 cells. The 
infection was not prevented in 100 %, and it cannot be predicted how many cells were 
infected, or the way that the cells would proliferate and transmitted the PrPres between 
them. Infection of Rov9 cells has been previously shown to be inhibited by sulfated 
glycans. It was found that the glycans had no inhibition effect on the PrPSc uptake by 
the Rov9 cells when pre-incubated with sulfated glycans for 24 h prior to infection. In 
contrast, the presence of sulphated glycans at the time of infection with PrPSc and 
cultured in the presence of glycans for a week inhibited the Rov9 cells infection (Paquet, 
Daude, et al., 2007).  
A second experiment tested the impact of 250 nM of each rPrP on persistently infected 
Rov9 cells. The cells were incubated with rPrPs over 4 days and then the changes in 
PrPres profile and signal were analysed, over four independent experiments. The data 
showed high variations for all samples and changes were not significant, however the 
trend was that the rRRQ and rPRQ were the most likely to reduce the PrPres levels. These 
experiments could be furter developed and new experimental approaches could be 
tested. For example, peristently infected Rov9 cells could be incubated with rPrPs for 
longer periods of time and with higher rPrPs concentrations. Moreover, additional control 
that has been described in the literature and have been proved to have PrPres reducing 
capabilities in persistently infected cells could be added as an inhibiton control.  
Persistently infected Rov9 cells have been used to screen a range of therapeutic 
compounds that were found to inhibit PrPres production in N2a cells. It was found that 
some compounds such as the tannic acid and PPS inhibited the PrPres accumulation in 
infected Rov9 cells, whereas for example curcumin had no effect on PrPres in Rov9 cells 
(Kocisko et al., 2005). The data indicates that different cell models of prion replication 
can produce very different results when assessing potential therapeutic agents. In 
addition, Beringue and co-workers tested the impact on different monoclonal antibodies 
of PrPres accumulation in Rov9 cells. The antibodies were produced in mice immunised 
with truncated human rPrP (sequence 91-231) (Beringue et al., 2003). The 
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accumulation of PrPres was inhibited in scrapie infected Rov9 cells that where treated 
with antibodies that recognised residues 96-109 according to mouse PrP sequence 
numbering (Beringue et al., 2004). In comparison to the current study, Beringue et al. 
treated the cells with the antibodies for a much longer time-frame than (3 weeks), and 
this could be potentially beneficial for investigating inhibition mechanisms in cells 
actively propagating scrapie infection (Beringue et al., 2004). On the other hand, to the 
date no recombinant prion proteins have been tested in scrapie infected Rov9 cells, 
however rPrPs have been tested in other prion infected cells. Recombinant human PrP 
was found to inhibit the murine PrPSc accumulation in ScN2a cells in a concentration 
dependent manner over 4 days of incubation. The significant decrease in PrPres signal 
from infected N2a cells was observed when 100 nM of human rPrP was added to the 
cells; the EC50 value reported for the same rPrP in PMCA was 60 nM (Yuan et al., 2013). 
Moreover, other scrapie infected cells – MNB – were tested with two hamster PrP derived 
peptides and their impact on PrPres accumulation over 3-4 days. The peptide containing 
hamster positions 119-136 in the sequence effectively reduced the PrP conversion, with 
an IC50 values between 68 – 75 µM in a cell-free conversion assays (for different 
isolates) and 11 µM in cell culture (Chabry et al., 1999). In our experiments, 250 nM of 
each rPrP were tested in persistently infected cells. The experiment showed that 250 
nM of rRRQ had no effect on PrPres accumulation in cell culture. In addition, other 
mutants (rKRQ, rPRQ) or natural variants (rVRQ and rARR) that were tested had no 
significant effect on the resistant prion propagation in the infected cells.  
The results reported in the cell culture research differ from results obtained from PMCA. 
In PMCA lower concentration of inhibitors were required to noticeably inhibit the 
amplification of scrapie prion protein whereas in cell culture experiments much higher 
amounts of rPrP were used but still with different outcome. As an example, the average 
IC50 value from PMCA experiment for rRRQ was 11 nM, whereas in cell culture 
experiments 250 nM was used and prevented the infection with scrapie. That amount 
of inhibitor was 22x more than IC50 value reported from PMCA. In contrast, 50 nM of 
rRRQ had no effect in preventing infections with SSBP1. In addition, rARR that was 
previously reported to have higher IC50 value (505 nM) than rVRQ (122 nM), was found 
to prevent the cellular infections with prions at the same level and similarly to other 
tested at the same concentration rPrPs but did not reduce the PrPres levels in persistently 
infected cells (Workman, Maddison and Gough, 2017). There are multiple factors that 
could be causing these differences in rPrPs performance. Firstly, these changes could 
be triggered by using a different TSE isolate. PMCA was performed for natural classical 
scrapie PG1361/05 (ARQ/VRQ), whereas in cell culture experiments experimental 
SSBP1 (VRQ/VRQ) isolate was used. Secondly, the SSBP1 isolate was not tested in the 
inhibition PMCA, in which other isolates (that also needed multiple rounds to amplify) 
were inhibited using higher amounts of rPrPs (50 nM). Thirdly, PMCA is a method 
specifically designed for amplification of misfolded prion protein. Experiments using cell 
cultures are more complex and many possible processes are associated in prion uptake 
 193 
and propagation. Moreover, different mechanisms could be involved in the primary prion 
uptake by the cells and cell to cell spreading. To enhance the contact of rPrPs with 
scrapie PrPSc and allow potential rPrP-PrPSc binding, in preventing infections experiment, 
the rPrPs were pre-incubated with SSBP1 in cell culture media. The current results 
described high impact of some of rPrPs in preventing infections but not curing infections 
experiments. The previously published data suggest that transmission of PrPres between 
cells could occur through the contact to neighbouring cells via endocytosis or direct 
penetration of cell membrane by PrPSc monomers from cell culture media (Fevrier et al., 
2004; Guo and Lee, 2014; Aguzzi and Lakkaraju, 2016). Additionally, the transport 
could also occur to more distant cells via TNTs (Gousset et al., 2009; Victoria et al., 
2016). Whereas the present in media PrPSc would be accessible to potential binders (like 
rPrPs), PrPres located in endosomes and TNTs could not be easily available for inhibitors. 
Furthermore, none of these PrPres spreading mechanisms might be exclusive (Paquet, 
Langevin, et al., 2007). Therefore, we could not exclude the possibility that the rPrPs 
reduce the accessible fraction of PrPres in persistently infected cells but the difference 
could not be measured using used in the current research tools leading to the detected 
high level of PrPres.  
The reported cell culture experiments investigated if the rPrPs that were previously 
found to be potent inhibitors of prion replication in in vitro prion amplification, reduce 
the infection of cells and/or can cure infection in persistently infected cells. The rPrPs 
tested (except for rVRQ) were effective at reducing infection efficiency or preventing 
cell infection with prions but could not (under the conditions tested) reduce prion 
replication in already infected cells. This may indicate that the rPrPs used in this research 
bound to PrPSc inoculum and that this interaction prevented the PrPSc from either being 
taken up by the cells and/or from binding PrPC or cofactors required for prion replication. 
However, the rPrPs could not interact with cell surface or intracellular PrPSc. Whether 
the rPrPs would have been more effective at reducing infection in infected cells over a 
longer duration or following passage remains to be established. Overall, the data 
demonstrates that the ovine rPrPs can effectively inhibit prion replication in PMCA and 
also prevent prion from infecting cells.  
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This study focused on the development of candidate therapeutics for transmissible 
spongiform encephalopathies. The work included production and use of recombinant 
XRQ mutants as inhibitors for in vitro prion misfolding for different TSE isolates. The 
most effective rPrPs were then analysed structurally. Moreover, the recombinant PrPs 
were also used in a cell culture model of scrapie infection to determine their efficacy in 
preventing and curing infection.  
8.2 Analysis of the ability of rPrP mutants at position 136 to inhibit prion 
replication 
The current study focused on producing and testing rPrPs with substitutions at position 
136 in an in vitro prion replication assay and their effect was compared to natural variant 
rVRQ. Previously, rVRQ was reported to inhibit prion amplification in vitro for different 
species regardless of the prion disease isolate or genotype (Workman, Maddison and 
Gough, 2017). Moreover, this PrP genotype was a more efficient inhibitor than the other 
rPrPs tested, for example rARQ was reported to have an IC50 of 228 nM, rARR 505 nM 
and rVRQ 122 nM. This result clearly suggested that the position 136 in ovine PrP could 
have a significant impact on misfolding of the prion protein during PMCA (Workman, 
2017; Workman, Maddison and Gough, 2017). In addition, previous research showed 
the ability of human, mouse, bank vole, bovine and hamster rPrP to inhibit the 
amplification of human prion protein in PMCA (Yuan et al., 2013; Skinner et al., 2015). 
At the beginning of the current study, the rVRQ inhibition of a classical ovine scrapie 
was verified and the result was consistent with previous outcomes with similar IC50 
values reported in the two independent studies (Workman, 2017; Workman, Maddison 
and Gough, 2017). Moreover, this study was the first to demonstrate the use of mutated 
rPrPs inhibitors, genetically modified at position 136 of ovine rPrPs with non-natural 
mutations. It was shown here that the change in amino acid at 136 position had an 
impact on the inhibition effectiveness in the PMCA. All 20 amino acids variants at position 
136 were tested and arginine, lysine and proline were found to create the most potent 
rPrPs inhibitors were more effective than previously reported rVRQ with rRRQ being 22x 
more effective than rVRQ (Workman, Maddison and Gough, 2017). This novel result 
showed the importance of position 136 in ovine PrP in inhibition. Previously, the 136 
position was found as crucial when determining the disease susceptibility or resistance 
in sheep (Goldmann, 2008). This, together with previous research could suggest that 
modified ovine rPrPs, could potentially be used as a therapeutic for prion diseases (Yuan 
et al., 2013; Skinner et al., 2015; Seelig, Goodman and Skinner, 2016). More research 
in this filed could focus on further characterisation of rPrP mutants for other species, for 
instance position 129 in human rPrP is polymorphic. It was found that V/V129 and M/M129 
are more susceptible for sCJD and vCJD than heterozygotes M/V (Mead, 2006; 
Mastrianni, 2010; Brown et al., 2012; Acevedo-Morantes and Wille, 2014). Research 
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focusing on investigating recombinant human PrP in the inhibition of in vitro prion 
protein misfolding could be designed with focus on position 129 and also other amino 
acids substitutions could be implemented in human PrP at position 129. Moreover, the 
mechanisms of rPrP action could be investigated to determine whether the rPrPs added 
into PMCA act as a PrPC binder to block access to substrate or a PrPSc binder to block 
the sites for PrP conversion. Yuan and co-workers using magnetic beads binding assays 
demonstrated that recombinant human PrP bound to the PrPSc but not the PrPC. They 
described that human rPrP had higher than PrPC affinity to the same binding site within 
the PrPSc. This suggests that rPrPs and PrPC are likely to be the active competitors for 
PrPSc binding (Yuan et al., 2013). Additionally, RT-QuIC has been described as another 
method of misfolding the PrP protein (Atarashi, Sano, et al., 2011). This assay presents 
a model for the misfolding of a wide range of TSEs using bank vole rPrP substrate and 
so could be developed to further screen the best inhibitors (Orrú, Groveman, et al., 
2015). Moreover, using the RT-QuIC could help improve the inhibitors screening not 
only for ovine rPrP but also human in order to develop and could potentially give more 
accurate results. This method could also improve the quality and quantity of the data 
and help to produce IC50 values for rPrPs.  
In the current research the shortest possible peptide with inhibition abilities containing 
the 136 position was sought. The ovine PrP derived peptides were applied to PMCA and 
their inhibitory properties determined. The PrP derived peptides were smaller in size 
than the full-length protein which could be beneficial in production and drug delivery, 
as the small molecules could pass the brain blood barrier more efficiently (Soto et al., 
2000). The result presented here showed that none of the peptides exhibited the 
inhibition observed for ovine full-length proteins. This was consistent with previous 
research investigating the impact on human PrP on PMCA misfolding. Authors found that 
the full-length recombinant human PrP was the most efficient inhibitor of PMCA, with 
the C- or N-terminally truncated peptides being less effective (Yuan et al., 2013). On 
the other hand, using a cell-free conversion assay, Chabry et al., presented data that 
indicated the potential for PrP derived peptides with the same inhibition properties as 
the full length PrP (Chabry, Caughey and Chesebro, 1998; Chabry et al., 1999). This 
could indicate that the power of inhibition of PrP derived peptides depends on the model 
of prion misfolding being used and would differ between assays and types of isolates. 
Furthermore, the possibility that the PrP derived peptides formed aggregates and 
therefore lost their inhibitory properties cannot be excluded. This problem was observed 
with Aβ derived peptides, that self-assembled into fibrils and did not inhibit the 
misfolding of amyloid β (Yan et al., 2013). To further investigate the use of PrP derived 
peptides, it should be investigated whether the peptides were in a monomeric or 
aggregated state. Moreover, these peptides could be applied in different methods of 
protein misfolding such as RT-QuIC and the results could be compared to those obtained 
with PMCA. In addition, peptides could also be used alongside rPrP in preventing 
infections of cells or curing perisistently infected cells. This experiment could act as an 
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addition to PMCA and RT-QuIC and would help to investigate peptides effect of blocking 
the cells infection with prion protein. Using the peptides in further experiment could help 
in providing new data and ideas about the inhibition mechanisms.  
One of the tested recombinant PrPs was rPRQ (P136). Interestingly, the presence of 
proline in the protein sequences was observed in unstructured regions of the protein. 
Moreover, the thermodynamic studies showed that prolines were not compatible with 
β-sheets and also could prevent or even disturbs forming β sheet rich structures (Smith, 
Regan and Withka, 1994; Li et al., 1996; Williams et al., 2004). Additionally, 
introduction of prolines into the peptide or protein chains helped with the whole molecule 
solubility and reduced the potential of amyloid formation (Wood et al., 1995; Williams 
et al., 2004). Because of these features, β-sheet breaker peptides with extra proline 
residues were described in AD models (Soto et al., 1996, 1998; Shuaib et al., 2019). 
These consisted of partial Aβ sequence with additional proline inserted into the peptide 
chain (Soto et al., 1998). A similar approach was also tested in PrP studies, where β-
sheet blocker peptides with additional prolines inserted in the peptide sequence were 
designed. Purified PrPSc from both mice infected with scrapie 139A isolate and human 
sCJD and vCJD were incubated with specific peptides. The result showed that the 
incubation with proline rich peptide (β-sheet blocker) reduced the amount of PK 
resistant protein however, the effect was species specific. Moreover, the proline-rich 
peptide reduced the misfolding of prion more effectively than the non-modified PrP 
sequence derived peptides (Soto et al., 2000). In the current research, proline was 
introduced into the polypeptide chain in an unstructured region, however this was 
a substitution rather than insertion of an additional amino acid. Further research could 
look into expanding the PrP-derived peptides into creating β-sheet breaker peptides by 
introducing more proline residues into the polypeptide chain.  
The study also presented preliminary insights into the structural analysis of ovine PrP 
variants. The outcome showed that each of the ovine rPrP mutants analysed exhibited 
similar structure to natural ovine VRQ. The PrP molecule consisted of a flexible N-
terminus and globular C-terminus, with three α-helices (Haire et al., 2004). Results 
confirmed the hypothesis that the newly produced prion proteins differed only in amino 
acid at position 136 and the protein substitution did not have an impact on the secondary 
structure of distant regions or the whole molecule. In addition to that, when 
investigating the differences between of presence of valine, alanine, arginine, lysine and 
proline at 136 position, it was noticed that two amino acids that were present in PrP 
mutants – arginine and lysine – had longer side chains. This feature allowed for more 
interactions with other amino acids within the structure and could potentially stabilise 
the whole PrP molecule. These interactions did not influence more distant sites in the 
whole PrP molecule possibly due to the presence of a structural pocket created by the 
region in α-helix 2. These preliminary insights into the structural analysis of rPrP 
inhibitors could be developed into more detailed analysis. The further research could 
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involve the investigation of whether the rPrP bind to PrPC or PrPSc, which could then be 
followed by some molecular dynamic’s simulations. Previously, similar analysis was 
performed for the complexes of prion protein with phenothiazine compounds (promazine 
and chlorpromazine). The authors revealed the crystal structure of prion-promazine 
complexes and found that the these compounds prevented the misfolding of PrPC by 
using the protein stabilisation mechanisms (Baral et al., 2014).  
The structural analysis of the most effective rPrP inhibitors could indicate that not only 
one but perhaps more mechanisms were involved in the rPrP inhibition in PMCA. These 
could be further analysed both in vitro and in silico.  
8.3 Recombinant prion proteins as inhibitors across prion diseases 
What would be the best rPrPs for prion amplification inhibition research? Based on the 
ovine system as a model of the prion diseases therapeutic development, we could 
hypothesize that an effective inhibitor would not only be characterised by the lowest 
IC50 value but it would need to show its effectiveness among many tested TSE isolates 
and distinct TSE diseases. The main focus for developing successful therapeutic would 
be on human prion diseases – e.g., sCJD, vCJD, FFI, GGS. Investigating an ovine system 
of prion disease could give insights on some processes and features that could be 
reflected to those seen in human TSEs. In the current research, we reported three 
inhibitors that exhibited both: very low IC50 value in comparison to other natural and 
mutant variants of rPrP and the ability to inhibit different prion disease isolate from field 
and experimental cases. These included ovine classical scrapie isolates, bovine BSE and 
experimental ovine BSE. This together with previously reported research that rVRQ was 
found to inhibit the misfolding of multiple TSE isolates, could suggest that these proteins 
could act as inhibitors across different TSE isolates and in different species. This finding 
is consistent with previously reported data for ovine rVRQ that also worked across 
different TSE isolates (Workman, Maddison and Gough, 2017). In contrast, a contrary 
hypothesis was reported by Yuan et al., who indicated that the inhibition of PMCA with 
recombinant PrP was species specific (Yuan et al., 2013). Findings reported here could 
be enhanced by analysing the most effective rPrP in more prion diseases from more 
genotypes across many different TSE isolates. More importantly, the testing of rPrP 
should be implemented in human TSE models (PMCA, RT-QuIC and cell culture) in order 
to help creating a new inhibitor for human prion protein misfolding.  
In addition, the recombinant ovine PrPs were also tested as inhibitors for other protein 
misfolding diseases. In the current research, the inhibition of α-synuclein misfolding 
during PMCA was investigated. The rationale was that the rPrP could act as a β-sheet 
breaker, which were described for amyloid beta inhibition research (Soto et al., 1996, 
1998; Shuaib et al., 2019). The current research showed no effects of recombinant PrPs 
on the misfolding of α-synuclein during PMCA. However, this analysis could be expanded 
into testing also natural rPrPs, like VRQ, with α-synuclein PMCA. Additionally, misfolded 
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α-synuclein could also be produced using the RT-QuiC assay (Fairfoul et al., 2016). The 
use of recombinant PrP could be implemented in that assay in order to analyse the 
possible inhibition mechanisms. Additionally, rPrPs could also be tested, as potent 
inhibitors for amyloid β and tau misfolding using established in vitro misfolding assays 
(Nieznanska et al., 2018). 
8.4 A cell culture model for investigation of rPrP inhibition of scrapie 
propagation  
In the current research, the inhibition of prion protein misfolding in vitro with rPrPs was 
further validated using a cell culture model of scrapie infection. Cell cultures are 
incredibly practical in testing therapeutic compounds for various diseases including TSEs 
(Kocisko and Caughey, 2006b). Here, the optimisations steps for the infection of ovine 
VRQ Rov9 cells were described. The research produced Rov9 cells persistently infected 
with scrapie SSBP1. These protocols were previously described, but they were 
implemented and modified in the current research (Vilette et al., 2001; Falanga et al., 
2006; Neale et al., 2010). The introduced modified cell infection resulted in a cell 
phenotype, the widespread occurrence of vacuoles, that has not been reported before 
for TSE infections in Rov9 cells. Ovine rPrPs were tested for preventing or curing 
infection with SSBP1. rRRQ, rKRQ, rPRQ and rARR were found to prevent infection with 
SSBP1, whereas natural rVRQ gave inconsistent results when passage 1 was analysed. 
Furthermore, low infection level was also maintained for latter passages for rRRQ and 
rARR, but the reproducibility for others – rKRQ, rPRQ, rVRQ – was poor. This data 
demonstrated that ovine rPrP could have a significant impact on preventing the 
infections with scrapie isolates. On the other hand, the rPrPs were tested for the 
possibility of clearing the PrPres in the persistently infected cells. The data showed 
a trend for some clearance of PrPSc in the cells for mutant rPrPs and natural rARR but 
not the natural rVRQ. This research could be further pursued by increasing the time of 
incubation of persistently infected cells with rPrP. In addition, higher concentrations of 
rPrPs could be used in the cell treatment. Additionally, previously reported agents that 
decreased the PrPres in infected cells like PPS, quinacrine or antibodies could be tested 
alongside the ovine rPrP to determine their relative efficacies (Beringue et al., 2003; 
Kocisko et al., 2005). Moreover, other infected with scrapie infected cell lines e.g. ScN2a 
or MNB could be used in testing ovine rPrPs as inhibitors of PrPres formation (Chabry et 
al., 1999; Yuan et al., 2013). Once successful in cell culture models, ovine rPrPs could 
be validated in in vivo TSE mouse models (Seelig, Goodman and Skinner, 2016).  
The cell culture results showed that the time of delivery of the successful therapeutic 
agent could significantly increase its effectiveness (Panegyres and Armari, 2013). The 
data presented in this thesis showed that when cells were treated with the therapeutic 
agent (rPrPs) at the time of infection with prions, the infection was less effective in 
comparison to rPrP treatment of persistently infected cells. Indicating that early 
 200 
diagnosis could improve the effectiveness of any treatment of prion diseases (Collinge, 
2005).  
Reseach using prion protein and prion diseases isolates has many limitations. Because 
of the prions infectious nature (and proved BSE transmissibility to humans), all 
experiments have to be performed in higher biosafety security laboratory and in fully 
controlled environment. Extra caution needs to be taken when working with prion 
diseases brain homogenates and PMCA products. Because of these conditions, the 
number and sort of experiments was determined by the instruments localised within the 
laboratory. However, the type of experiments presented in this work allowed to fully 
investigate the subject and produce a great amount of work and information about the 
topic. Range of methodology, starting from protein purification, PMCA and towards cell 
culture experiments allowed to show and analyse the subject in many details and 
provide proper scientific data. 
Overall, the current study demonstrates that mutant rPrPs are effective inhibitors of TSE 
propagation in an in vitro protein misfolding model. The mutants were considerably 
more effective than the natural PrP variants tested. Furthermore, mutant rPrP was also 
effective at preventing infection of cells. Further optimisation for the rPrPs at other 
amino acid residues known to be important in TSE propagation in ovine disease, such 
as 154 and 171 could be further mutated and tested. Finally, the study is based on 
a model TSE, scrapie in sheep, therapeutic intervention is required for human TSE 
diseases. The ovine rPrP mutants could be tested against models of human TSEs to 
determine their direct therapeutic potential and an analogous strategy for mutating and 






Representative dotblots show inhibition of ovine scrapie PG1361/05 (ARQ/VRQ) with 
rKRQ, OvK and randomised peptide (OvRND112-144) (A), rPRQ and OvP (B), rVRQ 
and OvV peptides (C and D). In all cases, there was no peptide inhibition of scrapie 
ARQ/VRQ PG1361/0550 nM rRRQ, 1 µM and 100 nM of peptides were compared to 
PG1361/05 amplified in relevant buffers. PrPC controls amplified in PBS, 0.05 % 
acetronitrile and 0.04 % HCOOH, 0.3 % acetonitrile were included as a PK digestion 
control. Amplification products were PK digested and 2.5 µl of each sample were added 
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captures the PhD training experienced by the candidate as a BBSRC Doctoral Training 
Partnership student. 
The Professional Internship for PhD Students is a compulsory 3-month placement which 
must be undertaken by DTP students. It is usually centred on a specific project and 
must not be related to the PhD project. This reflective statement is designed to capture 
the skills development which has taken place during the student’s placement and the 
impact on their career plans it has had. 
PIPS Reflective Statement 
I have spent 3 months of my Professional Internship for PhD Students (PIPS) working 
as a Research Associate in Arden Biotechnology Ltd in Lincoln. The company’s main 
research focus is to develop a novel biocontrol for Clostridium perfringens – anaerobic, 
Gram-positive bacteria that causes necrotic enteritis in poultry.  
During this placement, I was a part of the molecular lab team and involved in different 
projects. My main project was focused on the analysis of the Clostridium perfringens 
bacteriophages protein profiles. The aim of this project was to design an experiment 
using the SDS-PAGE electrophoresis in order to see differences in an environmental 
bacteriophage profiles. The methodology was familiar to me, however I had to use many 
online resources like scientific publications and articles available in the company to fully 
understand the topic. It allowed me to learn basic information about the bacteria and 
the disease – necrotic enteritis. By the end of the placement, I successfully managed 
to design and optimize the SDS-PAGE electrophoresis conditions for environmental 
bacteriophage proteins. Furthermore, I analysed and compared 25 different 
bacteriophages profiles.  All the data I have obtained, were described, handled and 
explained to my Line Manager and the Director of Research. By doing this I have 
improved my communication and presenting scientific data skills. In addition, 
completing this project was very beneficial for the company, as my presence, knowledge 
and work allowed them to learn all the necessary skills required for protein analysis.  
Moreover, I also took part in bacteriophage DNA analysis project. During this project, 
I learned new methods like Pulse Field Gel Electrophoresis, which allowed us to 
determine our environmental bacteriophage genomes size. Furthermore, I was involved 
in a sequencing project, in which we used one of the newest sequencing technology 
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DNA extraction and the DNA preparation for the sequencing. Then, I had the great  
opportunity to observe the sequencing process but unfortunately not the DNA 
sequences analysis process. self-confidence in exploring and trying out new, previously 
unknown methods has increased.  
These two events taught me not to be afraid of any challenges, especially in terms of 
applying new technology in research. In addition, my self-confidence in exploring and 
trying out new, previously unknown methods has increased.  
The placement helped me to refresh existing and obtain some new microbiology skills. 
For the first time during my career, I learned how to grow anaerobic bacteria but also, 
I had an opportunity to gain experience in phage enumeration and propagation 
techniques.  
In addition, my placement gave me the opportunity to observe infection models using 
the Wax moth larvae – Galleria mellonella and Clostridium perfringens. That expanded 
my knowledge in using different organisms as infection/disease models.  
During my placement, I was also asked to prepare a written report for the company 
funder, explaining the progress and all the used methods. That allowed me to practise 
scientific reports writing and will be beneficial in both my PhD work and future career.  
The placement in Arden Biotechnology gave me some important ideas about my future 
career planning. It allowed me to meet new people and learn how they started 
a company from scratch and gave a better understanding of the possible funding 
sources. Furthermore, my work and the performance helped to develop the company 
product which will be beneficial in the future. Moreover, the work from the placement 
in Arden Biotechnology has a potential to be published. However, the biggest take away 
from this placement is that I realised that I am passionate about science and I am happy 
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